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Abstract  
 
Liposome systems are well reported for their activity as vaccine adjuvants; however novel lipid-based 
microbubbles have also been reported to enhance the targeting of antigens into dendritic cells (DCs) in cancer 
immunotherapy (Suzuki et al 2009). This research initially focused on the formulation of gas-filled lipid coated 
microbubbles and their potential activation of macrophages using in vitro models. Further studies in the thesis 
concentrated on aqueous-filled liposomes as vaccine delivery systems.   
 
Initial work involved formulating and characterising four different methods of producing lipid-coated 
microbubbles (sometimes referred to as gas-filled liposomes), by homogenisation, sonication, a gas-releasing 
chemical reaction and agitation/pressurisation in terms of stability and physico-chemical characteristics. Two of 
the preparations were tested as pressure probes in MRI studies. The first preparation composed of a standard 
phospholipid (DSPC) filled with air or nitrogen (N2), whilst in the second method the microbubbles were 
composed of a fluorinated phospholipid (F-GPC) filled with a fluorocarbon saturated gas. The studies showed 
that whilst maintaining high sensitivity, a novel contrast agent which allows stable MRI measurements of fluid 
pressure over time, could be produced using lipid-coated microbubbles. The F-GPC microbubbles were found to 
withstand pressures up to 2.6 bar with minimal damage as opposed to the DSPC microbubbles, which were 
damaged at above 1.3 bar. However, it was also found that DSPC-filled with N2 microbubbles were also 
extremely robust to pressure and their performance was similar to that of F-GPC based microbubbles. Following 
on from the MRI studies, the DSPC-air and N2 filled lipid-based microbubbles were assessed for their potential 
activation of macrophages using in vitro models and compared to equivalent aqueous-filled liposomes. The 
microbubble formulations did not stimulate macrophage uptake, so studies thereafter focused on aqueous-filled 
liposomes.   
 
Further studies concentrated on formulating and characterising, both physico-chemically and immunologically, 
cationic liposomes based on the potent adjuvant dimethyldioctadecylammonium (DDA) and immunomodulatory 
trehalose dibehenate (TDB) with the addition of polyethylene glycol (PEG). One of the proposed hypotheses for 
the mechanism behind the immunostimulatory effect obtained with DDA:TDB is the ‘depot effect’ in which the 
liposomal carrier helps to retain the antigen at the injection site thereby increasing the time of vaccine exposure 
to the immune cells. The depot effect has been suggested to be primarily due to their cationic nature. Results 
reported within this thesis demonstrate that higher levels of PEG i.e. 25 % were able to significantly inhibit the 
formation of a liposome depot at the injection site and also severely limit the retention of antigen at the site. This 
therefore resulted in a faster drainage of the liposomes from the site of injection.  
 
The versatility of cationic liposomes based on DDA:TDB in combination with different immunostimulatory 
ligands including, polyinosinic-polycytidylic acid (poly (I:C), TLR 3 ligand), and CpG (TLR 9 ligand) either 
entrapped within the vesicles or adsorbed onto the liposome surface was investigated for immunogenic capacity 
as vaccine adjuvants. Small unilamellar (SUV) DDA:TDB vesicles (20-100 nm native size) with protein antigen 
adsorbed to the vesicle surface were the most potent in inducing both T cell (7-fold increase) and antibody (up to 
2 log increase) antigen specific responses. The addition of TLR agonists poly(I:C) and CpG to SUV liposomes 
had small or no effect on their adjuvanticity.  
 
Finally, threitol ceramide (ThrCer), a new immunostimulatory agent, was incorporated into the bilayers of 
liposomes composed of DDA or DSPC to investigate the uptake of ThrCer, by dendritic cells (DCs), and 
presentation on CD1d molecules to invariant natural killer T cells. These systems were prepared both as 
multilamellar vesicles (MLV) and Small unilamellar (SUV). It was demonstrated that the IFN-γ secretion was 
higher for DDA SUV liposome formulation (p<0.05), suggesting that ThrCer encapsulation in this liposome 
formulation resulted in a higher uptake by DCs. 
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1.1 Liposomes  
Liposomes are defined as microscopic spherical vesicles that form when phospholipids are 
hydrated or exposed to an aqueous environment (Bangham et al 1965). Liposomes were first 
discovered by Alec D. Bangham in the early 1960s while studying cell membranes (Bangham 
et al 1965). It was shown that amphiphiles, which are molecules that consist of a hydrophobic 
and a hydrophilic part such as phospholipids spontaneously form closed structures when they 
are hydrated in aqueous solutions (Chrai et al 2002). Since then, research in this field has 
expanded enormously. Today, most research into applications of liposomes is in the field of 
drug delivery (Gregoriadis & Florence 1993).  
 
 
Table 1.1 lists some liposomal products that have been approved in the past 15 years (Zhang 
et al 2008). Doxil was the first liposomal-based product approved for use in humans by the 
United States Food and Drug Administration (FDA) in 1995 (Northfelt et al 1998). This 
liposomal drug formulation is used in the treatment of AIDS associated with Kaposi’s 
sarcoma. Doxil has considerably extended the circulation half-life of doxorubicin, a drug used 
in anticancer chemotherapy, and furthermore it has increased the delivery of the drug into 
tumour tissues, thus resulting in an enhanced response (Northfelt et al 1998). This has been 
achieved by coating doxorubicin with stealth liposome carriers. Such carriers are composed of 
hydrogenated soy phosphatidylcholine, cholesterol, and PEGylated phosphoethanolamine. 
Other liposomal drugs used in clinical practice today include DaunoXome (daunorubicin 
liposomes) which is also a chemotherapy drug that is given to treat AIDS-related Kaposi's 
sarcoma, AmBisome (amphotericin B liposomes) in the treatment of fungal infections and 
DepoCyt (cytarabine liposomes) used to treat lymphomatous meningitis. The pharmacokinetic 
behaviour of a drug varies considerably in vivo when the drug is in its free state and when it is 
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encapsulated in liposomes. The benefits of such encapsulation are numerous. Liposome 
carriers can decrease drug toxicity by ensuring specificity to target organs and reducing any 
risks associated with the drug reaching organs that could be adversely affected (e.g. 
doxorubicin) (Rahman et al 1980). Additionally, the half-life of the drug is considerably 
increased in vivo, where the drug can remain stable in organs for prolonged periods (e.g. 
cytarabine). Furthermore, liposome carriers can often reduce the effective dose of the drug 
(cytarabine, methotrexate) (Zee-Cheng & Cheng 1989). Liposomes are also good vehicles for 
lipophilic drugs, which would otherwise be difficult to administer (Ali et al 2010). 
 
Table 1.1 Liposome-based products either approved or licensed for use in humans. 
Marketed product Drug used Target diseases Company 
DoxilTM or CaelyxTM Doxorubicin Kaposi’s sarcoma SEQUUS, USA 
DaunoXomeTM Daunorubicin Kaposi’s sarcoma, breast & 
lung cancer 
NeXstar, USA 
AmphotecTM Amphotericin-B Fungal infections, 
Leishmaniasis 
SEQUUS, USA 
Fungizone® Amphotericin-B Fungal infections, 
Leishmaniasis 
Bristol-squibb, 
Netherland 
Avian retrovirus 
vaccine 
Killed avian retrovirus Chicken pox  Vineland lab, USA  
Epaxal –Berna Vaccine Inactivated hepatitis-A 
Virions 
Hepatitis A  Berna Biotech 
Depocyt Cytarabine Cancer therapy Skye Pharm, USA 
Doxil® Doxorubicin Hcl Refractory ovarian cancer ALZA, USA 
EvacetTM Doxorubicin Metastatic breast cancer The liposome company, 
USA 
AutragenTM Tretinoin Kaposi’s sarcoma Aronex Pharm, USA 
NyotranTM Nystatin Systemic fungal infections Aronex Pharm, USA 
Mikasome® Amikacin Bacterial infection NeXstar, USA 
Verteporfin Visudyne Age-related macular 
degeneration 
Novartis 
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Liposomes are considered to be good candidates for drug carriers because they are relatively 
easy to prepare, exhibit little or no immunogenicity and toxicity by themselves, are 
biodegradable and can carry a diverse range of compounds, either encapsulated in the water 
phase (hydrophilic compounds) or incorporated in the lipid bilayer (hydrophobic compounds) 
(Chrai et al 2002) (Figure 1.1). Furthermore, liposome properties can be easily modified by 
changing the liposomal lipid composition, the charge or particle size, or chemical 
modification of the liposomal surface (Poste 1983; Gregoriadis 1985). Liposomes provide a 
unique opportunity to deliver pharmaceuticals into cells or even inside individual cellular 
compartments (Torchilin et al 1993). In many cases, therapeutic applicability was shown to 
improve through the use of liposomes as a drug carrier system (Chrai et al 2002).  
 
1.2 Structure and biophysical properties of liposomes  
Phospholipids are the main component of naturally occurring bilayers (O’Doherty 2004) and 
are amphipathic moieties with a hydrophilic head group and generally fatty acid two 
hydrophobic chains (tails) (Figure 1.1). When these lipids are exposed to an aqueous 
environment, intermolecular interactions between lipid molecules (hydrophilic interactions 
between polar head groups and van der Waals interactions between hydrocarbon chains) and 
with water molecules (hydrophilic interactions between the head groups) lead to spontaneous 
formation of closed bilayers (Uhumwangho & Okor 2005). As shown in Figure 1.1, the polar 
head groups contact water and the hydrophobic alkyl chains form a non-polar interior. The 
phospholipid molecules can move around within their lateral side bilayer, but there is a 
significant energy barrier preventing migration/flipping of the lipid molecules to the other side 
of the bilayer (Alberts et al 2002). 
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Figure 1.1 Schematic representation of a liposome. When these lipids are exposed to an aqueous environment, 
intermolecular interactions between lipid molecules and with water molecules lead to spontaneous formation of 
closed bilayers. 
 
The two types of phospholipids used within liposome formulations can be classified as natural 
and synthetic. The most common natural phospholipid is phosphatidylcholine (PC), also 
known as lecithin and it can be extracted from animal (hen egg) and vegetable (soyabean) 
sources (Zhang et al 2002). Other natural phospholipids include phosphatidylethanolamine 
(PE) and phosphatidylserine (PS). These natural phospholipids are heterogeneous with respect 
to their fatty acid chains and usually have a high degree of polyunsaturation, which can affect 
liposome characteristics (Frezard 1999). Synthetically prepared phospholipids have well-
defined fatty acid compositions and can be obtained with different or identical saturated or 
unsaturated chains (New et al 1990). The structures of the most commonly used bilayer-
forming lipids are illustrated in Table 1.2 (Frezard 1999).  
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Table 1.2 Examples of bilayer-forming lipids. 
Lipid family 
Structural formula 
Hydrophobic chains (R) 
(name) 
Abbreviation of lipid 
name (Tc) 
 
Phosphatidyl choline 
 
 
 
 
 
CH3-(CH2)7-CH=CH-(CH2)7-C(O)- (oleyl) 
CH3-(CH2)12-C(O)- (myristoyl) 
CH3-(CH2)14-C(O)- (palmitoyl) 
CH3-(CH2)16-C(O)- (stearoyl) 
 
 
 
 
DOPC ( < 0 OC) 
 DMPC (+ 23 OC) 
DPPC (+ 42 OC) 
DSPC (+ 55 OC) 
 
Phosphatidyl ethanolamine 
 
 
 
 
 
CH3-(CH2)7-CH=CH-(CH2)7-C(O)- (oleyl) 
 
 
 
 
DOPE (< 0 OC) 
 
Phosphatidyl glycerol 
 
 
 
CH3-(CH2)12-C(O)- (myristoyl) 
CH3-(CH2)14-C(O)- (palmitoyl) 
 
 
 
DMPG (+ 13 OC) 
DPPG (+ 35 OC) 
 
 
Phosphatidylcholine is the major component of most biological membranes and is often used 
as bulk lipid for the preparation of liposomes due to its non-toxic biodegradable profile 
(Zhang et al 2002). Depending on the nature of the phospholipid component, the lipid bilayer 
of the liposomal vesicles can exist within a fluid or rigid state at ambient temperature. The 
state and characteristics of amphiphiles is dependent on the lipids gel-liquid crystalline phase 
transition temperature (Tc). This means that the liposome bilayers can be in fluid or rigid state, 
in which the transition temperature is below or above ambient temperature, respectively 
(Gregoriadis et al 1998). The phase transition temperature of phospholipids is influenced by 
numerous factors including the lipids alkyl hydrocarbon chain length and degree of saturation. 
As the alkyl chain increases in length, the van der Waal interactions between the lipid chains 
become stronger, thereby in order to disrupt the stringent and rigid lipid packing of the 
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liposome bilayer, more energy needs to be applied, thus increasing the phase transition 
temperature. For example, dimyristoylphosphatidylcholine (DMPC) has a hydrocarbon chain 
length of C14 and a phase transition temperature of 23 oC, whereas 1,2-distearoyl-sn-glycero-
3-phosphocholine (DSPC) has a hydrocarbon chain length of C18, resulting in a higher phase 
transition temperature of 55 oC, as more energy is required to disrupt the ordered packing and 
to subsist in a fluid state. In terms of liposomal drug delivery, the phase transition temperature 
is important as it can dictate the stability and drug release profile of the systems. For example 
early work by Gregoriadis and Ryman (1971) showed that liposomes formulated with DSPC 
had higher drug retention and longer circulation times than liposomes formulated with lower 
transition temperature lipids. 
 
1.2.1 Liposome composition 
Liposomes are often classified into groups by size and number of membranes (lamellarity) 
(Rongen et al 1997) (Figure 1.2):  
• Multilamellar vesicles (MLV) are onion-like structures that have series of substantially 
spherical shells, formed of five to twenty lipid bilayers, interspersed with aqueous layers 
and range in diameter from around 100 - 4000 nm (Rongen et al 1997).  
• Large unilamellar vesicles (LUV) are vesicles that have a size above 100 nm, and 
normally consist of one concentric lamella (New 1990). 
• Small unilamellar vesicles (SUV) are defined as the smallest phospholipid vesicles 
approximately 45 nm, with a maximum size of up to 100 nm. The size depends on the 
ionic strength of the aqueous medium and the lipid composition in the membrane. They 
usually consist of one lamella (Rongen et al 1997). 
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Depending on its physico-chemical properties, a drug can either be incorporated in the lipid 
bilayer (for lipophillic drugs) or encapsulated in the water phase of the liposome (for 
hydrophilic drugs). A lipophillic drug will be accommodated between the lipid molecules of 
the bilayer (Weiner et al 1989; Scherphof et al 1987) and thus the amount of drug that can be 
incorporated will depend on how well the drug fits in between the bilayer molecules and on 
the strength of the lipid interaction (Zhang et al 2002). This will also determine the stability of 
the drug-liposome complex in vivo. Because of the relatively large amount of lipid in the lipid 
bilayers of MLV, they are considered best for encapsulation or transportation of lipophilic 
materials, whereas for LUV because of their large aqueous/lipid volume ratio, they are 
considered best for encapsulation of hydrophilic molecules, particularly macromolecules 
(Szoka & Papahadjopoulos 1978). SUV have the advantage of a small size, which allows 
relatively easy access to the cells of tissue, but their small volume limits delivery of 
hydrophilic aqueous materials to trace amounts (Waalkes 1992). However, SUV may be 
useful in the transportation of lipophilic materials (Keller & Lasic 2005; Mohammed & Perrie 
2005).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic representation of three types of liposomes. These are small unilamellar (SUV), large 
unilamellar vesicles (LUV) and multilamellar (MLV). SUV have diameters of less than 100 nm, LUV have a 
lipid bilayer surrounding a large, unstructured aqueous phase. MLV have a series of substantially spherical shells 
formed of five to twenty lipid bilayers interspersed with aqueous layers. 
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1.2.2 Liposome morphology 
There are numerous ways to generate liposomes and the number of lipid bilayers present 
within the liposomal vesicle is dependent on the method of preparation.  
 
1.2.2.1 Lipid hydration method 
MLV are the simplest liposomal vesicles to make and can be prepared by the established lipid 
hydration method (Bangham et al 1965). This involves mixing of the selected lipid 
components within a solvent (i.e. chloroform/methanol) mixture, which is then evaporated by 
rotary evaporation. Once the solvent is completely removed, a dry lipid film forms and as the 
aqueous solution (i.e. water) is added to hydrate the film, the lipid components begin to break 
away gradually forming large spherical liposomes, with each consisting of numerous 
concentric lipid bilayers entrapping water. As these vesicles form, the lipid components 
arrange themselves in a random manner and the size of MLV liposomes cannot be controlled. 
Therefore within the liposomal solution there are heterogeneous population of MLV sizes, 
ranging from as small as 100 nm to a few microns in size (Gregoriadis et al 2002). 
 
1.2.2.2 Sonication 
After preparation of MLV liposomes, these large liposomal structures can be dramatically 
reduced in size and their morphology can be modified by probe or bath sonication of the MLV 
suspension, generating SUV (Huang 1969; Johnson et al 1971). For larger volumes and dilute 
samples, bath sonication is more suitable. Normally, a 5 to 10 minute sonication above the Tc 
of lipids is sufficient for producing SUV of 100 nm or even smaller (Zhang et al 2002). The 
advantages of bath sonication include a controllable operating temperature, freedom from 
contamination, and no loss of lipid material. Probe sonication on the other hand, dissipates 
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more energy into the sample and therefore is often used for achieving the smallest size 
possible, for concentrated samples or suspension in more viscous aqueous solutions (Zhang et 
al 2002).  
 
LUVs can be produced using a range of methods including reverse-phase evaporation and 
ether vaporisation method (Frezard 1999).  
 
1.2.2.3 Reverse-phase evaporation method 
In reverse-phase evaporation, several phospholipids (pure/mixed with cholesterol) can be 
used. The lipid mixture is added to a round bottom flask and the solvent is removed under 
reduced pressure by a rotary evaporator. The system is purged with nitrogen and the lipids are 
re-dissolved in the organic phase. This is the point when the reverse phase vesicles will form 
(O’Doherty 2004). Diethyl ether and isopropyl ether are the usual solvents of choice. After the 
lipids are re-dissolved, the aqueous phase (contains compound to be encapsulated) is added. 
The system is kept under continuous nitrogen and the two-phase system is sonicated until the 
mixture becomes a clear one-phase dispersion. The mixture is then placed on the rotary 
evaporator and the organic solvent removed until a gel is formed. The resulting liposomes are 
called reverse-phase evaporation vesicles (REV). The large unilamellar vesicles formed have 
the ability to encapsulate large macromolecular vesicles with high efficiency (Szoka & 
Papahadjopoulos 1978). 
 
1.2.2.4 Ether vaporisation method 
In the ether vaporisation method, osmotically active unilamellar vesicles are produced 
following the slow injection of a lipid mixture in organic phase into a warm aqueous solution. 
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Such vesicles have a well-defined size distribution (O’Doherty 2004). Additionally in 
comparison to sonicated and hand shaken preparations, vesicles formed using the ether 
vaporisation method have a ten times greater high volume trapping efficiency (Deamer & 
Bangham 1976). 
 
1.2.2.5 Dehydration-rehydration method 
In a bid to enhance the efficiency of drug incorporation within liposomes, Kirby and 
Gregoriadis (1984a) developed a method of producing liposomes known as the dehydration-
rehydration procedure. The method produces vesicles that undergo various transformations in 
physical characterisation, in order to generate the ideal completed liposomes. The procedure 
involves mixing the material to be entrapped together with the SUV before freeze-drying. In 
this way all of the lipid can be brought into contact with all of the solute in the anhydrous 
state. During the dehydration-rehydration procedure, the concentration of vesicles combined 
with the reduction in hydrophobic forces causes loss of vesicle stability. This promotes fusion 
of these destabilised SUV into larger multilamellar vesicles entrapping solute as they form 
(Deamer & Barchfield 1982) into dehydration-rehydration vesicles (DRV).    
 
1.3 Application of liposomes  
As noted, liposomes have a wide range of biomedical applications such as carriers for 
controlled drug release of tumours therapeutic agents and antibiotic, for gene and antisense 
therapy through nucleic acid sequence delivery, immunisation through antigen delivery and as 
radiodiagnostic carriers. In this thesis, liposomes have been investigated as radiodiagnostic 
contrast agents and as vaccine adjuvants, these applications will be explored in detail in the 
following sections.   
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1.3.1 Liposomes as radiodiagnostic carriers 
Liposomes have been recognised as promising carriers for diagnostic agents and contrast 
agents to locate sites specifically (Torchilin 1997). Contrast agents are defined as substances 
used to enhance the contrast of structures or fluids within the body in medical imaging 
(Torchilin 1996). These agents are used in imaging to increase the signal difference between 
the area of interest (e.g. the blood pool) and the background (Gregoriadis 1988; Torchilin 
1985). The ability of liposomes to entrap different substances into both the aqueous phase and 
the liposome membrane compartment made them suitable for carrying the diagnostic moieties 
used with all imaging modalities: gamma-scintigraphy, magnetic resonance (MR) imaging, 
computer tomography (CT) imaging and even sonography (Torchilin 1997). The different 
chemical nature of reporter moieties used in different modalities requires different protocols to 
load liposomes with the given contrast agent. Such characteristics of liposomal contrast agents 
led to the development of an entire family to be used in various settings such as tumours, liver 
and spleen, infection and inflammation sites, the cardiovascular system, and other regions of 
interest in the clinical field (Torchilin 1997).  
 
1.3.1.1 Lipid-coated microbubbles in magnetic resonance imaging (MRI)  
In medicine, MRI is used as a diagnostic tool where cross-sectional images of soft tissue can 
be produced. Water molecules in tissues absorb and transmit high frequency radiowaves when 
placed in strong magnetic fields, which is analysed using MRI (Vangala et al 2007a). The 
MRI signal from different water densities within the biological material is used to create 
images on the basis of the difference in relaxation time (Vangala et al 2007a).  
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In addition to its application in medical imaging, a study by Vangala and co-workers (2007a) 
have investigated the potential of MRI to quantify and map the oil content in rock by 
measuring the different relaxation times of the MRI signal coming from oil and water. It was 
suggested that this technology could be enhanced by the application of gas filled lipid-coated 
microbubbles (Vangala et al 2007a). Lipid-coated microbubbles are liposomes that are 
prepared with entrapped gases, such as air, oxygen or fluorinated gases, rather than with an 
aqueous core (Perrie 2005). Lipid-coated microbubbles can act as MRI pressure probes, as 
when these microbubbles are present in a pressure-varying medium, changes in liposome size 
(resulting from changes in pressure) would cause a change in the MRI signal allowing an 
accurate three-dimensional image of the pressure changes in porous rock (Vangala et al 
2007a). Indeed, pressure sensitive MRI systems have already been suggested for applications 
in health care. For example, they have been used to measure haemodynamic pressures for 
evaluating cardiovascular function and arterial pressure and for such applications, lipid-coated 
microbubbles have been tested as pressure sensitive contrasting agents (Perrie 2005).  
 
1.3.2 Liposomes as vaccine adjuvants  
1.3.2.1 Vaccines 
Vaccines have been defined as ‘any preparation made from a pathogen that is used for 
vaccination and provides protective immunity against infection with the pathogen’ (Parham 
2009). The ultimate goal of a vaccine is to develop long-lived immunological protection, 
whereby the first encounter with a pathogen is ‘remembered’ by the immune system (Pashine 
2005).  
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1.3.2.2 Innate and adaptive immune responses  
The immune system has two main functions; to recognise invading pathogens and then to 
trigger pathways that will destroy them (Hames & Hooper 2000). Such pathogens are 
controlled and terminated by the innate immune response and is ready to react quickly. Most 
components of innate immunity, are present before the onset of infection and constitute a set 
of disease-resistance mechanisms that are not specific to a particular pathogen that include 
cellular and molecular components that recognise classes of molecules different to frequently 
encountered pathogens (Goldsby et al 2003). Phagocytic cells such as neutrophils, 
macrophages, in addition to pattern recognition receptors, NK cells, complement, and variety 
of antimicrobial compounds synthesised by the host all play important roles in innate 
immunity (Goldsby et al 2003).  
 
The adaptive immune response is made up of B and T lymphocytes that have unique receptors 
specific to various microbial antigens (Sudhakar & Subramani 2005), in contrast to the 
receptors of the innate immune system which are of many different types but not specific to a 
particular pathogen (Parham 2009). These antigen-specific receptors are encoded by genes 
generated during a complex process of gene rearrangement that occurs during the course of 
lymphocyte development. As each B and T lymphocyte contains a unique antigenic receptor, 
it allows for large and diverse population of cells capable of recognising a wide spectrum of 
pathogens. This is termed the lymphocyte repertoire (Sudhakar & Subramani 2005). In 
response to an infection lymphocytes bearing receptors specific for the pathogen are then 
selected to participate in the immune response. The proliferation and differentiation of these 
cells, termed clonal selection and expansion, generates a large population of specific effector 
cells. To assist in future invasion by the same pathogen, some of the lymphocytes persist in 
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the body and provide long-term immunological memory, thus resulting in a faster and stronger 
response (Parhan 2009).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Schematic representation of the immune response. (A) Innate immune response. Non-self cells 
are rapidly attacked in the innate immune system. Key players in the innate system are neutrophils, macrophages, 
pattern recognition receptors, NK cells, and complement. The desired end result is the destruction of the foreign 
substance, the non-self cell. (B) Adaptive immune response. The major players in this response are the B 
lymphocytes, T lymphocytes, and NK cells. The desired end result is destruction of the non-self cell but through 
a more complex and tightly orchestrated series of events (Bingham 2008). 
A. Innate immune response 
B. Adaptive (acquired) immune response 
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1.3.3 Types of Vaccines 
There are four types of traditional vaccines: (1) live attenuated, (2) inactivated, (3) toxoids, 
and (4) subunit vaccines. 
 
1.3.3.1 Live Attenuated Vaccines 
Live attenuated vaccines consist of live virus that has mutated so that it has a reduced ability 
to grow in human cells and is no longer pathogenic to humans (Parhan 2009). These 
microorganisms are still able to infect their target cells. However, infection is inefficient 
(mild) and there are limitations in the replication of the microorganisms. Vaccines produced in 
this manner include the bacillus Calmette-Guérin (BCG) and the measles, mumps, yellow 
fever vaccines and rubella combination vaccine (MMR) (Harper et al 2003; Nichol et al 1999; 
Arving & Greenberg 2006), and such vaccines are generally capable of stimulating both a 
humoural and cell-mediated immune response. However, there is a risk of reversion to 
virulence, and this type of vaccine is not considered safe for use in immunocompromised 
individuals.  
 
1.3.3.2 Inactivated Vaccines 
Inactivated vaccines consist of microorganisms that have been killed or viruses, usually by 
heat or chemicals such as formaldehyde, thus destroying infectivity while retaining 
immunogenicity (Mackett & Williamson 1995). While offering advantages in terms of safety, 
such vaccines are generally less effective than live attenuated vaccines, usually only 
stimulating humoural immunity and often requiring booster doses (Mackett & Williamson 
1995). Examples of these vaccines include: trivalent inactivated influenza vaccine (TIV), 
cholera, bubonic plague and hepatitis A vaccines (Fiore et al 2006; Cox et al 2004).  
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1.3.3.3 Toxoids  
Some microorganisms produce toxic compounds that are the responsible for causing the 
disease (i.e. tetanus toxin and diphtheria toxin). Toxoids are inactivated forms of these toxic 
compounds. In addition to being successful vaccines in their own right, toxoids may also be 
used to increase the immunogenicity of some other vaccines, such as the Haemophilus 
influenzae type B (Hib), which contains a polysaccharide unit from the virus conjugated to 
diphtheria or tetanus toxins (Perrie 2006).  
 
1.3.3.4 Subunit Vaccines 
Subunit vaccines initiate strong immune responses using a small part of the organism that 
could include a gene from the genome. Recombinant DNA technology has greatly facilitated 
the development of such vaccines, a process where are foreign genes are introduced into yeast 
or bacteria expression systems. This allows the production of large quantities of antigen that is 
purified and used as a vaccine (Arvin & Greenberg 2006). The immune response induced by 
such vaccines is short-lived and thus several boosts are required to achieve protection. For 
Hepatitis B virus for example, only the surface protein of the virus is used to generate the 
subunit vaccine. Before recombinant DNA technology, this was extracted from the blood 
serum of chronically infected patients (Berman et al 1990; Edlich et al 2003).  
 
1.3.4 Improvement of the potency of subunit vaccines 
To improve subunit vaccines, the trend now is to produce highly purified recombinant 
proteins that do not induce strong immune responses and lack natural immunostimulatory 
substances. However, such vaccines fail to induce an effective immune response despite their 
increased safety, since they lack immunostimulatory components of whole-cell vaccines key 
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to activating an innate immune response. Additionally, vaccines need to induce a cell-
mediated as well as humoural immune response against pathogens causing chronic infection 
such as hepatitis C virus, human immunodeficiency virus (HIV), tuberculosis and malaria, but 
subunit vaccines have been ineffective at inducing such a response (Fearon 1997). In order to 
make subunit vaccines capable of inducing potent immune responses, adjuvants and novel 
vaccine strategies are required (Fearon 1997, Janeway 1989).  
 
1.3.5 Adjuvants 
Adjuvants (derived from the latin word adjuvare, meaning help or aid) are defined as 
substances used in combination with a specific antigen that produced a robust immune 
response than the antigen alone (Gupta et al 1993, Vogel 1995). The concept of adjuvants 
arose in the 1920s from observations such as those of Ramon et al (1926) who noted horses 
that developed an abscess at the inoculation site of diphtheria toxoid generated higher specific 
antibody titers (Petrovsky & Aguilar 2004). They subsequently found that an abscess 
generated by the injection of unrelated substances, along with the diphtheria toxoid, increased 
the immune response against the toxoid (Ramon 1959). The most appropriate adjuvant for a 
given vaccine antigen will depend to a large extent on the type of immune response that is 
required for protective immunity. Moreover, some adjuvants are strikingly potent, but also 
very harmful to the host. Therefore, the potency of an adjuvant often conflicts with host safety 
and tolerability. Adjuvants can be used for various purposes, (a) firstly to enhance the 
immunogenicity of recombinant antigens (McElrath 1995), (b) to reduce the amount of 
antigens or the number of immunisations needed for protective immunity, (c) to improve the 
efficacy of vaccine in newborns, the elderly or immunocompromised persons and (d) as 
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antigen delivery systems for the uptake of antigens by the mucosa (Petrovsky & Aguilar 2004, 
Marx et al 1993, Douce et al 1995). 
 
1.3.5.1 Role of adjuvants in the immune responses 
To date, it is not clear how the immune response is augmented by adjuvants but the immune 
response to vaccine antigens is improved in more than one way. These include: 
 (a) Improve antigen delivery to APCs, increase cellular infiltration, inflammation, and 
trafficking to the injection site (Aguilar & Rodriguez 2007).  
(b) Promote the activation state of APCs by up regulating co-stimulatory signals or MHC 
expression, inducing cytokine release (Aguilar & Rodriguez 2007).  
(c) Enhance antigen processing and presentation to the cells of the immune system 
(Aguilar & Rodriguez 2007).  
(d) Modulate antibody avidity, affinity as well as the magnitude, isotype or subclass 
induction (Pashine et al 2005).  
(e) Stimulate cell-mediated immunity and lymphocyte proliferation non-specifically 
(Pashine et al 2005). 
 
1.3.6 Classification of adjuvants 
The source, physiochemical properties and mechanism of action are amongst the features that 
help classify adjuvants (Vogel 1998). Considering their mechanism of action, Edelmann 
(1991) (reviewed in Allison and Byars 1991) classified adjuvants into three groups: (a) 
immunostimulatory adjuvants, being substances that increase the immune response to the 
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antigen by directly activating APCs through specific receptors e.g. TLRs, known as adjuvant 
receptors (Kaisho and Akira 2002), (b) carriers that provide help to T-cells as immunogenic 
proteins and, (c) particulate or vehicle adjuvants (vaccine delivery systems), serve as a matrix 
for antigens, mainly function to localise vaccine components and to target vaccines to APCs 
(Petrovsky & Aguilar 2004) . So, delivery systems are used to promote the interaction of both 
antigens and immunostimulators with the key cells of the innate immune system. 
Immunostimulatory adjuvants provide the inflammatory context necessary for optimal 
antigen-specific immune activation by activating APCs and amplifying the innate immune 
response (Aguilar & Rodriguez 2007). Some of the most common adjuvants are described in 
the following section. 
 
1.3.6.1 Alum 
Alum are aluminum-based mineral salts (generically called alum) (Gupta 1998). Aluminium 
salts are insoluble, gel like precipitates of aluminium hydroxide or aluminium phosphate. 
Immunogen is bound by electrostatic interactions to pre-formed gel or during gel formation in 
situ (Levine et al 1955). The major mode of action appears to be depot formation at the site of 
injection. The antigen is only slowly released from the gel, ensuring its sustained exposure to 
immune surveillance. Alum induces strong Th2 responses, and work in vitro indicated that 
alum up-regulated co-stimulatory signals on human monocytes and promoted the release of 
IL-4 (Ulanova et al 2001). Unfortunately, alum is a poor adjuvant for cell-mediated immunity 
and can induce IgE antibody responses, which are associated with allergic reactions (Gupta 
1998). 
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1.3.6.2 Freund’s adjuvants 
Freund’s complete adjuvant was developed in 1937 and is a powerful immunogenic adjuvant 
composed of a mixture of paraffin (i.e. mineral) oil, a surfactant (Aracel A), and heat killed 
Mycobacterium tuberculosis (MTB) (Stuart-Harris 1969). This adjuvant functions to prolong 
antigen persistence. The mycobacterial components in FCA have additional direct 
immunostimulatory activities making FCA very potent. However, it is not used for human 
vaccination because of problems associated with its use, mainly ulcerating tissue necrosis 
(Claassen et al 1992). In contrast, Freund’s incomplete adjuvant (FIA) does not contain the 
mycobacteria component and, consequently displays somewhat less adjuvanticity (Walsh 
2007). 
 
1.3.6.3 CpG (cytidine-phosphate-guanosine) 
Bacterial components are often potent immune activators; however, these are commonly 
associated with toxicity, for example, bacterial DNA with immunostimulatory CpG motifs is 
one of the most potent cellular adjuvants (Weiner et al 1997). Immunostimulatory CpG are 
unmethylated cytosine-guanine dinucleotides found in bacterial DNA, but absent in 
mammalian DNA (Petrovsky & Aguilar 2004). These DNA sequences stimulate the immune 
system through a specific receptor, TLR 9, which is intracellularly expressed in human, and 
mouse B-cells and plasmacytoid DCs (Krug et al 2001). Within minutes of exposure of B-
cells or plasmacytoid DCs to CpG motifs, they interact with TLR 9, leading to the activation 
of cell signaling pathways. The adjuvant effect of CpG appears to be maximised by the 
conjugation to plasmid protein antigens (Klinman et al 1999), or their formulation with 
delivery systems (Singh et al 2001). 
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1.3.6.4 Liposomes 
The immunological role and adjuvant properties of liposomes were first identified by Alison 
and Gregoriadis (1974) for diphtheria toxoid. Since then the immunological adjuvanticity of 
liposomes has been well recognised and they been extensively investigated as potential 
vaccine adjuvants for more than 20 years for a number of antigens, including tetanus toxoid 
(Davis & Gregoriadis 1987), Leishmania major antigen (Kahl et al 1989) and hepatitis B 
surface antigen (Brunei et al 1999). Liposomes have been researched for their role in 
enhancing transfection of DNA plasmids (Perrie et al 2001; Perrie et al 2003), and as efficient 
adjuvants for subunit vaccine delivery (Davidsen et al 2005; Smith Korsholm et al 2007), with 
some liposomal based vaccines (i.e. virosomes) having been licensed for human use (i.e. 
Inflexal vaccine for influenza).  
 
1.4 Liposomes delivery of protein antigens 
The use of liposomes as carrier systems has been ongoing for many years. Liposomes are used 
as a carrier system for various types of substances and thus their versatility, both structural 
and functional, make them ideal for the delivery of protein antigens. In vivo, protein antigens 
are recognised by major histocompatibility complex (MHC) molecules that are expressed on 
the surface of APCs. These include dendritic cells and macrophages. There are two different 
classes of MHC molecules, MHC I and MHC II. MHC molecules process foreign antigens 
and by transporting it through the cytosol, the peptide and MHC complex is displayed on the 
surface of the APC. Thus, the complex interacts with the T-cell receptor and facilitates an 
interaction between APCs and T-cells (Madigan et al 2002). The source of protein antigen 
however determines which MHC molecule will bind, process and present the antigen. For 
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instance, the immune system processes subunit protein antigens as exogenous antigens. These 
antigens can be processed by MHC class II molecules and effectively induce a humoural 
immune response once presented to the Th1 pathway CD4+ lymphocytes. Such antigens are 
unable to gain access into the cytosol of the target cell that is important for MHC class I 
presentation of antigen to cytotoxic T lymphocytes (Spack & Sorgi 2001). The use of a 
liposomal delivery system, however, can artificially direct exogenous antigen into the 
cytoplasm of the target cell and induce MHC class I presentation (Rao & Alving 2000). This 
will also provoke the release of Th1 cytokines that will additionally stimulate strong CTL 
responses (Spack & Sorgi 2001).   
 
1.4.1 Liposome composition: cationic lipids and immunomodulators 
Liposomal systems can enhance specific immune responses to protein antigens. This has been 
shown from the introduction of cationic lipids into the lipid bilayer, and from ligand and co-
adjuvant incorporation. A possible strategy showing potential in this field is combining 
liposomal delivery systems with adjuvants and/or immunomodulating molecules such as 
cytokines (Rao et al 2002). Olsen et al (2001) showed an increase and an induction of 
protective immunity against tuberculosis when isolated protein antigens, found in 
mycobacterial culture filtrates, were incorporated within liposomal vesicles combined with 
dimethyldioctadecylammonium (DDA; when hydrated in an aqueous environment this 
cationic lipid self assembles into closed bilayers) (Olsen et al 2001). Yet these identified 
proteins possess low inherent immunogenicity when injected alone (Andersen 1994). The 
authors reached a conclusion that in order for immune protection to remain high over an 
extended period, a depot must have been formed at the injection site by DDA (Holten-
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Andersen et al 2004; Olsen et al 2001). Holten-Andersen and co-workers conclude DDA may 
act to increase antigen and immunostimulator uptake into APC when it forms the depot. Table 
1.3 highlights other immunomodulators that like DDA when incorporated into liposomal 
delivery systems act to enhance immunogenicity against tuberculosis and other infectious 
organisms.  
 
Table 1.3 A selection of immunomodulators, which could enhance the immunogenicity of liposome 
systems.  
 
 
 
 
 
 
 
 
 
 
 
 
1.4.2 Liposome preparation: surface adsorbed versus entrapped antigen 
The preparation method used in producing liposome vesicles may have a strong influence in 
the way they are processed in vivo. Protein antigens can be incorporated into liposome 
vesicles at a high concentration and this is not influenced by vesicle size, since smaller 
vesicles with a diameter of 100 – 200 nm are also capable of achieving this (Lima 2004). This 
therefore suggests liposomal preparation method does not dictate the amount of antigen 
Immunomodulator  Description 
MPL 
(monophosphoryl lipid A) 
Induces the synthesis and secretion of various cytokines (Ulrich & 
Myers 1995) and is effective at potentiating mucosal and systemic 
immune responses to the incorporating antigen. This adjuvant has no 
observed side effects, other than minor irritation at the injection site 
(Thoelen et al 1998). 
 
MPD (muramyl dipeptide) 
 
 
Derived from bacterial cell walls and activates macrophages thus 
regulates the immune system (Murata et al 1997). 
 
TDM 
(trehalose 6,6’dimycolate) 
Cord factor, which is a glycoprotein present on the cell membrane 
surface of M. tuberculosis. Activates macrophages and synthesis of 
cytokines, to drive a Th1 immune response. It is extremely toxic as 
it induces hypersensitivity granulomas, complex inflammatory 
events and apoptosis (Yamagami et al 2001). 
   
TDB 
(trehalose 6,6’ dibehenate) 
An analogue of trehalose 6,6' dimycolate (TDM) but consists of a 
shorter fatty acid chains therefore is considered to be less toxic 
(Davidsen et al 2005). Very immunogenic as a co-adjuvant for 
eliciting protective immunity against tuberculosis (Holten-Andersen 
et al 2004; Davidsen et al 2005). 
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entrapped by the liposomal vesicles. Factors that could, however, influence how liposomal 
vesicles are processed by the immune system include morphology, preparation and location of 
protein antigen. This could further influence which immune pathway is activated (Therien & 
Shahum 1996).  
 
Depending on the antigen location and its physical association with the liposomal delivery 
system, the type and strength of the immune system can vary (Shahum & Therien 1988; Fortin 
et al 1996). Antigen can either be encapsulated or bound to the surface of the delivery system. 
These different locations can thus influence the route in which the antigen is processed within 
APCs, which further dictates the cell populations activated and the immune response initiated 
(Fortin et al 1996). In contrast, an early study showed that for toxoid delivery via liposomal 
formulation, antibody responses to the immunopurified tetanus toxoid was no different 
between toxoid linked to the surface MLV and toxoid entrapped within DRV, implying that 
the physical location of the antigen has no influential effect on induction of specific immune 
responses (Davis & Gregoriadis 1987).  
 
Various studies however have shown both encapsulated and surface linked antigens to be 
beneficial, thus suggesting how the antigen is associated could be antigen specific (Fortin et al 
1996). For a range of antigens including e.g. Factor VIII protein, the DRV procedure in terms 
of high antigen entrapment efficiency has been shown to be highly immunogenic (Kirby & 
Gregoriadis 1987b). 
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1.5 Aims and objectives    
Given the ability of liposome-based systems to be formulated to deliver a range of moieties 
their application initially to act as possible contrast agents and then further use these systems 
as potential vaccine adjuvants was considered. The feasibility of contrast agents as novel 
antigen delivery tools to dendritic cells has been assessed previously in cancer immunotherapy 
(Suzuki et al 2009). The authors found that exogenous antigen delivery into cytosol by lipid 
coated microbubbles could induce antigen-specific CTLs and lead to a strong anti-tumour 
effect. Therefore the overall aim of this thesis was to investigate the potential of liposomes in 
the application of contrast agents and as vaccine delivery systems.   
 
The objectives of this study were: 
• To compare and evaluate four different methods of producing lipid-coated 
microbubbles/gas-filled liposomes and to test the stability and physico-chemical 
characteristics of these preparations in order for their use as contrast agents to fluid 
pressure.  
• To examine the effect of liposome and microbubble formulations on macrophage cells 
to assess their potential as possible vaccine adjuvants. 
• To investigate the effect of liposome formulation on their biodistribution and adjuvant 
properties. 
• To investigate the versatility of cationic liposomes in combination with 
immunostimulatory ligands including TLR ligands, polyinosinic-polycytidylic acid 
(poly(I:C), TLR 3 ligand), and CpG (TLR 9 ligand). 
• To prepare delivery systems containing a new immunostimulatory agent threitol 
ceramide (ThrCer) and test the stability and efficacy of the system. 
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Chapter 2 
Formulation, characterisation and application of lipid-coated 
microbubbles 
 
 
Graphical Abstract: 
 
 
 
 
 
 
 
 
Whilst maintaining high sensitivity a novel contrast agent, which allows stable MRI 
measurements of fluid pressure over time, can be produced. 
 
 
 
 
 
 
 
 
Some of the results presented in this chapter have been published in the paper:  
Kaur, R., Morris, R., Bencsik, M., Vangala, A., Rades, T., Perrie, Y. (2009) Development of a 
novel magnetic resonance imaging contrast agent for pressure measurements using lipid-
coated microbubbles. Journal of Biomedical Nanotechnology. 5: 1-9.   
Standard or fluorinated phospholipid 
Air, nitrogen (N2) or perfluorohexane-saturated N2 gas a
 
GAS 
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2.1 Introduction 
Microbubbles are comprised of shells (commonly surfactant based) encasing spherical voids 
or cavities filled by a gas. However, it has been shown that gas microbubbles are prone to 
dissolution, even in gas-saturated solutions as a consequence of the Laplace pressure across 
the gas-liquid interface (Duncan & Needham 2004). The Laplace pressure is the pressure 
difference between the inside and the outside of a bubble. The effect is caused by the surface 
tension of the interface between liquid and gas. The Laplace pressure is given as: 
 
Equation 2.1 
 
– Pinside is the pressure inside the bubble  
– Poutside is the pressure outside the bubble  
– γ (also denoted as σ) is the surface tension  
– r is the radius of the bubble 
 
Stabilisation of micron sized gas bubbles (microbubbles) against such dissolution has been 
shown to be achieved by the creation of a radial shell, typically composed of a polymer or 
surfactant such as a phospholipid (Fox & Herzfield 1954; Strasberg 1959). The amphiphilic 
nature of phospholipid molecules results in their accumulation and ordering at the gas-liquid 
interface with the hydrophilic head-group region exposed to the aqueous phase, whilst the 
hydrophobic tail region of the lipid is oriented towards the gas phase (Figure 2.1) (Tanford 
1980). The phospholipid molecules therefore tend to self-assemble and form a monolayer 
shell at the surface of a gas bubble at appropriate temperature and concentration. These 
phospholipid shells are highly flexible and are capable of accommodating surface area 
changes of at least 40 % for condensed monolayers (Needham & Kim 2001). Such flexibility 
  ∆P = Pinside - Poutside = 2γ, 
                r 
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may be due to the ability of phospholipid monolayers to expand through multiple phase 
transitions (i.e. liquid condensed, liquid expanded, as the lateral surface pressure is reduced 
and the area per lipid molecule is increased) (Needham & Kim 2001).  
 
 
 
 
 
 
 
 
Figure 2.1 Schematic representation of a lipid-coated microbubble. The hydrophilic head-group region 
exposed to the aqueous phase, whilst the hydrophobic tail region of the lipid is oriented towards the gas phase. 
 
Lipid-coated microbubbles are important in biomedical applications because of their potential 
as ultrasound contrast agents and drug and gene delivery vehicles. In the following sections, 
some of the applications of microbubbles are summarised. 
 
2.1.1 Microbubbles and ultrasound 
Ultrasound (US) is one of the most common medical imaging methods used therapeutically. 
US imaging has developed into a very successful modality in clinical diagnosis because it can 
provide real-time images of soft tissue structures and blood flow without ionising radiation. 
Ultrasound waves have frequencies greater than 20 KHz (Zagzebski 1996) and above the 
audible range of humans (which is from 20 Hz to 20 kHz) and diagnostic ultrasound typically 
operates in the frequency range of 1 - 10 MHz.  
 
Standard or fluorinated phospholipid 
 
Air, nitrogen (N2) or perfluorohexane-saturated N2 gas 
 
GAS 
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Medical ultrasound is now a well-established technique for clinical diagnostics and is likely to 
play an important role in the foreseeable future (de Jong and Ten Cate 1996). However, 
ultrasound images do not have a very sharp contrast, and often the area being imaged is buried 
and shadowed by tissues. This problem can be resolved, in part, by using ultrasound contrast 
agents when imaging. Ultrasound contrast agents are exogenous substances that can be 
administered, either in the blood pool or in a cavity, to enhance ultrasonic signals (Ohlerth & 
O’Brien 2007). These contrast agents can enhance the acoustic backscattering of blood 
significantly. This has numerous advantages when conducting ultrasound imaging, including 
the ability to improve blood flow imaging, and enhancing the ability to determine the 
delineation of organs (Hasik et al 2002). The microbubbles in the contrast agents cause this 
enhancement of the backscattering signal (Phillip et al 1996). The key factor in the 
enhancement of acoustic backscattering is the high compressibility of a gas relative to water. 
Two types of responses are generated when the gas bubble is insonified by a US wave:  
1. The surrounding medium and the gas inside the bubble have a very large difference in 
acoustic impedance, which causes the bubble to reflect the US waves at its surface.  
2. However, more importantly the bubble is forced into volume pulsation, causing the 
bubble to resonate. The significance of this event results from the difference in the 
orders of magnitude between the wavelength of the US wave and the diameter of the 
bubble, with the wavelength of the US wave being two to three orders of magnitude 
greater. The ratio of the scattering cross sections to the physical ratio significantly 
increases by having the ultrasound signal set to the resonance frequency of the 
microbubble (Hoff 1996). This increase in scattering cross section results in an 
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increase in the backscattering of up to three orders of magnitude above the level 
frequencies (Hoff 1996).  
 
2.1.1.1 Classification of ultrasound contrast agents 
There are four classes or generations of ultrasound contrast agents and many of these agents 
have been approved for clinical use (Table 2.1) (Bauer & Solbiati 2003). Although the 
approved indications are restricted, ultrasound contrast agents have also been used and tested 
widely for off-label indications in humans.  
 
Table 2.1 General classification of ultrasound contrast agents (Ohlerth & O’Brien 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generation Composition Characteristics Commercial agent 
(Manufacturer) 
Clinical 
approval in 
humans 
0 Free air microbubbles No lung passage  
 
 
1 Air microbubbles  
covered by a 
galactose and 
palmitic acid shell  
Lung passage Levovist (Schering 
AG) 
EU, Canada 
2 Coated inert gas 
microbubbles formed 
by a perflutren lipid 
microspheres  
Increased stability Definity (Bristol–
Myers Squibb) 
USA, 
Canada 
  Imagent (Alliance) USA 
   Optison (Amersham 
Health, Inc.) 
EU, USA, 
Canada 
   Sonovue (Bracco) EU 
3 Gas/air microbubbles, 
hard shell  formed by 
a thin layer of a 
biodegradable 
cyanacrylate polymer  
Controlled 
acoustic 
characteristics 
SHU 563 (Schering 
AG) 
– 
   Bispheres (Point 
Biomedical) 
– 
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Initially contrast agents were hand-made through agitating the agents in a physiological saline 
solution prior to injection. Using this method free air microbubbles are produced however, 
they cannot pass the capillary bed of the lungs because of their large size (50 µm), but hand-
made agents have the capability to diagnose an intra or extracardiac right to left shunt 
(Ohlerth & O’Brien 2007). The persistence and stability of the microbubbles was increased 
using two principal methods: 1) the selection of gases with low diffusion coefficient and 2) 
the encapsulation of the bubble with or without surfactants. This has led to the development of 
the first generation of transpulmonary contrast agents using air as the gas in the microbubbles 
covered by a shell. Levovist is one of the first generation contrast agents to be investigated 
(Quaia 2005; Ohlerth & O’Brien 2007). Levovist has a mean diameter of 2 - 3 µm and is 
characterised by air microbubbles covered by a galactose and palmitic acid shell. The shell 
allows the microbubble recirculation and capillary passage in addition to increasing the 
stability of the microbubble (Ohlerth & O’Brien 2007).  
 
To achieve better stabilisation and lower microbubble diffusion, the second generation of 
ultrasound contrast agents use insoluble gases. The survival of the microbubble is increased 
thereby increasing the diagnostic window. In addition, after intravenous (IV) bolus injection 
the half-life is greater than 5 minutes (Ohlerth & O’Brien 2007). One group of second-
generation ultrasound contrast agents is composed of perfluorocarbon-filled (PFC) 
microbubbles, which have a higher molecular weight and a longer residence time in blood. 
Table 2.2 lists solubilities and other characteristics of some PFC and other materials useful in 
making microbubbles. 
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Table 2.2 Physical characteristics of materials used for making microbubbles and emulsions (Unger et al 
2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in the above table, perfluoropropane and perfluorobutane are both relatively 
insoluble and are gases below room temperature. However, perfluoropentane is a liquid at 
room temperature and boils to gas at temperatures above 29.5 oC. In the United States, there 
are currently two perfluoropropane-based microbubble products marketed for diagnostic 
imaging with ultrasound. One of these products, Definity®, was developed by ImaRx and is 
currently marketed by Bristol-Myers Squibb for diagnostic ultrasound imaging. The other 
currently marketed product is Optison®, microbubbles stabilised by human serum albumin 
(Table 2.1).  
 
Second-generation ultrasound contrast agents also have another group composed of sulphur 
hexafluoride-filled microbubbles, e.g. Sonovue (Table 2.1). Sulphur hexafluoride-filled 
microbubbles have a number of advantages ranging from the prolonged stability in the vial 
(up to 6 hours), and the peripheral blood (half-life of 6 minutes), and the uniformity of their 
size, which improves backscattering and harmonic behaviour at low acoustic power. The 
Compound Molecular weight Boiling point (oC) Solubility in water 
Nitrogen (N2) 28 -195.79 Sparingly 
Sulfur hexafluoride (SF6) 147.07 -82.7 Sparingly 
Perfluoroethane (C2F6) 138.01 -78.1 N/A 
Perfluoropropane (C3F8) 188.02 -36.7 Insoluble 
Perfluorobutane (C4F10) 238.04 -2 Insoluble 
Perfluoropentane (C5F12) 288.05 29.5 Insoluble 
Perfluorohexane (C6F14) 338.06 59-60 Insoluble 
Perfluorooctylbromide (C8F17Br) 499 143 Insoluble 
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prolonged stability in the peripheral blood maybe due to a high molecular weight gas with low 
solubility in water which confers a good resistance to pressure changes (Schneider 1999). 
Sonovue, similar to Levovist at low acoustic pressures, produces a clinically useful signal and 
a non-linear response limiting microbubble destruction (Ohlerth & O’Brien 2007). Third 
generation agents (e.g. Bispheres; Table 2.1) use the stabilisation of a hard shell (polymer 
shells) and contain either air or perfluorocarbons resulting in much longer persistence time 
(Leen & Horgan 2003).  
 
2.1.2 Microbubbles and magnetic resonance imaging (MRI) 
Magnetic resonance imaging (MRI) is frequently used within medicine as a diagnostic tool to 
produce cross-sectional images of soft tissue. MRI analyses the absorption and transmission 
of high frequency radio waves by water molecules in tissue placed in strong magnetic fields. 
Images are then created based on the differences in relaxation times of the MRI signal coming 
from different water densities within the biological material. Under current proposals, MRI 
could also be potentially used to quantify and map the oil content in the porous rock by 
measuring the different relaxation times of the MRI signal coming from oil and water, and this 
technology could be enhanced by the application of lipid-coated microbubbles. These can act 
as MRI pressure probes since when these microbubbles are present in a pressure varying 
medium, the change in microbubble size (resulting from changes in pressure) can cause a 
change in the MRI signal (Bencsik & Ramanathan 2001; Morris et al 2007). This would allow 
an accurate three-dimensional image of the pressure changes in porous rock and sandstone, 
which has particular application in oil recovery. Current techniques for oil recovery include 
drilling two wells into the non-porous layer. Water and detergents is then pumped into the first 
hole, which forces the oil out through the second hole (Figure 2.2). In these applications 
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between half and up to two-thirds of the produced oil returns. The remainder is trapped in the 
oil reservoir by various means. Therefore, oil recovery using such methods is often low with 
oil being retained in smaller porosity regions. The combination of MRI and microbubbles 
could potentially address this by offering the ability to investigate and determine appropriate 
fluid pressures required to enhance oil recovery from the smaller pore regions of the rock, thus 
enhancing the efficiency of oil extraction (Figure 2.2).  
 
 
 
 
 
 
 
 
 
Figure 2.2 Schematic representation of recovery of oil from porous rock. This usually involves drilling two 
wells into the non-porous layer. Water and detergents is pumped into the first hole, which forces the oil out 
through the second hole. Lipid-coated microbubbles can be pumped into porous rock. As the microbubbles flow 
into porous rock they will change size to fit into the various pores. As they change size the pressure inside will 
change, so with different pressures there are different MRI signals. Therefore the MRI signal can be measured 
and information on the porosity of the stone where the oil is trapped can be obtained (Rentech 2009).  
 
Similar microbubbles have also been demonstrated as an effective contrast agent for non-
invasive manometry using MRI (Alexander et al 2006). The authors suggested the potential 
for detecting intravascular pressure with the aid of a lipid-coated microbubble contrast agent. 
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While the early experimental results in vitro have shown this successfully, an in vivo use of 
this technique for early detection of pulmonary hypertension was limited by inadequate 
sensitivity. Furthermore, it has been shown that using MRI, a gas encapsulated within 
suspended micrometer-sized phospholipid monolayer spheres (liposomes) causes changes in 
nuclear magnetic resonance (NMR) signal intensity, as a result of fluid pressure changes 
(Alexander et al 1996). The technique presented here again relies on compressible 
microbubbles suspended in a medium containing virtually unrestricted water to generate 
contrast to pressure. The microbubbles generate perturbations in the static magnetic field, 
which are dependent on their radii. A change in pressure causes a change in radius, which 
induces variations in signal intensity and relaxation due to water molecule diffusion (Morris et 
al 2008).  
 
2.2 Aims and objectives 
The aim of the experimental work reported in this chapter was to develop and characterise 
lipid-based microbubbles as potential contrast agents. To achieve this, the objectives were: 
• Initially looking at potential characterisation methods for comparing and evaluating 
microbubble sizing methods using three techniques. This consisted of two different 
laser diffraction techniques and microscopic imaging analysis to ensure reproducibility 
and reliability of sizing data. 
• Secondly, four different methods of producing lipid-coated microbubbles were 
evaluated and compared in terms of stability and physico-chemical characteristics.  
• Potential formulations identified from these studies were then further investigated as 
contrast agents for fluid pressure. 
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2.3 Materials and Methods 
2.3.1 Materials 
Chemicals      Supplier  
Chloroform 
Cholesterol (Chol) 
Citric acid 
Gellan gum (CP Kelco’s Kelcogel AFT) 
Headspace vial (beveled top, flat bottom) 
ISOTON II diluent 
Pluronic-F68 
Polyethylene-glycol distearate 
Methanol 
Phosphate buffered saline tablets (PBS) 
Perfluoropropane 
Perfluorohexane 
Sodium chloride (NaCl) 
Sodium bicarbonate (NaHCO3) 
Tris (ultra pure) 
 
Lipids 
3β-[N-(N’,N’-(dimethylaminoethane)-
carbamoyl] Cholesterol  (DC-Chol) 
1,2-distearoyl-sn-glycero-3-phosphocholine  
     (DSPC) 
Thermo Fisher Scientific, Loughborough 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
CP Kelco, USA 
Sigma-Aldrich, Poole, Dorset, UK 
Beckman-Coulter, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Thermo Fisher Scientific, Loughborough 
Sigma-Aldrich, Poole, Dorset, UK 
Fluorochem Ltd, Derbyshire, UK  
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Biomedicals, Inc. Ohio, USA 
 
Supplier 
Avanti lipids, Alabaster, AL, USA 
 
Avanti lipids, Alabaster, AL, USA 
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1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) 
1,2-dipalmitoyl-sn-glycero-
phosphoethanolamine-N-(Lissamine 
Rhodamine B Sulfonyl) (Ammonium Salt) 
Avanti lipids, Alabaster, AL, USA 
 
Avanti lipids, Alabaster, AL, USA 
 
The perfluoroalkylated phosphatidylcholine (F-GPC) was synthesised and obtained from the 
Institute Charles Sadron, France. 
 
2.3.2 Methods  
2.3.2.1 Preparation of air-filled microbubbles by homogenisation 
Air-filled microbubbles were prepared by modifying the method previously described by 
Unger et al (1999). 50 mg of DSPC was transferred into a 50 ml container and was 
homogenised with 5 ml of double-distilled water in the presence or absence of desired 
amounts of cholesterol and/or PEG-distearate and homogenised for 4 minutes below the phase 
transition temperature (Tc) of the lipid using a high-speed homogeniser (Ultra-Turrax T8, UK) 
(Figure 2.3). A thick foam comprising of air-filled microbubbles was produced over the 
aqueous medium. 
 
 
 
 
 
 
 
Figure 2.3 Schematic representation of microbubble formation by the homogenisation process.  Lipid 
powder is hydrated in water, homogenised below the phase transition temperature (Tc) of the lipid. Following 
homogenisation, thick foam of microbubbles was formed. 
Lipid powder 
 
  
Lipid powder is hydrated in 
water, homogenised under 
high sheer below phase 
transition temperature (Tc) of 
lipid. 
Thick foam of 
microbubbles is formed. 
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2.3.2.2 Preparation of nitrogen-filled (N2) microbubbles by homogenisation 
N2-filled microbubbles were prepared as described above, but during homogenisation the 
headspace above the dispersion was filled with N2 gas. The N2 gas was passed into the 
container via a syringe needle with the tip of the needle placed at the top of the dispersion. 
Following homogenisation, a thick foam comprising of N2-filled microbubbles was produced 
over the aqueous medium.  
 
2.3.2.3 Morphological analysis using microscopic imaging analysis 
Microbubbles were viewed under an optical light microscope (Zeiss Axioskop, Germany) 
fitted with a colour Axio camera. Photomicrographs were obtained to assess the 
morphological characteristics such as microbubble size, shape and aggregation. 
 
2.3.2.4 Fluorescent staining of microbubbles 
For fluorescent staining either fluorescein sodium was included in the aqueous phase or a lipid 
based dye 1,2-dipalmitoyl-sn-glycero-phosphoethanolamine-N-(Lissamine Rhodamine B 
Sulfonyl) included to the lipid phase. The resulting fluorescent stained microbubbles were 
viewed under the optical microscope and photomicrographs taken.  
 
2.3.2.5 Production of multilamellar vesicles (MLV) 
MLV were prepared by the lipid-hydration method first observed by Bangham et al (1965). 
The lipids used throughout these experiments were dissolved in either chloroform:methanol 
(9:1 v/v) for the preparation of bubble liposomes or only chloroform (10 v/v) for the 
preparation of microbubbles by gas releasing chemical reaction as detailed in Table 2.3. The 
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required lipid solutions were placed in a 50 ml round-bottom Quick-fit flask and the solvent 
was removed by rotary evaporation at 37oC. This yields a thin lipid film on the walls of the 
flask, which was flushed with oxygen-free nitrogen (N2) in order to ensure complete removal 
of all solvent traces. The dry lipid film was hydrated by addition of 2 ml of double distilled 
water (ddH2O) or with sodium bicarbonate (NaHCO3) in the case of microbubbles prepared 
by gas releasing chemical reaction (as described later) and agitated vigorously until the thin 
lipid film was completely dissolved and transformed into a milky suspension. The hydration 
of the lipid film was maintained above the gel-liquid crystal transition temperature Tc of the 
phospholipid (>Tc) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), has a Tc above 55 oC. 
Therefore, the hydration medium added to hydrate the lipid film was pre-warmed to a 
temperature above 55 oC and the liposome solution was maintained at this temperature during 
liposome formation. 
 
Table 2.3 The concentration and the volumes used in the preparation of microbubbles in chloroform (10 
v/v). Formulations were prepared such that they had a total concentration of 16 µmoles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation  
Molar ratio (%) 
DSPC (µl 
 10 mg/ml 
Cholesterol (µl) 
10 mg/ml 
PEG 
distearate (µl) 
10 mg/ml 
DC-Chol (µl) 
10 mg/ml  
DOPE (µl)  
10 mg/ml 
 DSPC (100 %) 1264 µl     
 DSPC: Chol (50:50 %) 632 µl 309 µl    
 DSPC: Chol:PEG 
distearate (47.5:47.5:5 %) 
600 µl 294 µl 74.4 µl 
 
  
 DSPC:Chol:PEG 
distearate (45:45:10 %) 
 DSPC:Chol:DC-Chol 
(33:33:33%) 
570 µl 
 
417 µl 
278 µl 
 
204 µl 
149 µl  
 
284 µl 
 
 DSPC:DOPE:DC-Chol 
(33:33:33%) 
417 µl   284 µl 393 µl 
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2.3.2.6 Production of small unilamellar vesicles (SUV) 
To generate SUV, the MLV produced were disrupted using sonic energy to fracture the large 
liposomes into smaller structures (< 100 nm). A probe sonicator (Soniprep 150) was used to 
produce SUV. The tip of the sonication probe was placed on the surface of the mixture. Table 
2.3 provides the details of the formulations, the concentration and the volumes used in the 
preparation of aqueous liposomes and microbubbles. 
 
2.3.2.7 Preparation of microbubbles by a gas releasing chemical reaction 
Formulations were prepared at specific ratios in chloroform (10 v/v) as shown in Table 2.3. 
MLV were prepared by the lipid-hydration method as discussed previously in section 2.3.2.5. 
Following hydration of lipid film using an aqueous solution of 0.1 M sodium bicarbonate 
(NaHCO3), the flask was briefly sonicated using a water bath sonicator. The liposome 
suspension was then dialysed against a large volume of 0.1 M sodium chloride (NaCl) 
solution for about 10 minutes, and then 0.1 M citric acid solution was added into the 
suspension and incubated for several minutes. By adding acid solvent into liposome 
suspension, hydrogen ions diffused through the membrane phase of the lipid particles and 
initiated carbon dioxide (CO2) formation (Liu et al 2005) (Equation 2.2). The actual product is 
sodium citrate.  
Citric acid + NaHCO3 (s) + H2O (l) → H2O (l) + CO2 (g) + products (Equation 2.2)  
 
2.3.2.8 Preparation of microbubbles by sonication  
Fluorinated microbubbles were prepared using the method as described by Gerber et al 
(2006). Fluorinated surfactant F8H11PC was mixed with Pluronic F-68 at a molar ratio of 10:1 
64 
 
in ISOTON II at a final concentration of 20 mM. Homogeneous dispersions were obtained 
after magnetic stirring for 12 hours at room temperature. The dispersions were sonicated using 
a Vibracell sonicator operating at 20 kHz with a total output power of 600 W. The dispersion 
was pre-sonicated for 30 seconds, at 30% power whilst keeping the tube immersed in a 
cooling bath to maintain the sample at room temperature. The dispersion was then sonicated 
for 15 seconds at 50 % power whilst keeping the headspace above the dispersion filled with 
N2 saturated with perfluorohexane (C6F14). Following sonication, the gas flow was stopped 
and 14 ml of ISOTON II diluent was added to the bubble dispersion before turning the tube 
upside down three times. Microbubbles were formed with a fluorinated lipid constituting the 
shell component and perfluorocarbonated gas as the internal compartment (Figure 2.4).  
 
 
 
 
 
 
 
Figure 2.4 Schematic representation of microbubble formation by the sonication process. 1. The lipid is 
produced by adding perfluoroalkyl chains to a lipid molecule. 2. Powdered lipid is hydrated in isotonic diluent in 
a three neck round bottom flask. 3. N2 gas is bubbled through perfluorohexane and into the headspace above the 
lipid suspension. 4. The third neck provides access for a probe type sonicator, which is used for 45 seconds at 20 
kHz to generate PFC gas microbubbles, coated with a PFC lipid membrane. 
 
2.3.2.9 Preparation of bubble liposomes 
Formulations were prepared at specific ratios in chloroform:methanol (9:1 v/v) as shown in 
Table 2.3. MLV were prepared by the lipid-hydration method (as discussed previously in 
section 2.3.2.5). Following this, MLV were sonicated to produce SUV (as discussed 
previously in section 2.3.2.6). Bubble liposomes were prepared from liposomes and 
PFN2 
collect
N2
Sonicator
2
1
3
4
4
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perfluoropropane gas. The 6 ml sterilised vials containing 2 ml of liposome suspension were 
filled with perfluoropropane gas, capped and then pressurised with perfluoropropane gas. The 
vial was placed in a bath type sonicator for 10 - 15 minutes to form bubble liposomes (Suzuki 
et al 2007). 
 
2.3.2.10 Determination of size and zeta potential  
The size of MLV was determined using laser diffraction particle size analyser Sympatec 
Helos, equipped with an R2 lens allowing measurements in the range of 0.25 - 87.5 µm 
(Sympatec Limited, UK). Particle sizes were measured three times and the average expressed 
as the volume mean diameter (vmd) in micrometres (µm). For SUV, sizes were determined 
using a ZetaPlus (Brookhaven Instrument Corporation, NY) using the photon correlation 
spectroscopy (PCS) technique. PCS is based on the theory that the observed time dependency 
of the fluctuations in intensity of scattered light from a colloidal dispersion, is a function of 
the rate of diffusion, or Brownian motion of the scattering particles and hence their size in 
suspension (Tscharnuter 2000; Gun’ko et al 2003). For analysis, the liposome suspension was 
diluted as appropriate using ddH2O or in citric acid for microbubbles prepared by the gas-
releasing chemical reaction and the measurements recorded at 25 ºC. The size reported for 
each sample was the average of three readings and each reading was a mean of measurements 
recorded for 3 minutes. 
 
Surface charge was measured indirectly as zeta potential. The measurements were performed 
at 25 °C using a ZetaPlus instrument (Brookhaven Instrument Corporation, NY) using 50 µl 
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of the sample diluted to 2 ml in 0.1 M phosphate-buffered saline. The reported measurements 
are the mean of three samples, each of which is the average values of 10 readings.  
 
2.3.2.11 Colloidal stability and Polyelectrolyte theory  
Colloidal systems have been defined as dispersions of a finely divided phase in a dispersion 
medium (Skarba 2008). Dispersion medium, also identified as the continuous phase, is a 
liquid in most colloidal systems (Gurumoorthy & Khan 2011). The subdivided phase can be a 
solid, known as sol, or liquid, known as emulsion. Colloidal particles in colloidal systems can 
range in size from 1 nm to 1 µm (Hiemenz & Rajagopalan 1997). Since the particles exhibit 
Brownian motion they collide frequently with each other resulting in adherence and floc 
formation (flocculation). This destabilises the colloidal system. However, a dispersed state is 
maintained if the particles repel each other that stabilises the system. The attraction between 
colloidal particles results from van der Waals forces that range between 5 – 10 nm in many 
colloidal systems (Skarba 2008). Long-range repulsion (~ 10 nm) is therefore required 
between the particles to impart stability that should be at least as strong as the attractive force 
and comparable in the range of the attractive interaction (Gurumoorthy & Khan 2011). 
Colloidal particles surrounded with an electrical double layer (electrostatic or charge 
stabilisation) contribute to the stability. The theory by Derjaguin, Landau, Verwey and 
Overbeek (DLVO) (Skarba 2008) provides a very useful tool to understand colloid stability 
that is based on balance of forces between electrical double layers. For charged particles of 
similar nature such forces are repulsive and the long-range van der Waals forces are attractive. 
Thus, the sum of these two contributions dictates the potential energy of the particles. The 
colloidal system stability can be assessed against aggregation from the plot of potential energy 
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as a function of separation between the surfaces of charged colloidal particles (Figure 2.5). 
The presence of an electrolyte in colloidal systems facilitates the screening of the repulsive 
forces between electrical double layers. In the latter case, the potential energy curve has deep 
attractive minimum at small separations, the system will be unstable and aggregation will 
occur (Skarba 2008). 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Potential energy as a function of separation between the surfaces of charged colloidal particles. 
Dispersion is stable with no salt added (grey line), but at high salt concentration (black line) aggregation occurs. 
 
Polyelectrolytes have been defined as polymers carrying charged ionisable groups and 
depending on the charge, polyelectrolytes can be anionic or cationic (Skarba 2008). Synthetic 
polyelectrolytes have a wide range of industrial applications in oil recovery, paper making, 
mineral processing, etc. DNA and proteins are examples of natural polyelectrolytes (Skarba 
2008). Properties of colloidal particles can be substantially modified by attaching 
polyelectrolyte to the particle surface (Adamson 1997).  
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2.3.2.12 MRI studies - preparation of microbubbles as pressure probes for MRI 
To prevent buoyant advection of lipid coated microbubbles through the suspending medium, 
the gas-filled microbubbles were stabilised by a polysaccharide gel, gellan gum. The dry 
powder was dissolved in distilled water to a concentration of 2 % w/v whilst stirring 
vigorously for 8 hours under vacuum (450 torr) until a gas free homogeneous preparation was 
achieved. Lipid coated microbubbles were then blended with an equal concentration of 
glycerol before mixing with the gellan gum to a concentration of 1.25 % v/v. Having achieved 
a homogeneous preparation, the fluid can be used directly as an MRI contrast agent to 
pressure. The MRI experiments were performed using a 2.35 T Biospec small animal scanner 
(Bruker, Germany). The samples were placed in the holder, which is placed in the bore of the 
magnet. As the fluid is static, ultra fast imaging can be used without concern for flow 
artefacts. The fluid pressure was varied using a remotely connected syringe pump whilst the 
RARE sequence is run, monitored and recorded using a traditional piezoelectric pressure 
sensor (Figure 2.6). The average signal over the sample volume was plotted alongside the 
recorded pressure to test for correlation between external pressure and the signal intensity. A 
control sample, containing just gellan gum, was also tested to ensure that sensitivity is indeed 
coming from the presence of lipid coated microbubbles and not from trapped gas or other 
unintentional contrast mechanisms. 
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Figure 2.6 Schematic representation of the MRI experiment. The MRI experiments are performed using a 
2.35 T Biospec small animal scanner (Bruker, Germany). The samples and a control are placed in the holder, 
which is placed in the bore of the magnet. The fluid pressure is varied using a remotely connected syringe pump 
whilst the RARE sequence is run and monitored, recorded using a traditional piezoelectric pressure sensor. 
 
2.3.2.13 Statistical analysis 
For all experiments, means and standard deviations were calculated. To determine statistical 
significance the one way analysis of variance (ANOVA) was performed on all data, with the 
statistical significance determined to 0.05 confidence intervals (p<0.05). Tukey’s post hoc test 
was conducted to determine which conditions differ significantly from each other.  
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2.4 Results and discussion 
2.4.1 Particle size analysis of lipid-coated microbubbles 
Particle size measurements are used to monitor a number of industrial processes (Etzler & 
Deanne 1997). The most appropriate representation for the particle size distribution measured 
using a given technique will depend on the sensitivity of the technique. There are a range of 
methods employed in particle size analysis including laser diffraction, which measures the 
volume of material of a given size, since the light energy reported by the detector system is 
proportional to the volume of material present. This contrasts with counting-based techniques 
such as image analysis, which measure and report the number of particles of a given size 
(Malvern Instruments Ltd 2009).  
 
In this work, microbubble size distributions were compared and collected using two laser 
diffraction instruments: Sympatec Helos (UK) and Malvern Mastersizer (Model-S) (UK), to 
those distributions determined by microscopic imaging analysis. To investigate and develop 
protocols for sizing of microbubbles, DSPC microbubble formulations were prepared in the 
presence or absence of cholesterol and/or PEG-distearate and sizes determined.  
 
From Table 2.4, it can be seen that there is a good consistency between the size of 
microbubbles measured by the Sympatec Helos and those recorded by image analysis, with 
the measured sizes not being significantly different (p>0.05), whereas a large difference is 
seen with the sizes measured by Malvern Mastersizer. Comparison between the two laser 
diffraction instruments show that although they employ the same principle of laser diffraction, 
they produced significantly different particle size distributions (p<0.05). This difference 
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suggests that each manufacturer’s choice of numerical algorithms used to analyse the 
diffraction data are critical to the calculation of the particle size distribution. Sympatec Helos 
has a size measuring range of 1 µm to 87.5 µm, whereas Malvern Mastersizer measures 
materials from 0.02 µm to 2000 µm. The objective of this study was to identify a fast and 
reliable method to size the microbubble formulations; sizes obtained from image analysis 
were used as a benchmark of accuracy and the sizes obtained from Sympatec Helos have been 
shown to closely reflect these sizes. Therefore the Sympatec set-up was subsequently used to 
analyse microbubble particle diameters. The difference in size for the various formulations is 
discussed later in section 2.4.2.1. 
 
Table 2.4 Comparison of sizes produced by laser diffraction and by microscopic imaging analysis.  
Formulation Volume mean distribution (VMD) (µm)  
 Sympatec Helos Malvern Mastersizer Microscopy 
DSPC 30.9 ± 1.2 µm 139.1 ± 7.25 µm* 32.4 ± 5.81 µm 
DSPC:Chol 31.6 ±1.2 µm 119.9 ± 16.34 µm* 31.3 ± 3.78 µm 
DSPC:Chol:PEG-distearate 5 % 40.4 ± 1.1 µm 74.95 ± 42.72 µm* 32.5 ± 3.09 µm 
Results represent mean ± SD of triplicate experiments. (Significance, measured by one-way ANOVA is shown 
by *p<0.05). 
 
2.4.2 Preparation of microbubbles by homogenisation 
The formation of microbubbles by homogenisation is critically dependent on the phase 
transition temperature (Tc) of the lipid, with microbubbles being formed only at temperatures 
below this. The Tc is the temperature required to induce a change in the physical state of the 
lipid from the ordered gel phase, where the hydrocarbon chains are fully extended and closely 
packed, to the disordered liquid crystal phase, where the hydrocarbon chains are randomly 
oriented and fluid (Figure 2.7) (Lees 2008).  
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Figure 2.7 Schematic representation of phase transition temperature of lipids. The Tc is the temperature 
required to induce a change in the physical state of the lipid from the ordered gel phase, where the hydrocarbon 
chains are fully extended and closely packed, to the disordered liquid crystal phase, where the hydrocarbon 
chains are randomly oriented and fluid. 
 
The lipids are in their lowest energy state when their hydrophobic chains are together and 
away from hydrophilic regions, and their hydrophilic head groups are in the surrounding 
medium. When the lipids are subjected to high shear mixing in the presence of gas and liquid, 
the lipid molecules orient themselves to form a monolayer at the gas liquid interface of the 
microbubbles. Since DSPC has a Tc of 55 oC (Frezard 1999), it was possible to form 
microbubbles at room temperature ~ 25 oC. However, when the Tc of the lipid was below 
room temperature, the formation of microbubbles was not possible (results not shown). This 
was further supported with an attempt to produce microbubbles containing the cationic lipid 
3β-[N-(N’,N’-(dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) and/or 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE), which was unsuccessful due to the low Tc (i.e. 
below 4 oC in some instances) of both lipids, which when used the outlined methods resulted 
in the formation of  liposomes with an aqueous core rather than lipid-coated microbubbles 
(results not shown). 
 
Typical air-filled DSPC microbubbles prepared using the homogenisation method described in 
section 2.3.2.1 are shown in Figure 2.8. Four different formulations were tested to see: 
Lipid phase transition  
(Tc) 
 
Crystalline state 
Solid, gel-like phase 
Acyl chains 
ordered 
Polar head group 
Liquid-crystalline state 
Fluid phase 
Acyl chains 
disordered 
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1. The effect of cholesterol: cholesterol has been shown to improve the stability of 
aqueous liposomes bilayer (Gregoriadis 1979); therefore the potential of cholesterol to 
similarly influence microbubbles would be of value. 
2. The effect of PEGylation: liposomes with hydrophilic coatings are subject to less 
aggregation due to the highly solvated PEG groups on their surface. Close overlap of 
these liposomes is limited by steric hindrance, where on overlap the PEG chains would 
have to lose their conformational freedom and their water of hydration, thus increasing 
the free energy of the system (∆H) (Florence & Attwood 2005).  
 
Figure 2.8A shows microbubbles prepared by DSPC only. The microbubbles are shown to be 
heterogeneous in nature and range from 2 - 3 microns up to over 30 microns in diameter. The 
inclusion of cholesterol into the formulation (Figure 2.8B) results in a slightly more 
homogenous distribution. The addition of 5 % or 10 % PEG to this DSPC:Chol formulation 
(Figure 2.8C and D respectively) results in size distributions similar to that of DSPC only 
formulation (Figure 2.8A). Previous work investigating microbubbles prepared by the method 
(Vangala et al 2007a) also used microscopic analysis and found DSPC based systems to be 
more heterogeneous in size compared to 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) formulations. 
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Figure 2.8 Microscopic images of microbubbles. (A) air-filled DSPC microbubbles (B) DSPC:Chol (C) 
DSPC:Chol 5 % PEG-distearate (D) DSPC:Chol 10 % PEG-distearate on day 0. For all four formulations 
microbubbles were observed to be polydisperse. 
 
To confirm the liquid and gas phases within the lipid-based microbubbles, air-filled DSPC 
microbubbles were also prepared with fluorescein sodium in the aqueous phase and visualised 
under the light microscope with a fluorescent filter (Figures 2.9A and B, respectively). 
Microbubble structures can be seen with the aqueous background dyed fluorescent green, with 
the gas core of the microbubble showing no colour. Figures 2.9C and D show microbubbles 
prepared with the inclusion of the lipophillic dye 1,2-dipalmitoyl-sn-glycero-
phosphoethanolamine-N-(Lissamine Rhodamine B Sulfonyl). Again, microbubble structures 
can be seen under the light microscope and the rhodamine filter (Figure 2.9C) with the lipid 
layers being stained red by rhodamine (Figure 2.9D). Excess rhodamine-lipid is seen as 
precipitate in the aqueous phase.  
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Figure 2.9 Fluorescent staining of microbubbles. DSPC-based microbubbles with the inclusion of fluorescein 
sodium (A) light microscope and (B) fluorescent filter. The inclusion of 1,2-dipalmitoyl-sn-
glycerophosphoethanolamine-N-(Lissamine Rhodamine B Sulfonyl) (C) light microscope and (D) rhodamine 
filter. 
 
2.4.2.1 Stability of microbubbles prepared by homogenisation  
To investigate the stability of various lipid-coated microbubble formulations over time, the 
four formulations described in section 2.4.2 were prepared and stored at room temperature (25 
oC) for up to 28 days. After initial preparation, the microbubble size distribution, as measured 
by the laser diffraction technique, of air-filled DSPC microbubbles was 30.9 ± 1.2 µm. By day 
7 this had increased to 44.5 ± 8.3 µm, a 14 % increase (Figure 2.10), suggesting possible 
aggregation and/or coalescence of the microbubbles. Thereafter no significant change in size 
was noted. Given that cholesterol is an important component in lipid vesicles for improving 
the mechanical stability of the lipid bilayers (Zhang et al 2002; Gregoriadis 1979), studies 
were conducted to investigate the effect of its inclusion on microbubble characteristics. After 
A B 
 C D 
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initial preparation, formulations containing DSPC supplemented with cholesterol (1:1 molar 
ratio) were not significantly different in size from the microbubble formulation containing 
only DSPC. However, unlike the DSPC formulation, microbubbles formulated from 
DSPC:Chol (1:1) remained stable in terms of microbubble size over the 28 days (28.6 ± 4.1 
µm value with no significant change in size; p>0.05; Figure 2.10), suggesting that cholesterol 
has a stabilising effect on these microbubbles in a similar nature to aqueous-filled liposomes, 
which display reduced vesicle aggregation/coalescence (Liu et al 2000). 
 
The effect of PEG-distearate on microbubble size was also determined. The addition of 
coatings such as polyethylene-glycol onto the surface of liposomes is believed to act by 
forming a hydrophilic coat and causing steric hindrance at the membrane surface (Kenworthy 
et al 1995). PEG-distearate is the most widely used polymer to impart steric stabilisation, as it 
is quite soluble in organic solvents and water, and it is a very flexible polymer due to high 
anisotropy of its monomer i.e. high length:thickness ratio (Lasic & Papahadjopoulos 1995). 
The addition of PEG-distearate to DSPC and cholesterol microbubble formulations at 5 % and 
10 % was therefore investigated as a potential mechanism to stabilise the liposomes. For both 
formulations, initial microbubble sizes were significantly larger (p<0.05) than the DSPC:Chol 
formulations (40.4 ± 1.1 µm and 40.9 ± 3.8 µm respectively; Figure 2.10). However 
comparing the two PEG formulations, the 5 % PEG-distearate formulation remained stable 
over 28 days with no significant change in size (p>0.05), whilst the 10 % PEG-distearate 
microbubbles decreased in size over 28 days to 26.6 ± 7.4 µm (p<0.05) (Figure 2.10). 
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Figure 2.10 Size (µm) of air-filled DSPC supplemented with cholesterol and/or PEG-distearate at 5 % and 
10 %. Microbubbles were prepared by homogenisation, determined by dynamic light scattering technique on a 
Sympatec Helos (Sympatec Limited, UK) in ddH2O at 25 °C over 28 days. Results represent mean ± SD of 
triplicate experiments.  
 
As a thick foam was produced over the aqueous medium comprising of air-filled 
microbubbles, stability was also assessed in terms of foam volume over time (Figure 2.11). In 
general, foam consists of a non-equilibrium dispersion of gas in a relatively small quantity of 
solution usually containing surface-active materials. Surfactants such as phospholipids, 
proteins, or polymers, whose molecules cover the air-liquid interfaces to prevent collapse of 
the foam, are generally effective in increasing the foam stability (Shrestha et al 2006). From 
Figure 2.11, it can seen that the foam volume of DSPC microbubbles on day 0 was 6.3 ± 1.2 
ml and did not significantly change (p>0.05) over the 28 day period. Whilst the microbubbles 
containing cholesterol in the formulation were stable in terms of microbubble size, the overall 
foam was shown to be unstable; on day 0 the foam volume was 3.7 ± 0.3 ml, however, this 
volume decreased over time to 1.1 ± 1.3 ml (p<0.05; Figure 2.11) by day 28. This suggests 
that the foam was less stable following the addition of cholesterol to DSPC formulations and 
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the decrease in volume may be due to the collapse of the foam and the destruction of bubbles 
over time (Figure 2.11). It has been noted previously that when DSPC is intercalated with 
cholesterol this results in a lowering of the transition temperature with respect to the DSPC 
(Dopico 2007). Therefore, it is possible that by decreasing the transition temperature of the 
lipid mixture, cholesterol may have decreased the stability of the microbubbles and this is 
reflected by the decrease in foam volume.  
 
Similar to the microbubbles prepared with cholesterol, a decrease in foam volume was 
observed for both the 5 % PEG-distearate formulation (4.2 ± 0.3 ml on day 0 to 0.5 ± 0.1 ml 
by day 28) and 10 % PEG-distearate formulation (3.8 ± 1.5 ml on day 0, to 0.7 ± 0.0 ml by 
day 28) (Figures 2.12C and D). This suggests that the addition of PEG-distearate did not 
stabilise the microbubble monolayers against foam collapse (p<0.05).  Visual images of these 
foams over time are shown in Figure 2.12. 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Foam volume (ml) of air-filled DSPC supplemented with cholesterol and/or PEG-distearate at 
5 % and 10 %. Results represent mean ± SD of triplicate experiments.  
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Figure 2.12 Observation of foam volume (ml).  (A) air-filled DSPC microbubbles supplemented with either 
(B) cholesterol and/or PEG-distearate at (C) 5 % or (D) 10 %. The thick foam comprises of air-filled 
microbubbles which was produced over the aqueous medium i.e. water.   
 
 
2.4.3 Preparation of microbubbles by a gas-releasing chemical reaction 
As shown in the previous sections, using the homogenisation method it was possible to 
prepare a range of gas filled microbubbles from high transition temperature lipids. However, it 
was also noted that microbubbles containing cationic lipids could not be prepared using this 
method. Therefore a second method, based on the work of Liu et al (2005), was also 
investigated to prepare lipid-coated microbubbles. This method is based on the application of 
citric acid being added to an aqueous suspension containing liposomes, which have sodium 
bicarbonate (base) entrapped within them. Hydrogen ions from the acidic external solution 
can diffuse through the membrane phase of the lipid particles to initiate CO2 formation within 
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the liposomes. As citric acid is a triprotic acid, it can donate three protons when reacting with 
a base. Therefore in addition to the gas three salts can be produced, monosodium citrate, 
disodium citrate and trisodium citrate. H2O will also be produced in the reaction. As shown in 
Figure 2.13, after the addition of citric acid, CO2 gas bubbles started to form. These bubbles 
were previously shown to be entrapped within the intravesicular space of the liposomes (Liu 
et al 2005). Previous work by Quaia (2005) has also shown that such CO2 microbubbles can 
be employed to detect hepatocellular carcinomas and to characterise focal liver lesions after 
injection through a catheter placed within the hepatic artery, as for selective hepatic 
angiography.  
 
 
 
 
 
Figure 2.13 Images of microbubbles before and after pressurisation. DSPC:Chol (A) before and (B) after 
addition of citric acid and DSPC:DOPE:DC-Chol formulation (C) before and (D) after addition of citric acid. By 
adding an acid solvent into the liposome suspension, hydrogen ions diffuse through the membrane phase of the 
lipid particles to initiate CO2 formation. 
 
This method was therefore used to prepare microbubbles of the same lipid composition as 
those previously prepared by the homogenisation technique (i.e., DSPC, DSPC:Chol, 
DSPC:Chol:PEG 5 % and 10 %). Furthermore, two cationic formulations were prepared, 
DSPC:Chol:DC-Chol (33:33:33 % molar ratio) and DSPC:DOPE:DC-Chol (33:33:33 % 
molar ratio). These systems were prepared to investigate the possibility of formulating 
cationic microbubbles and to look at the effect of cholesterol and DOPE as helper lipids. 
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The sizes of microbubbles were determined using photon correlation spectroscopy. Whilst the 
measurement of these microbubbles was difficult to validate by this method (the buoyancy of 
the vesicles could interfere with the accuracy, or remaining aqueous-filled vesicles may also 
be present and therefore sized), the sizes determined were consistent with those of Liu et al 
(2005) and so were employed to further investigate the systems. From Table 2.5, it can be 
seen that in all cases the average sizes of the CO2 microbubbles formed were significantly 
smaller than those previously prepared by the homogenisation method (Figure 2.10 vs Table 
2.5 respectively) with microbubbles sizes of 2 microns or less. In addition, cationic 
microbubbles were able to be prepared by the CO2 microbubble method unlike the 
homogenisation method. 
 
Table 2.5 Size (nm) and zeta potential (mV) of microbubbles formed by gas-releasing chemical reaction.  
 
 
 
 
 
 
 
The size of the microbubble was measured in ddH2O and zeta potential was determined in 0.001M phosphate 
buffered saline (PBS) at 25 oC using a zeta potential analyser. Results represent mean ± SD of triplicate 
experiments. 
 
 
 
Formulation Size (nm)  Zeta Potential 
(mV)  
 DSPC 843.5 ± 176.4 1.6 ± 3.9 
 DSPC:Chol 983.3 ± 427.2 4.7 ± 2.7 
 DSPC:Chol:PEG-distearate 5 % 1768.0 ± 786.6 4.9 ± 3.8 
 DSPC:Chol:PEG-distearate 10 % 1439.0. ± 564.0 5.5 ± 3.7 
 DSPC:Chol:DC-Chol 270.8 ± 37.84 41.7 ± 1.6 
 DSPC:DOPE:DC-Chol 301.0 ± 29.2 45.2 ± 1.9 
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Figure 2.14 Images of CO2 microbubbles of various liposome formulations. (A) DSPC, (B) DSPC:Chol, (C) 
DSPC:Chol:PEG-distearate 5 %, (D) DSPC:Chol:PEG-distearate 10 %, (E) DSPC:Chol:DC-Chol, (F) 
DSPC:DOPE:DC-Chol liposome suspensions containing gas bubbles. After adding citric acid, CO2 gas bubbles 
started to form in the intravesicular space of the liposomes. 
 
Comparison between the six different formulations prepared by the gas-release method of Liu 
et al (2005) show that liposomes prepared from DSPC were 843.5 ± 176.4 nm, with the 
addition of cholesterol to DSPC formulations resulting in a slight increase in microbubble 
size, 983.3 ± 427.2 nm (Table 2.5). A similar observation with aqueous-filled liposomes has 
been reported by Szoka and Papahadjopoulos (1980) where it was found that the inclusion of 
cholesterol at a 1:1 molar ratio increased both the mean size and the size heterogeneity of the 
liposomes, as measured by negative-stain electron microscopy. The addition of PEG-
distearate to the DSPC-cholesterol microbubble formulations at 5 % and 10 % resulted in an 
increase in microbubble size to 1768.0 ± 786.6 nm and 1439.0 ± 564.0 nm respectively (Table 
2.5). It can be seen that as the concentration of PEG-distearate increased from 5 % to 10 %, 
there was a decrease in microbubble size. It is generally expected that the particle size of a 
liposome becomes larger by addition of PEG-lipid because the curvature of liposomal particle 
decreases as the component of lipid bilayer increases (Yoshida et al 1999). The particle size of 
liposomes was, however, seen to decrease with increasing amount of PEG-lipid added. This 
correlates with previous studies of aqueous-filled liposomes. For example, Garbuzenko et al 
A B C D E F 
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(2005) reported a decrease in liposome size and specific turbidity when PEG-DSPE mol% 
was increased in liposomes composed of hydrogenated soy phosphatidylcholine (HSPC). 
Similarly, Yoshida and co-workers (1999) found that the particle size of liposomes prepared 
from DPPC decreased with increasing mole fraction of PEG-lipid. The authors suggest that 
this is due to a steric repulsion among the PEG chains exposed from the outer leaflet of 
liposomal bilayer membranes, thereby increasing the curvature of liposomal particle.  
 
With regard to the zeta potential, from Table 2.5 it can be seen that the DSPC formulation had 
a charge of 1.6 ± 3.9 mV indicating a near neutral zeta potential. The addition of cholesterol to 
the DSPC formulation had no significant effect on the zeta potential (4.7 ± 2.7 mV; Table 
2.5). A similar result was found for the formulations containing PEG-distearate, where as the 
percentage of PEG increased to 10 %, there was only a slight change in zeta potential to 5.5 ± 
3.7 mV. This is supported by previous work (Malvern Instruments Ltd 2008), where it was 
found that with increasing concentration of PEG derivatised phospholipid, the zeta potential 
decreased. This decrease in zeta potential is caused by the presence of the PEG chains on the 
liposome surface reducing the mobility of the liposomes and hence the zeta potential. The zeta 
potential is defined as the difference in potential between the surface of the Stern layer (Stern 
(or shear) plane) and the distant electroneutral region of the bulk solution, and is measured by 
means of electrophoretic mobility in response to an electrical field (Shaw 1992). 
 
Microbubble formulations were also prepared containing the cationic DC-Chol lipid within 
the DSPC:Chol formulations. In comparison to DSPC:Chol, there was a decrease in measured 
size (983.3 ± 427.2nm for DSPC:Chol compared with 270.8 ± 37.8 nm for those containing 
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DC-Chol), and the zeta-potential increased to  41.7 ± 1.6 mV as would be expected with the 
DC-Chol systems (Table 2.5). Replacement of cholesterol with DOPE in these formulations 
resulted in no difference in the size and zeta-potential, with DSPC:DOPE:DC-Chol 
microbubbles being 301.0 ± 29.2 nm in size with a positive zeta potential of 45.2 ± 1.9 mV 
(Table 2.5). Both cholesterol and DOPE have been suggested to have a stabilising effect on 
aqueous liposomes (Malcharek et al 2005), and this stabilising effect is reflected by the 
similarity in size and surface charge for both formulations indicating that both cholesterol and 
DOPE are serving a similar role. DOPE has been used as a neutral complement lipid in 
cationic reagent mixtures; it is believed to facilitate transfection due to its tendency to form 
hexagonal phase structures at temperatures above 10°C (www.avantilipids.com).  
 
The method used above is based on a previous study reported by Liu et al (2005). The authors 
developed stable CO2 encapsulated echogenic liposome formulations and characterised the 
acoustic properties by ultrasound imaging and intensity analysis. In the present study, it can be 
concluded that this method has allowed the development of in situ CO2 gas bubble formation 
inside liposomes using a range of formulations including cationic lipids, which was a 
drawback with the microbubbles prepared by homogenisation. Whilst the systems were 
characterised and compared based on photon correlation spectroscopy methods, it cannot at 
this stage be confirmed if the characterised systems were lipid-coated microbubbles or 
remaining aqueous-filled systems. However using facilities available, the characterisation of 
the system gave some indication of the properties of the various systems. Studies to further 
investigate these systems were not undertaken as the microbubbles developed by this 
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technique had poor stability (being stable for only 45 minutes) and their use was subsequently 
discontinued, with no further analysis or development undertaken.    
 
2.4.4 Preparation of microbubbles by sonication 
A further method to prepare lipid-coated microbubbles was based on the use of fluorinated-
lipid perfluoroalkylated glycerol-phosphatidylcholine. Fluorinated-lipid based microbubbles 
(F-GPC) were produced according to the method of Gerber et al (2006) who previously 
compared air-filled microbubbles with a standard phospholipid 
dimyristoylphosphatidylcholine (DMPC) membrane against microbubbles filled with 
perfluorocarbonated-nitrogen gas and a fluorinated phospholipid F-GPC membrane. The 
authors found a synergistic stabilisation effect between the fluorinated lipid and fluorocarbon 
gas that allows long-lived microbubbles to be produced. This synergy led to microbubbles that 
have a half-life in an ultrasound field that can reach 70 minutes. PFCs, when used as part of 
the filling gas, retard bubble dissolution very effectively due to very low water solubility 
(Gerber et al 2006). Due to high biological inertness, high oxygen solubility and extremely 
low solubility in water, PFCs are being investigated for a range of biomedical uses, including 
intravascular oxygen transport, (Riess 2001) diagnosis and drug delivery.  
 
Following the protocol of Gerber et al (2006), microbubbles were prepared and were around 
500 nm in diameter and spherical in nature based on microscopic analysis (Figure 2.15). The 
sizes were also measured by photon correlation spectroscopy (PCS), and were measured to be 
357.0 ± 95.5 nm (Table 2.6). 
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Figure 2.15 Optical image of F-GPC (PFC) based microbubbles (A) optical image (B) microscopic image of 
F-GPC based microbubbles. Following sonication, microbubbles with a fluorinated lipid constituted the shell 
component and internal fluorocarbon gas component were produced.  
 
Table 2.6 Size (nm) of F-GPC based microbubbles.  
 
 
The size of the microbubbles was measured in ddH2O at 25 oC using PCS. Results represent mean ± SD of 
triplicate experiments. 
 
From Table 2.6, it can be concluded that using this method microbubbles of less than 500 nm 
can be prepared when fluorinated lipid constituted the shell component and internal 
fluorocarbon gas component is used. However, these microbubbles were also found to be 
unstable and break down over a short period (30 minutes) similar to microbubbles prepared by 
the gas-releasing chemical reaction (section 2.4.3). 
 
2.4.5 Preparation of ‘bubble liposomes’ 
The fourth method looked at the preparation of so-called ‘bubble liposomes’ (Suzuki et al 
2007). Bubble liposomes have a monolayer-covered air bubble similar to lipid-coated 
microbubbles, however, when prepared by the method of Suzuki et al (2007) they are 
commonly referred to as bubble liposomes. Previous studies have investigated liposomal 
bubbles for gene delivery (Suzuki et al 2007); the authors found that the combination of 
bubble liposomes and ultrasound exposure could be an effective and novel gene delivery 
Formulation Size (nm)  Polydispersity (PI) 
F-GPC microbubbles 357.0 ± 95.5 0.347 ± 0.04 
B A 
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method in vitro and in vivo. In the present work, bubble liposomes were produced by placing 
SUV liposomes in vials, supercharging with perfluoropropane gas and then placing the vial in 
a bath sonicator (Figure 2.16). Formulations were prepared with lipid compositions similar to 
those previously outlined in Table 2.7. 
 
 
 
 
 
 
Figure 2.16 Preparation of bubble liposomes. Bubble liposomes were produced by placing SUV liposomes in 
vials, supercharging with perfluoropropane gas and then placing the vial in a bath sonicator. 
 
Table 2.7 Size (nm) and zeta potential (mV) before and after pressurisation with perfluoropropane.  
The size (nm) of the microbubbles was measured in ddH2O and zeta potential (mV) was determined in 0.001M 
PBS at 25 oC using a zeta potential analyser. Results represent mean ± SD of triplicate experiments. 
 
Formulation Size (nm)  and zeta potential (mV)  
         Before pressurisation                                After pressurisation 
 
Size (nm) Zeta potential 
(mV) 
Size (nm) Zeta potential 
(mV) 
1. DSPC  181.7 ± 82.2 -0.34 ± 1.0 148.2 ± 85.4 -0.04 ± 0.4 
2. DSPC:Chol 120.6 ± 5.7 -1.24 ± 1.8 125.0 ± 2.3 -0.60 ± 0.4 
3. DSPC:Chol:PEG-
distearate 5 % 
140.1 ± 16.3 -0.87 ± 1.7 132.6 ± 11.8  0.28 ± 0.7 
4. DSPC:Chol:PEG-
distearate 10 % 
250.1 ± 23.5 0.27 ± 1.0 413.0 ± 41.8  -0.27 ± 0.5 
5. DSPC:Chol:DC-Chol  107.1 ± 6.0 9.0 ± 5.3 107.2 ± 3.3 0.60 ± 1.0 
6. DSPC:DOPE:DC-Chol 101.5 ± 5.0 8.5 ± 2.3 106.3 ± 3.5 1.2 ± 1.5 
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Sonication has long been used as a convenient method for producing SUV, with the smallest 
size possible. Following three minutes of sonication of MLV, the sizes of the liposomes 
ranged from 100 to 250 nm (Table 2.7). However, it can be seen that the size of the liposomes 
produced depended on lipid concentration and composition. After three minutes of sonication, 
the 10 % PEG formulation was found to have a size of around 250 nm compared to the 
cationic formulations, which were around 100 nm in size. Given the hydrated PEG on the 
surface of liposomes is reported to extend around 3 - 5 nm (depending on the PEG molar 
mass) (Medscape 2010) from the surface of the vesicles, this would not be responsible for the 
increased measured size however it may be due to the presence of 10 % PEG causing a 
reduced curvature of the vesicle construct and a subsequent larger vesicle size (Schiffelers et 
al 2006). Alternatively it has been suggested, that the vesicle size may start to increase after a 
minimum size has been achieved, due to vesicle fusion resulting from colliding of vesicles in 
the process (Zhang et al 2002).  
 
Following pressurisation, the sizes of the microbubbles formed were again measured. The 
DSPC systems were measured at 148.2 ± 85.4 nm with a zeta potential of -0.04 ± 0.4 mV. The 
addition of cholesterol to the DSPC formulations resulted in slightly smaller microbubble size 
of 125.0 ± 2.3 nm with a surface charge of -0.60 ± 0.4 mV. The addition of PEG-distearate at 
5 % to DSPC and cholesterol formulations resulted in microbubble sizes of 132.6 ± 11.8 nm. 
However at 10 %, an increase in microbubble size was found 413.0 ± 41.8 nm. As previously 
reported, the addition of PEG-distearate to the phosphate head group of the lipid may have 
improved the longevity and stability of the liposomes. The addition of PEG to lipids is useful 
in that the liposomes are significantly stabilised, their size distribution becomes more narrow, 
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and a mobile non-rigid surface is created on the outside of the liposome (Heldt et al 2001). 
The addition of a cationic lipid, DC-Chol, to DSPC and cholesterol formulations resulted in 
microbubble sizes of 107.2 ± 3.3 nm and a surface charge of 0.60 ± 1.0 mV. The addition of 
DOPE to DSPC and DC-Chol formulations resulted in microbubble size of 106.3 ± 3.5 nm 
and a surface charge of 1.2 ± 1.5 mV. Interestingly the zeta potentials of the cationic 
liposomes were significantly lower than previously measured prior to pressurisation (Table 
2.7). 
 
However from Table 2.7, it can be seen that there is very little difference in the sizes of all 
formulations and zeta-potentials of the non-cationic formulations of the samples before and 
after pressurisation. It is therefore difficult to justify if indeed gas is incorporated within these 
systems. Figure 2.17A-L shows each of the formulations before and after pressurisation and in 
some cases a change in visual turbidity is noted. However again this does not support a 
conclusion that gas was incorporated within lipid constructs. Previous work (Suzuki et al 
2007) used ultrasound imaging to confirm that the perfluoropropane gas was trapped within 
the bubble liposomes and echo signals were apparently enhanced when compared with 
conventional PEG-liposomes. However, Pitt & Husseini (2009) have suggested that there is 
no experimental or theoretical evidence to substantiate the claim that perfluoropropane gas is 
trapped within the bubble liposomes. Pitt & Husseini (2009) have argued that the authors have 
not presented any physical studies or theoretical arguments that prove that the resulting 
product consists of the gas trapped within the liposomes. Since liposomes are vesicles with 
one or more bilayers of amphiphilic surfactant surrounding an aqueous interior, it has been 
suggested that there is no thermodynamic driving force that would induce the hydrophobic 
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PFP gas to form bubbles inside the aqueous interior of the liposome (Pitt & Husseini 2009). It 
is likely that the pressurised gas would dissolve into the liposomal suspension and remove 
surfactant from the liposomes to form gas bubbles that are stabilised by a surfactant 
monolayer on their exterior surface (Pitt & Husseini 2009). Furthermore, it is well known that 
insonation in an ultrasonic cleaning bath redistributes the size of liposomes, most likely by 
shearing existing liposomes into smaller ones. The sheared and broken liposomes would 
provide the surfactant required to nucleate and grow the dissolved PFP into surfactant-
stabilised gas bubbles (Pitt & Husseini 2009). The authors suggest that the bubble liposomes 
produced may have been similar to Definity®, a gas bubble contrast agent made from PFP gas 
stabilised by a lipid shell that is similar in chemistry to what these authors used for their 
liposomes (Pitt & Husseini 2009). In Definity®, a single phospholipid monolayer forms the 
interface between the PFP gas and the aqueous environment. On the basis of the size 
distribution data and on the assumptions made above, we undertook no further validation or 
optimisation of the procedure.  
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Figure 2.17 Images of various bubble liposome formulations. DSPC (A) before pressurisation (B) after pressurisation became bubble liposomes in the vial. DSPC:Chol 
(C) before pressurisation (D) after pressurisation. DSPC:Chol:PEG-distearate 5 % (E) before pressurisation (F) after pressurisation. DSPC:Chol:PEG-distearate 10 % (G) 
before pressurisation (H) after pressurisation. DSPC:Chol:DC-Chol (I) before pressurisation (J) after pressurisation. DSPC:DOPE:Chol (K) before pressurisation (L) after 
pressurisation.  
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2.4.6 Formulations to proceed forward into subsequent studies 
Summarising from the above studies, microbubbles were produced using four 
different methods, by homogenisation, gas-releasing chemical reaction, sonication and 
pressurisation/agitation and the results are summarised in Table 2.8. 
 
Table 2.8 Summary of the characterisation data. 
Preparation method 
Parameter Homogenisation Gas release Sonication Pressurisation 
Vesicle size range 2-35 microns 300nm – 2µm  400nm 100-420nm 
Able to prepare 
cationic systems 
    
Stability 28 days 45 minutes 30 minutes 2 days 
 
All four methods showed differences in characterisation for each of the different 
formulations tested. DSPC microbubbles prepared by homogenisation were found to 
produce microbubbles in the size range of 30 µm, and were found to be the most 
stable over time (28 days). This formulation has previously been reported to remain 
stable under high pressures exerted in MRI (Vangala et al 2007a), and therefore was 
chosen for further MRI studies. Microbubbles produced by gas-releasing chemical 
reaction, sonication and pressurisation/agitation were all found to be unstable within a 
few hours. Of these three methods, sonication produced microbubble sizes of less than 
500 nm, which would be a useful comparison along with the DSPC microbubbles. 
Therefore this method was also chosen for further investigation. As discussed 
previously (Gerber et al 2006), a strong synergy between a fluorinated lipid and a 
fluorocarbon gas component has been suggested; this formulation was therefore 
compared to a standard phospholipid DSPC to determine the potential of these 
formulations as pressure probes in MRI. 
93 
 
2.4.7 MRI studies - stability of the microbubbles as pressure probes 
Whilst lipid-coated microbubbles were reported to be more stable than free gas 
microbubbles, they were still noted to be damaged as a result of the application of 
pressure. This was proposed to be due to the fragile properties of their membranes and 
the propensity of the gas to dissolve into the surrounding fluid causing drifts in the 
NMR signal (Morris et al 2008). This effect, coupled with their intrinsic buoyancy, 
limits their application as contrast agents in MRI. To circumvent this problem, 
polysaccharide gels have been used to increase the viscosity of the surrounding 
medium and have been shown to allow lengthy and stable imaging of microbubbles 
using MRI, whilst retaining high diffusion of water (Morris et al 2008). As the F-GPC 
based microbubbles were unstable in water and to ensure fair characterisation, both of 
the F-GPC based microbubbles and the DSPC microbubble formulation were 
combined with gellan gum (2 %) to a concentration of 3 % gas v/v. Preliminary trials 
of this showed an increase in the stability of the F-GPC based microbubbles such that 
they could be used for the duration of the MRI experiment (results not shown). Work 
described in here was done in collaboration with Dr Martin Bencsik at the School of 
Science and Technology, Nottingham Trent University. 
 
2.4.7.1 Comparison of stability of air-filled DSPC and F-GPC microbubbles  
To investigate the stability of microbubbles under various pressures, and hence their 
applicability as MRI contrast agents, both formulations were subjected to cycling 
pressure fluctuations and the MRI signal intensity measured. By comparing the signal 
intensity before and after cycling the system pressure, the drift in NMR sensitivity due 
to microbubble damage can be measured. The preparations (and a control gellan gum 
sample containing no microbubbles) were synchronously subjected to time varying 
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pressure using an in-house manufactured acrylic cell containing three independent 
chambers connected to a PC controlled syringe pump with Swagelok® (Solon, OH) 
connectors. The MRI experiments were performed using a 2.35 T Biospec (Bruker, 
Germany) small animal scanner. The samples were driven into the holder, which is 
placed in the bore of the magnet. The fluid pressure is varied whilst the RARE 
(Hennig et al 1986) MRI sequence is run, during which the pressure is monitored 
using a traditional piezoelectric pressure sensor. The control sample permits 
confirmation that the sensitivity is due to the presence of lipid-coated microbubbles 
and not trapped gas or other unintentional contrast mechanisms.  
 
Whilst the DSPC microbubbles were found to drift by 20 % signal change per bar, the 
F-GPC microbubbles were considerably more stable at 5 % signal change per bar 
(Figure 2.18). By increasing the pressure to which the system is cycled, it is possible 
to assess the value, at which the microbubbles begin to become damaged, which is the 
point at this drift is measurable. Using this method, the F-GPC microbubbles were 
found to withstand pressures up to 2.6 bar with minimal damage as opposed to the 
DSPC microbubbles, which were damaged at above 1.3 bar (Figure 2.18). 
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Figure 2.18 Comparison of stability of air-filled DSPC and F-GPC microbubbles. The two 
preparations were combined with an aqueous preparation of gellan gum (2 % w/v) to a concentration of 
3 % gas v/v to prevent migration and improve stability. The preparations and a control gellan gum 
sample containing no microbubbles were synchronously subjected to time varying pressure using an in-
house manufactured acrylic cell. The averaged signal found in each well (axis on the left hand side), in 
addition to the measured pressure (axis on the right hand side) are plotted against time. Experiment 
conducted at the School of Science and Technology, Nottingham Trent University. 
 
2.4.7.2 Comparison of air-filled and N2-filled DSPC microbubbles as pressure probes 
In parallel to these studies, DSPC microbubbles were also formulated containing N2 
gas rather than air. In terms of the size of the microbubbles, the N2 filled 
microbubbles were found to be slightly larger in size (35.9 ± 1.2 µm) compared to air-
filled DSPC microbubbles which were 30.9 ± 0.5 µm after initial preparation. In 
contrast to the air-filled microbubbles, the N2 gas filled microbubble formulation was 
found to remain stable over 28 days with microbubble sizes showing no significant 
change (p>0.05) over the 28 day period of the study (Figure 2.19A). In terms of foam 
volume (Figure 2.19B), a small decrease from 19.3 ± 1.2 ml on day 0 to 15.0 ± 0.5 ml 
on day 28 was found (p<0.05) (Figure 2.20).  
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Figure 2.19 (A) Size (µm) and (B) foam volume (ml) of air-filled and N2-filled DSPC 
microbubbles over 28 days. N2 gas filled microbubble formulation was found to remain stable over 28 
day period of the study and a small decrease in foam volume was found. Results represent mean ± SD 
of triplicate experiments. 
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Figure 2.20 Observation of foam volume (ml) of N2-filled DSPC microbubbles over 28 days.  
 
From the MRI studies, it was also found that the N2-filled microbubbles exhibited a 
sensitivity of 36 % signal change per bar and the air-filled microbubbles exhibited a 
sensitivity of 20 % signal change per bar at the start of the experiment (Figure 2.21). 
At the end of the experiment, the N2-filled microbubbles exhibited a sensitivity of 
30% signal change per bar (a loss of 16 % of sensitivity), whilst the air-filled 
microbubbles exhibited a sensitivity of 9 % signal change per bar (a loss of 55 % of 
sensitivity) (Figure 2.21). After the first cycle of pressure change, the sensitivity 
exhibited by the N2-filled microbubbles remained fairly constant whilst that of the air-
filled microbubbles demonstrates a continuous drop due to continuous bubble 
damage. This is a good indicator that the microbubbles containing N2 gas are 
considerably more stable than their air filled counterparts and may allow for 
significantly more stable measurements of pressure using MRI. 
N2-filled DSPC  
day 21 
N2-filled DSPC  
day 0 
N2-filled DSPC  
day 7 
N2-filled DSPC  
day 14 
N2-filled DSPC  
     day 28 
98 
 
 
 
 
 
 
 
 
 
Figure 2.21 A comparison of the time course of the signal sensitivity for air and N2-filled DSPC 
microbubbles. The two preparations were combined with an aqueous preparation of gellan gum (2 % 
w/v) to a concentration of 3 % gas v/v to prevent migration and improve stability. The signal sensitivity 
is determined for each cycle of pressure and plotted against time. Experiment conducted at the School 
of Science and Technology, Nottingham Trent University. 
 
2.5 Conclusion  
A novel contrast agent, which allows stable MRI measurements of fluid pressure over 
time, has been produced using lipid-coated microbubbles. Both the formulation of the 
microbubble shell and the gas incorporated were shown to influence stability and 
sensitivity: the addition of 5 % PEG and/or cholesterol was shown to stabilise the 
structures in terms of microbubble size. However, an overall decrease in foam volume 
was noted with such formulations and therefore microbubbles formulated from DSPC 
alone were adopted for further studies. The sensitivity of these systems could be 
improved using nitrogen rather than air within the microbubbles and the inclusion into 
polysaccharide gel counteracted their intrinsic buoyancy without reducing NMR 
sensitivity. However, their large size limits their medical application to non-parenteral 
routes. Biomedical applications of these systems may still include their application as 
novel contrast agents for imaging of sites accessible via non-parenteral routes such as 
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in bladder cancer or in the imaging of various pressure regions within joints and 
chronic joint disorders. Smaller F-GPC microbubbles were also prepared which can 
withstand higher pressures than the DSPC microbubbles and further refinement to 
improve their stability will allow their biomedical application to include 
echocardiography and other diagnostic ultrasound techniques, whilst the large 
microbubble systems may also be suitable for petrochemical applications.  
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Chapter 3 
Cellular responses of macrophages to liposomes and lipid-
coated microbubbles: in vitro studies 
 
Graphical Abstract: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A diagram of phagocytosis of particulate carriers by macrophages. Macrophages take 
up the carriers by the process of endocytosis. Drugs are released from the carriers 
following intralysosomal degradation of the carriers. 
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3.1 Introduction 
Liposomes are of considerable interest as carriers for the controlled delivery of drugs 
because many substances can be encapsulated in aqueous and lipid phases. One of the 
most well known observations in the field of liposome research is that intravenously 
(IV) injected liposomes are rapidly taken up by macrophages in the mononuclear 
phagocyte system (MPS), such as the liver and spleen (Gregoriadis 1988). More 
recent studies have shown that after intramuscular (IM) injection of cationic 
liposomes, an infiltration of macrophages was noted (Henriksen-Lacey et al 2010). 
Since this characteristic may be advantageous for directing antigens or 
immunomodulating agents to macrophages, many investigators have used liposomes 
as adjuvants, depots for slow release of antigens, and targeting agents for delivery of 
antigens to macrophages, which are one of the antigen-presenting cells (APCs) 
(Gregoriadis 1990; Alving 1991). However, the changes liposomes exert in these cells 
with which they interact remain unresolved.   
 
3.1.1 Mononuclear phagocyte system (MPS) 
The mononuclear phagocyte system consists of a number of different cells. These 
include bone marrow monoblasts and promonoblasts, peripheral monocytes, and 
tissue macrophages (Ahsan et al 2002). Of these different cells, the major 
differentiating cells of the mononuclear phagocyte system are the macrophages. There 
are three types of macrophage precursors: monocytes, promonocytes, and monoblasts. 
These cells all come from a common progenitor termed the colony-forming unit 
granulocytes-macrophages. The least mature cell of the mononuclear phagocyte 
system, the monoblasts, differentiate into monocytes. For 24 hours they remain in the 
bone marrow before they enter the peripheral blood. The monocytes then migrate 
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from the peripheral blood to extravascular tissue where they differentiate into 
macrophages (Ahsan et al 2002). Macrophages colonise the liver (kupffer cells), lungs 
(alveolar-interstitial macrophages), spleen, lymph nodes, thymus, gut, and marrow 
(Ahsan et al 2002). Macrophages have a crucial role in host defence against a number 
of infectious agents, including viruses, parasites, bacteria, and protozoa. A variety of 
substances attract the macrophages to an infected area, which include bacterial 
components and endotoxins, complement components, immune complexes, and 
collagen fragments (Ahsan et al 2002). Once the macrophages reach the infected area, 
they use a variety of mechanisms to phagocytose and kill infectious agents. 
Macrophages take protein antigens from infectious agents and generate immunogenic 
fragments, which facilitate their important role in the induction and regulation of the 
immune response (Ahsan et al 2002). Liposomes have been evaluated as carriers to 
deliver encapsulated molecules to mammalian cells in vitro and in vivo. Once 
administered in the body, liposomes of conventional formulations are avidly removed 
from the circulation by the macrophages of the MPS (Katragadda et al 2000).  
 
3.1.2 Uptake of liposomes by macrophages 
A number of steps can describe the complex interaction of liposomes with phagocytic 
cells; cell surface adsorption, cellular intact vesicle uptake by an energy dependent 
mechanism and lysosomal degradation of the liposomes and their content (Figure 3.1). 
Liposome adsorption to the cell surface seems to be the rate limiting step, since it can 
be assumed that stably adsorbed vesicles are more susceptible to subsequent uptake 
than vesicles that are only loosely interacting with the cell surface (Ahsan et al 2002).  
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Figure 3.1 A diagram of phagocytosis of particulate carriers by macrophages. Macrophages take 
up the carriers by the process of endocytosis.     Drugs are released from the carriers 
following intralysosomal degradation of the carriers (Ahsan et al 2002). 
 
In order for the liposomes to deliver biologically active agents to mononuclear 
phagocytes, several conditions must be met i.e. macrophages in situ: liposomes must 
readily bind to and be phagocytosed by free and fixed phagocytes, they must prevent 
degradation of entrapped drug, they must retain the encapsulated agent for delivery to 
the intracellular compartment of the MPS cells and they must localise to macrophages 
in organs where metastases or macrophage-associated disorders occur (Fidler 1992). 
A number of factors of the intended liposomes determine the extent of liposome 
binding and ingestion by the macrophage. These include composition, type, size and 
surface properties of liposomes (Ahsan et al 2002).  
 
3.2 Aims and objectives 
The aim of the work presented in this chapter was to examine the effect of liposome 
formulations on macrophage cells, so as to assess their potential activation of 
macrophages using in vitro models.  
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Factors considered were: 
• Liposome composition 
• Liposome concentration 
• Incubation time of liposomes with macrophages in vitro. 
 
To achieve this, a murine macrophage J774 was used as the model cell line, which has 
been widely used in vitro because of its similar response to stimulation as naïve 
macrophages (Chen et al 1999; Stumpo et al 2003). To investigate macrophage 
responses in vitro, a range of markers were measured: 
 
1. Cell proliferation: using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Figure 3.2). 
The tetrazolium compound, MTS, in the presence of phenazine methosulfate (PMS), 
is converted to its formazan product by the dehydrogenase coenzymes, nicotinamide 
adenine dinucleotide phosphate (NADPH) or nicotinamide adenine dinucleotide 
(NADH), which only exists in metabolically active cells. The formazan product is 
water-soluble and can be quantitatively measured by absorbance at 490 - 500 nm 
(Cory et al 1991).  
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Figure 3.2 Structure of MTS tetrazolium and its formazan product. 
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2. Phagocytic activity: β-N-Acetylglucosaminidase (NAG, also known as N-acetyl-β-
D-glucosaminide), a lysosomal enzyme, is secreted by mammalian cells when 
phagocytosis takes place, and is a useful marker of phagocytic activity levels (Pettis et 
al 2000). Assay of NAG content can be undertaken using a colorimetric method based 
on the hydrolysis of 4-Nitrophenyl N-acetyl-β-D-glucosaminide (NP-GlcNAc) by 
NAG (Figure 3.3), and the consequent product o-Nitrophenol can be measured at 405 
nm (Product information of N-acetyl-β-D-glucosaminide assay kit). 
     
 
 
 
 
 
                
 
Figure 3.3 Reaction of NAG assay and relative compounds.  
 
Other cellular markers are available, including cytotoxicity and alkaline phosphatase, 
but initial studies focused on the cell proliferation and phagocytic activity markers. 
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3.3 Materials and methods 
3.3.1 Materials 
Chemicals     Supplier  
β-N-Acetylglucosaminidase (NAG) 
CellTiter 96® AQueous One Solution Cell 
      Proliferation Assay 
Chloroform 
Dulbecco's modified eagle medium (DMEM)  
ELISA plates (flat bottomed) 
Foetal bovine serum (Heat-Inactivated) 
Penicillin-streptomycin-glutamine (100X) 
Polyethylene-glycol distearate 
Methanol 
 
Lipids 
Cholesterol (Chol) 
3β-[N-(N’,N’-(dimethylaminoethane)-
carbamoyl] cholesterol  (DC-Chol) 
Dioleoylphosphatidylethanolamine (DOPE) 
1,2-distearoyl-sn-glycero-3-phosphocholine  
     (DSPC) 
Sigma-Aldrich, Poole, Dorset, UK 
Promega, Southampton, UK 
 
Thermo Fisher Scientific, Loughborough 
Invitrogen, Paisley, UK 
Grenier Bio-One Ltd, UK 
Invitrogen, Paisley, UK 
Invitrogen, Paisley, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Thermo Fisher Scientific, Loughborough 
 
Supplier 
Sigma-Aldrich, Poole, Dorset, UK 
Avanti lipids, Alabaster, AL, USA 
 
Avanti lipids, Alabaster, AL, USA 
Avanti lipids, Alabaster, AL, USA 
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3.3.2 Methods 
3.3.2.1 Resuscitation of frozen BALB/c cell line 
An ampoule containing BALB/c cells (murine macrophage-like cell line) was 
removed from liquid nitrogen storage and half submerged in a 37 oC water bath for 
approximately 2 minutes, until the cells had thawed. The outside of the ampoule was 
wiped with a tissue moistened with 70 % isopropanol, before placing into a sterile 
microbiological safety cabinet in order to maintain sterile conditions. Under sterile 
conditions, the ampoule lid was removed, and the cell solution was slowly pipetted 
into a 75 cm2 cell culture flask containing 20 ml of Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10 % foetal bovine serum (FBS) and 1 % 
penicillin / streptomycin / L-glutamine, in order to dilute the toxic effects of dimethyl 
sulfoxide (DMSO). The cells were incubated at 37 oC under sterile conditions in a 
humid 5 % CO2 conditions.   
 
3.3.2.2 Cell quantification 
Adherent BALB/c cells were brought into solution. From this cell suspension, 100 µl 
was removed and mixed with Trypan Blue. 10 µl of the Trypan Blue cell suspension 
was loaded onto a haemocytometer and viewed microscopically. The bright cells (i.e. 
viable cells) were counted and from this the cell concentration was calculated 
(including dilutions). The cells that stained blue indicated non-viable cells.   
 
3.3.2.3 Optimisation of cell number 
The concentration of macrophages was optimised using MTS assay by CellTiter 96® 
AQueous One Solution reagent, which is widely used for determining the number of 
viable cells in proliferation: Suzuki et al (2003) evaluated the effect of oxytocin on 
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proliferation of human endometrial endometriod adenocarcinoma cell lines; O’Hare et 
al (2005) measured the cell viability of Ba/F3 cells transfected with Bcr-Abl kinase; 
Garcia-Pedrero et al (2007) measured the cell proliferation of BT549 breast cancer 
cells. 
 
To establish working cell concentrations, macrophages were plated at serial 
concentrations of 0.01, 0.05, 0.1, 0.3, 0.5, 0.7 and 1 × 106 cells/well into a 96-well 
plate in 100 µl medium in triplicate, and 100 µl medium was also added into the plate 
in triplicate as blank. The plate was then incubated for 24 hours at 37 ºC in a humid 5 
% CO2 under sterile conditions to let macrophages adhere to the bottom of wells. 20 
µl CellTiter 96® AQueous One Solution reagent was added into each well followed by a 
4 hour incubation. The absorbance was read at 490 nm hourly to optimise the 
incubation time. The initial number of cells that produced an assay signal near the low 
end of the linear range of the assay (Product information of CellTiter 96® AQueous One 
Solution reagent) was selected. 
 
3.3.2.4 Optimisation of liposome concentration  
Macrophages were plated into 96-well plates at the cell number optimised in section 
3.3.2.3. To optimise the liposome concentration, the cationic liposome formulation 
DSPC:DOPE:DC-Chol was tested at concentrations of 0.05, 0.5, 5, 50 and 500 µg/ml.   
 
3.3.2.5 Preparation for assays 
Macrophages were plated into 96-well plates at the cell number optimised in section 
3.3.2.3, and the liposome concentration optimised in section 3.3.2.4. 100 µl of cells 
were loaded per well and subsequently incubated at 37 ºC in a humid 5 % CO2 under 
sterile conditions for 24 hours. The liposome formulations (prepared as described in 
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chapter 2) were re-suspended in culture medium at 5 µg/ml concentration and added 
to the wells to replace the supernatant in each well (Table 3.1); the supernatant of the 
untreated macrophage wells was replaced by fresh culture medium as control; 100 µl 
of culture medium in triplicate was used as background. The plate was ready for use 
in assays after 24 hour incubation. 
 
Table 3.1 Summary table of the formulations tested. Liposomes were prepared in a range of 
compositions and in some cases as either MLV or SUV (to compare the effect of vesicle size) and in 
the format of lipid-coated microbubbles, to compare gas versus aqueous-filled vesicles. 
 
3.3.2.6 Cell proliferation 
Cell proliferation was measured using the MTS assay with CellTiter 96® AQueous One 
Solution. Macrophages were plated and treated with liposome samples as described in 
section 3.3.2.5. 20 µl CellTiter 96® AQueous One Solution reagent was added into each 
well followed by a further incubation in a period which was also optimised in section 
3.3.2.3. The absorbance was measured at 490 nm. The reading of the background well 
was as used as a negative control; the reading of the untreated cell well was used as a 
positive control. 
 
3.3.2.7 Phagocytic activities 
Phagocytic activities were determined using a NAG assay with β-N-
Acetylglucosaminidase assay kit, following the product information. Macrophages 
were plated and treated with liposome samples as described in section 3.3.2.5. 10 µl 
Formulation Aqueous-filled liposomes Lipid-coated liposomes  
 MLV SUV Gas - Air Gas – Nitrogen 
DSPC √ √ √ √ 
DSPC:Chol √     
DSPC:Chol:PEG-distearate 5 % √    
DSPC:Chol:DC-Chol  √  √   
DSPC:DOPE:DC-Chol √    
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of supernatant in each well was mixed with 90 µl of substrate solution as test sample; 
2 µl of NAG control enzyme and 98 µl of substrate solution were mixed as positive 
control; 100 µl of substrate solution was used as the background; 300 µl of standard 
solution was used as the standard. The reaction components above were added into a 
96-well plate in triplicate. After incubation at 37 ºC for 10 minutes, the absorbance 
was measured at 405 nm. The concentration of NAG was calculated using the 
following equation: 
 
Units/ml = 
VenztimerdA405standa
DF0.30.05 A405blank)-e(A405sampl
××
×××
 
 
• Unit denotes that 1 unit will hydrolyse 1.0 µmole of 4-Nitrophenyl N-acetyl-β-
D-glucosaminide to p-nitrophenol and N-acetyl-β-D-glucosaminide per 1 
minute at pH 4.7 at 37 ºC. 
• A405sample denotes the absorbance of the sample at 405 nm. 
• A405blank denotes the absorbance of the blank at 405 nm. 
• 0.05 denotes the concentration (µmole/ml) of 4-nitrophenol in the standard 
solution. 
• 0.3 denotes the final volume (ml) of the reaction components after the addition 
of the stop solution. 
• DF denotes enzyme dilution factor, the value in this case is 100. 
• A405 standard denotes the absorbance of the standard solution at 405 nm. 
• Time denotes the incubation time (minutes). 
• Venz denotes the volume (ml) of the sample. 
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3.3.2.8 Statistical analysis 
For all experiments, means and standard deviations were calculated. To determine 
statistical significance the one way analysis of variance (ANOVA) was performed on 
all data, with the statistical significance determined to 0.05 confidence intervals 
(p<0.05). Tukey’s post hoc test was conducted to determine which conditions differ 
significantly from each other.  
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3.4 Results and discussion  
3.4.1 Optimisation of cell number 
Varying concentrations of macrophages were investigated using the CellTiter 96 
AQueous One Solution Cell Proliferation Assay in order to optimise the cell number for 
the assays. The initial number of cells per well that produced an assay signal near the 
low end of the linear range of the assay would be selected as the optimised cell 
number to be employed in further studies. The incubation time after the addition of 
CellTiter 96 AQueous One Solution reagent was also investigated in order to optimise 
the assay condition.  
 
The assay signals were determined hourly (up to 4 hours) (Figure 3.4). A general 
trend of increasing absorbance values with increasing cell numbers was noted. A 
comparison between the results showed that a longer incubation leads to higher 
absorbance levels which remained in the reading range of the micro-plate reader 
(Figure 3.4). However, the results of 2, 3 and 4 hour incubation, after the addition of 
the CellTiter 96 AQueous One Solution reagent, showed a larger and better signal range 
than that obtained after a 1 hour incubation. Therefore, a 2 hour incubation was 
chosen as the incubation time for all subsequent experiments, due to it offering the 
strongest linear correlation  (r2 = 0.928) compared with that of 3 hours (r2 = 0.894) 
and 4 hours (r2 = 0.924). Overall,  a cell count of 3 x 105 cells/well was chosen as the 
standard cell count number, due to it being near the low end of the linear range, 
therefore offering a range of responses to be measured. 
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Figure 3.4 Effect of cell number of macrophages on absorbance at 490 nm measured using the 
CellTiter 96® AQueous One Solution Cell Proliferation Assay. Cells were incubated for 1 to 4 hours 
after the addition of the CellTiter 96® AQueous One Solution reagent. Results represent mean ± SD of 
triplicate experiments. 
 
 
3.4.2 Optimisation of liposome concentration  
As it is well known, cationic liposomes are reported to show cytotoxic effects 
(McNeil & Perrie 2006). To optimise the liposome concentration, the cationic 
formulation DSPC:DOPE:DC-Chol was tested at a concentration of 0.05, 0.5, 5, 50 
and 500 µg/ml for further assays. It can be seen from Figure 3.5, that as the 
concentration of liposome increased, there was a reduction in the percentage of viable 
cells. At a liposome concentration of 500 µg/ml, the cell viability was around 60 %, in 
comparison to the least concentrated (0.05 µg/ml) having more than 95 % viable cells. 
5 and 0.5 µg/ml concentrations appear to be the optimum i.e. produced greater cell 
viability. Since the 5 µg/ml concentration has previously been reported for liposomes 
in cell culture studies (Majumdar et al 1992), this concentration was selected to be 
used for the rest of the formulations.  
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Figure 3.5 Effect of liposome concentration on cell viability. Cells were plated in triplicate at 3 x 105 
cells/well and the % cell viability of DSPC:DOPE:DC-Chol formulation added at liposome 
concentrations of 0.05, 0.5, 5, 50 and 500 µg/ml was determined. Results represent mean ± SD of 
triplicate experiments. 
 
 
3.4.3 Characterisation of liposomes 
The uptake of liposomes by resident, as well as cultured macrophages has been 
studied previously (e.g. Wassef et al 1984; Schwendener et al 1984; Ivanov et al 
1985). From these previous studies it is generally believed that cellular uptake of 
liposomes is mediated by adsorption of liposomes onto the cell surface and 
subsequent endocytosis. Early studies indicated that liposomes, which bind to the 
surface of some cells, are internalised through a coated pit-mediated pathway 
(Straubinger et al 1983; Chin et al 1989). However, the extent of liposome binding 
and subsequent ingestion by macrophages depends on a number of factors. These 
include composition, type, size and surface properties of liposomes. To investigate the 
interaction of liposome composition with macrophages a range of liposome 
formulations were prepared. Table 3.2 shows the size and the surface charge 
properties of the liposomes investigated.  
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MLV formulated from DSPC or DSPC:Chol showed no significant difference in their 
size (both 18 to 20 microns in size) or zeta potential (both near neutral) (Table 3.2). 
Sonication of the DSPC liposomes for 3 minutes produced small vesicles (126.9 ± 
12.6 nm), however, the zeta potential was not significantly different (Table 3.2). The 
inclusion of 5 % PEG-distearate to the DSPC:Chol formulation again caused no 
significant change in vesicle sizes of the MLV (18.2 ± 1.05 µm; Table 3.2). However 
the zeta potential for these formulations was significantly lower (p<0.05), which may 
reflect the highly hydrated PEG coating of the liposomes. Finally, two cationic 
liposome formulations containing DSPC in combination with the cationic lipid DC-
Chol and either DOPE or cholesterol were investigated. Interestingly, the MLV 
formed with these cationic formulations were significantly smaller in size (600 - 700 
nm) and cationic in nature compared to their neutral counterpart (Table 3.2). This may 
be a result of the reduced laminarity of the vesicles when cationic lipids are used: 
strong electrostatic repulsion on hydration may result in reduced bilayers and 
ultimately smaller vesicles (Perrie & Gregoriadis 2000a). The addition of cholesterol 
in replacement of the DOPE had no significant effect on the size, around 600 nm and 
the zeta-potential of 32 to 34 mV (Table 3.2). Previous reports have shown that 
sonication of cationic liposomes reduces their size but has no significant effect on 
their zeta potential (Perrie & Gregoriadis 2000a). Sonication of the cationic 
formulation DSPC:Chol:DC-Chol for 3 minutes were able to produce small vesicles 
(108.5 ± 22.5 nm), however, the zeta potential remained unchanged. 
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Table 3.2 Characterisation data for the various formulations. 
 
Formulation Moles 
(µmoles) 
Composition Size (nm)  Zeta Potential 
(mV)  
DSPC 
 
16 MLV 
 
18510.0 ± 8.4 
 
-3.25 ± 4.4 
 
DSPC 16 SUV 126.9 ± 12.6 -0.66 ± 1.9 
DSPC:Chol 8:8 MLV 19340.0 ± 0.4 -5.19 ± 11.0 
DSPC:Chol:PEG-
distearate 5 % 
7.6:7.6:0.8 MLV 18160 ± 1.0 -19.5 ± 7.9 
DSPC:Chol:DC-Chol 5.28:5.28:5.28 MLV 689.8 ± 56.8 34.7 ± 5.9 
DSPC:Chol:DC-Chol 
 
5.28:5.28:5.28 SUV 
 
108.5 ± 22.5 
 
26.4 ± 3.0 
DSPC:DOPE:DC-
Chol 
5.28:5.28:5.28 MLV 
 
589.5 ± 20.2 32.2 ± 6.8 
The size (nm) of the liposomes was measured in ddH2O and zeta potential (mV) was determined in 
0.001M phosphate buffered saline (PBS) at 25 oC using a zeta potential analyser. Results represent 
mean ± SD of triplicate experiments. 
 
 
3.4.4 Effect of liposome composition on cell viability  
Synthetically prepared phospholipids have well-defined fatty acid compositions and 
can be obtained with different or identical saturated or unsaturated chains (New 
1990). DSPC is a synthetic, 18-carbon, fully saturated, phospholipid and is often used 
as bulk lipid for the preparation of liposomes in order to stabilise and rigidify the lipid 
bilayer (Gregoriadis 1990). From Figure 3.6, it was found that the aqueous-filled 
DSPC neutral liposomes exhibited no measured influence on cell proliferation, with 
the cell viability being around 93 % and not significantly different from the control. 
This absence of significant impact on cell viability between neutral particles and cells 
in vitro is in line with previous studies. In the early work of Leserman et al (1981) no 
biological effect was detected with untargeted liposomes made of neutral lipids 
composed of dipalmitoylphosphatidylcholine, cholesterol, and 
dipalmitoylphosphatidyl-ethanolamine modified with N-hydroxysuccinimidyl-3-(2-
pyridyldithio)-propionate (SPDP). A study by Hsu and Juliano (1982) also found that 
neutral liposomes associate less effectively and are therefore less likely to be taken up 
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by the cells than negatively charged liposomes. This finding is also consistent with the 
study by Fidler (1988) who found that the binding of neutral MLV by macrophages 
composed exclusively of phosphatidylcholine (PC) is less efficient compared with 
MLV formulations composed of negatively charged phospholipids such as 
phosphatidylserine (PS) and phosphatidylglycerol (PG) (Ahsan et al 2002). 
Furthermore, a study by Ratner et al (1986) has suggested that liposomes composed of 
phosphatidylcholine (PC) are poorly internalised by the J774 macrophage cell line. 
However, other authors have also found low, but measurable, interactions between 
cells and neutral particles (Miller et al 1998; Lee et al 1993). The study by Miller et al 
(1998) examined the effect of liposome surface charge on liposomal binding and 
endocytosis in two different cell lines: a human ovarian carcinoma cell line (HeLa) 
and the J774 mononuclear macrophage cell line. The large unilamellar liposomes 
were composed of DOPE with and without the addition of either a positively charged 
lipid, 1,2-dioleoyl-3-dimethylammonium propanediol (DODAP), or a negatively 
charged lipid, 1,2-dioleolyl-sn-glycero-3-phosphatidylserine (DOPS). In some 
experiments 5 mol % of the anionic PEG2000-PE or a neutral PEG lipid of the same 
molecular weight was added. The authors found that the incorporation of a neutral 
PEG lipid into liposomes permits the independent variation of liposome steric and 
electrostatic effects in a manner that may allow interactions with cells of the 
reticuloendothelial system to be minimised, yet permit strong interactions between 
liposomes and proliferating cells. In this present work, since the cell viability was 
found to be above 90 %, the results are in good agreement with the general concept 
that cytotoxicity of liposomes depends on lipid composition and liposome 
concentration.    
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Figure 3.6 The effect of liposome composition on cell viability. Cell viability for DSPC in the 
presence and absence of cholesterol and PEG-distearate at 5 µg/ml concentration. Cells were plated in 
triplicate at 3 x 105 cells/well. Results represent mean ± SD of triplicate experiments. 
 
When cholesterol was added to DSPC-based liposomes, the effect of liposomes on 
cell viability was essentially the same (90.7 ± 3.6 % versus 92.8 ± 6.7 %) (Figure 3.6). 
Conversely, for the small unilamellar vesicles a difference in viability was seen of 
around 78 %. This decrease in cell viability may be due to the small particle size of 
the liposomes. Previous work (Gamon et al 1989; Crommelin 1984) has found that the 
smaller DSPC:Chol vesicles are unattractive for therapeutic applications because of 
several limitations including, low aqueous entrapped volume, particle instability due 
to lack of charge stabilisation and a strong dependence of circulation on particle size, 
length of the saturated acyl chains and lipid dose.  
 
The impact of PEG binding to cholesterol on in vitro behaviour of liposomes in terms 
of cell viability was also investigated. From Figure 3.6, it was found that following 
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addition of inert hydrophilic polymer PEG-distearate, there was a significant 
difference (p<0.05) in cell viability compared to the neutral DSPC formulation (74.4 
± 12.5 % versus 92.8 ± 6.7 % respectively; Figure 3.6). Compared with the 
DSPC:Chol MLV, again a significant difference was found (74.4 ± 12.5 % versus 
90.7 ± 3.6 % respectively). The polyethylene-glycol (PEG) chain of liposome surfaces 
has a steric hindrance effect on the liposomes with various molecules. This effect is 
also considered to reduce the interaction of liposomes with cells (Kuhl et al 1994). 
This stabilising effect has also been reported to be responsible for the prolonged 
circulation time within the systemic circulation after intravenous injection (Vertut-Doi 
et al 1996), as the liposomes are thought to be masked from uptake by macrophages 
of the MPS.  
 
Cationic liposomes are taken up by a variety of cells through electrostatic interactions 
between the cationic charge of the liposomes and the anionic charge of the cells 
(Aramaki et al 1999). From the results in Figure 3.7, it can be seen that the cell 
viability for both of the multilamellar formulations, including both helper lipids 
cholesterol and DOPE, was around 60 %, whereas for the small unilamellar vesicles a 
cell viability of 65 % was found. This is a significant reduction in cell viability 
compared to the neutrally charged formulations. Previous work has found that 
cationic liposomes display some disadvantages such as cytolytic and cytotoxic 
activities. Liang & Chou (2009) have found that cationic vesicles with more positive 
zeta potentials are associated with a significant poor survival of HaCaT and SCC25 
cells in mixed HSPC/DXDAB or EPC/DXDAB vesicular systems. However, no 
effect on particle size of cationic vesicles on the corresponding cytotoxicity of HaCaT 
and SCC25 was evident in this study, although some researchers have proposed that 
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smaller vesicles can be taken up by cells more easily (Win & Feng 2005). This 
absence of any difference between the MLV and SUV may be explained by the 
suggestion of Jubeh et al (2004) that the variation in the adhesion intensity of vesicles 
with particle size may drop as contact time increases. Notably, the zeta potential of 
cationic vesicles and not the particle size seems to dominate the cell viability. Cell 
membranes have large negatively charged domains, which should attract positively 
charged vesicles. A high affinity of cationic vesicles for cell membranes is expected, 
primarily because of the electrostatic interactions. After cationic liposomes are bound 
to cellular membranes, uptake may proceed by means of several mechanisms, such as 
endocytosis, pinocytosis or phagocytosis (Weinstein 1981; Lorenz et al 2006). Other 
studies of the interaction of cationic liposomes with cells have also established that 
the behaviour of liposomes on cells depends primarily on the charge density of 
cationic charge (Barbour & Hopwood 1983; Miller et al 1998). Pure DODAB cationic 
vesicles have also been demonstrated to generate a positive charge on the bacterial 
cell surfaces and induce bacterial death (Campanha et al 1999; Vieira & Carmona-
Ribeiro 2006). This fact may explain why cytotoxicity is a function of the zeta 
potential of cationic vesicles.       
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Figure 3.7 The effect of cationic liposomes on cell viability. Cell viability for cationic formulations 
at 5 µg/ml concentration. Cells were plated in triplicate at 3 x 105 cells/well. Results represent mean ± 
SD of triplicate experiments. 
 
3.4.5 Effect of microbubbles on cell viability 
As discussed previously in chapter 2, microbubbles were formulated by the 
homogenisation method composed of the neutral lipid, DSPC, filled with either air or 
N2. To investigate the potential of these systems for potential therapeutic and/or 
diagnostic applications, these microbubbles were investigated in terms of their effect 
on cell proliferation. The microbubbles were compared to aqueous-filled DSPC 
liposomes. From Figure 3.8, a similar result was found to that of aqueous-filled 
liposomes where 93 % cell viability was found for all three formulations with no 
significant difference. This suggests that incorporation of either air or nitrogen within 
the microbubbles had no significant impact on cell proliferation, and the microbubbles 
are not toxic to the cells. Previous work (Tran et al 2007) investigated the effect of 
ultrasound and microbubbles on cell viability. The authors found that using ultrasound 
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alone, Sonovue microbubbles alone, or a combination of both did not show any effect 
on cell viability using acoustic pressures up to 300 kPa, with no significant difference 
compared to the control (Tran et al 2007). 
Figure 3.8 The effect of microbubbles on cell viability. Cell viability for aqueous-filled and lipid-
coated microbubbles formulations at 5 µg/ml concentration. Cells were plated in triplicate at 3 x 105 
cells/well. Results represent mean ± SD of triplicate experiments. 
 
3.4.6 Phagocytic activities 
It is well known that macrophages internalise particulate carriers, such as those 
formulated in the above studies, by the process of endocytosis (Silverstein et al 1977; 
Van Oss 1978). However, there is no acceptable explanation about how the extent of 
phagocytosis by macrophages is related to physicochemical characteristic properties 
of particulate carriers. In particular, the influence of surface charge and size of 
particulate carrier on phagocytosis is not fully understood. Effects that have been 
noted include: 
• Surface charge: It is believed that charged carriers are better phagocytosed by 
macrophages because of the non-specific electrostatic interactions between cells 
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and carriers (Raz et al 1981; Van Oss, 1978). Some authors (Allen et al 1991a) 
also argue that macrophages may have receptors that help carriers adsorb by 
electrostatic attraction on the surface of the macrophages. Thus, a stable 
adsorption may lead to enhanced uptake of the carriers by macrophages. 
• Particle size: It has been postulated that the size of liposomes might influence their 
availability to interact with the microenvironment of the cell surface as well as the 
degree and strength of interaction necessary for adsorption (Schwendener et al 
1984). 
 
Therefore to investigate the uptake of the various formulations tested NAG release, as 
an indicator of phagocytic activity, in the culture supernatant of macrophages exposed   
for 24 hours to liposomes and microbubble formulations was determined. From 
Figure 3.9, it can be seen that in comparison to the positive control, all of the aqueous 
liposome formulations did not stimulate measurable phagocytic activity in the 
macrophages tested. According to the research of Horisawa et al (2002), large 
particles are likely to attach to the surface of the macrophage rather than to be 
uptaken, with the upper size limit for macrophage phagocytosis being 5 µm. This may 
be true for the multilamellar liposomes, however, not for the small unilamellar 
liposomes since they were around 150 - 200 nm in size. A study by Magee et al found 
that the initial interaction of the liposomes with cells seemed to rely only on the 
charge attraction between the positively charged particles and the negatively charged 
cells. Therefore, the cationic liposomes formulations (Table 3.2) were also tested. 
However similar to the neutral formulations, these formulations did not result in 
measurable release of NAG, suggesting that these formulations were effectively 
‘inert’ at the concentrations tested, i.e. low impact on phagocytosis.  
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Figure 3.9 Phagocytic activity (units/ml) measured for aqueous-filled liposomes. Cells were plated 
in triplicate at 3 x 105 cells/well and the phagocytosis of the various formulations at liposome 
concentration of 5 µg/ml was determined. The reading of background well was as used as a negative 
control; the reading of untreated cell well was used as a positive control. Results represent mean ± SD 
of triplicate experiments. 
 
For the microbubble formulations, again no phagocytic activity was found (Figure 
3.10) suggesting these formulations would not stimulate macrophage uptake with an 
aqueous or gas core making no difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Phagocytic activity (units/ml) measured for microbubbles. Cells were plated in 
triplicate at 3 x 105 cells/well and the phagocytosis of the various formulations at liposome and 
microbubble concentration of 5 µg/ml was determined. The reading of background well was as used as 
a negative control; the reading of untreated cell well was used as a positive control. Results represent 
mean ± SD of triplicate experiments. 
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3.5 Conclusion 
Both the aqueous-filled liposomes and gas-filled liposomes were tested for their effect 
on cell proliferation and phagocytic activity in a macrophage cell line. None of the 
formulations within the concentrations selected influenced either of the activities 
measured however this will be concentration dependent particularly in the case of the 
cationic formulations. In terms of the application of the lipid-coated microbubbles, 
this demonstrates their further potential in diagnostic imaging given that these lipid-
coated microbubbles were demonstrated in the previous chapter to act as potential 
contrast agents that allow stable MRI measurements of fluid pressure over time. 
Whilst their large size prohibits their delivery intravenously, given their low measured 
toxicity and contrast agent application, there remains a potential for these systems to 
be used for example as low cost imaging tools e.g. in bladder cancers.  
 
In addition to the application of microbubbles as contrast agents (Bauer & Solbiati 
2003; Ohlerth & O’Brien 2007), publications have suggested their potential as 
vaccine adjuvants due to their ability to enhance the targeting of antigens into 
dendritic cells (DCs) in cancer immunotherapy (Suzuki et al 2009). However the 
preliminary studies included in this chapter with regard to uptake within macrophages 
was not suitably encouraging to support further investigations into their application in 
this respect. Therefore, further studies into the development of vaccine adjuvants then 
focused on aqueous-filled liposome systems.    
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Chapter 4  
Investigating the use of liposomes as vaccine adjuvants 
 
Graphical Abstract: 
 
 
 
 
 
 
 
Freeze-fracture images of liposomes  prepared from dimethyldioctadecylammonium (DDA) and α’,α´-
trehalose 6,6´-dibehenate (TDB) liposomes with and without polyethylene glycol (PEG), prepared with 
2 µg of Ag85B-ESAT-6 and produced in three formats: multilamellar (MLV), small unilamellar (SUV) 
and as dehydration-rehydration vesicles (DRV). The method of production influenced size and location 
of the antigen. The DDA:TDB MLV liposomes presented a concentric lamellar structure in which the 
fracture faces were smooth, whereas the corresponding 25 % PEGylated formulation showed a phase 
change and/or disruption of the lamellae. The SUV were predominantly unilamellar vesicles but these 
small vesicles were clustered together. The corresponding DRV liposomes had a more regular 
morphology compared to MLV liposomes.  
25% PEG:2µg Ag85B-ESAT-6 MLV   25% PEG:2µg Ag85B-ESAT-6 SUV 25% PEG:2µg Ag85B-ESAT-6 DRV 
  DDA:TDB:2µg Ag85B-ESAT-6 MLV  DDA:TDB:2µg Ag85B-ESAT-6 SUV DDA:TDB:2µg Ag85B-ESAT-6 DRV 
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4.1 Introduction 
The use of liposomes as vaccine adjuvants has been investigated extensively over the 
last few decades and based on the studies reported in chapter 3 further investigations 
into the development of vaccine adjuvants focused on aqueous-filled liposome 
systems. In particular, cationic liposomal adjuvants have been investigated. In the 
literature the cationic lipid dimethyldioctadecylammonium (DDA) has been shown to 
enhance immune responses to a range of antigens including antigens for tuberculosis 
(TB) (Ag85B-ESAT 6) (Agger et al 2008a), malaria (Vangala et al 2006) and 
hepatitis B (Vangala et al 2007b). However, cationic liposomes are, in general, not 
sufficiently immunostimulatory, and therefore a range of immunostimulatory agents 
have been added to these formulations. One such combination consists of liposomes 
formed of DDA stabilised with the synthetic mycobacterial immunomodulator α,α´-
trehalose 6, 6´-dibehenate (TDB) inserted into the lipid bilayers at a molar ratio of 
5:1. This cationic liposome system was developed to mediate protection against TB 
but, in addition, has shown promising protective efficacy against other infectious 
diseases requiring different immunological profiles (Christensen et al 2009).  
 
4.1.1 Dimethyldioctadecylammonium (DDA) and α,α´-trehalose 6, 6´-dibehenate (TDB)  
DDA was discovered as an adjuvant by Gall in the mid 1960s (Gall 1966) and is a 
synthetic amphiphile, which contains a quaternary ammonium group with two 18-
carbon-long alkyl chains forming the hydrophobic moiety and two methyl groups, 
which together with the ammonium group form the polar head group (Figure 4.1). The 
positively charged head group carries a monovalent counterion, typically bromide or 
chloride. Due to its amphiphilic character DDA can form liposomal structures when 
dispersed in aqueous media at temperatures above its gel-to-liquid phase transition 
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temperature (~ 47 oC) (Davidson et al 2005). DDA is known to induce cell-mediated 
immunity and delayed-type hypersensitivity (Snippe et al 1982), and along with its 
cationic nature and surfactant properties, has been shown to be an effective adjuvant 
in numerous applications, including mucosal immunisation (Klinguer et al 2001), 
gene delivery (Esposito et al 1999) and subunit vaccine delivery (Lindblad et al 1997; 
Brandt et al 2000; Holten-Andersen et al 2004; Rosenkrands et al 2005).  
 
The mechanism of action behind the adjuvant effect of DDA has been attributed to its 
positive surface charge and its ability to associate antigens (Hilgers et al 1985). This 
was recently confirmed and further elaborated by using ovalbumin (OVA) as a model 
antigen (Korsholm et al 2007). Stimulation of immature bone marrow-derived 
dendritic cells (BMDCs) with fluorescently labelled OVA showed that adsorption of 
OVA onto DDA enhanced the cellular acquisition of the antigen. Further inhibition of 
active cellular processes by OVA stimulation at 4 °C or by the addition of 
cytochalasin D reduced the cellular uptake, suggesting that active actin-dependent 
endocytosis is the predominant uptake mechanism (Korsholm et al 2007). DDA-
mediated OVA uptake was further associated with a functional enhancement of the 
APCs. This was shown by measuring the increase in IFN-γ production and cellular 
proliferation of purified autologous DO11.10 T-cells transgenic for a T-cell receptor 
recognising a major histocompatibility complex (MHC) class II–restricted OVA-
epitope (OVA323-339). Both proliferation and IFN-γ production was increased upon 
interaction with either murine BMDCs or purified B-cells, stimulated with OVA 
adsorbed to DDA (Korsholm et al 2007, Christensen et al 2009). Recent studies 
replacing DDA with a neutral lipid, DSPC, further demonstrate the role of the cationic 
lipid in the liposomal adjuvant by showing that neutralisation of the surface charge of 
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the liposomes changes the biodistribution profile and diminishes their 
immunogenicity (Henriksen-Lacey et al 2010). 
 
 
 
 
 
 
Figure 4.1 Structure of dimethyldioctadecylammonium (DDA) 
 
 
The second component of the liposome adjuvant system, α,α‘-trehalose 6,6’-
dibehenate (TDB) (Figure 4.2), is a synthetic analog of trehalose 6,6'-dimycolate 
(TDM) with two saturated fatty-acid chains of 22 carbons (behenyl), each replacing 
the branched mycobacterial mycolic acids of >70 carbons. These two behenyl chains 
are linked by ester bonds to carbon number 6 of each of the two glucopyranose rings 
making up the trehalose head group (Figure 4.2). TDB has been shown to retain much 
of the bioactivity of the native form, whilst showing less toxicity as a result of the 
shorter fatty acid chains (Pimm et al 1979; Olds et al 1980). The combination of the 
DDA with TDB has been previously shown to be an efficient adjuvant for TB subunit 
vaccines (Holten-Andersen et al 2004), inducing a strong gamma interferon (IFN-γ) 
response, considered to be the key cytokine for induction of a Th1 immune response, 
essential for effective anti-mycobacterial immunity (Flynn et al 1993; Cooper et al 
1993). 
 
 
 
 
 
130 
 
 
 
 
 
 
 
 
Figure 4.2 Structure of α,α´-trehalose 6,6´-dibehenate (TDB) 
 
 
4.1.2 Antigen delivery system and immunostimulator 
DDA:TDB was first studied by Holten-Andersen et al (2004). Using ESAT-6 as a 
possible TB antigen they investigated the ability of seven different 
immunostimulators to increase the protective efficacy of DDA, which included four 
mycobacteria-derived immunostimulators. DDA combined with monophosphoryl 
lipid A (MPL) and/or TDB induced an effective IFN-γ response and protection in 
mice was equivalent to that provided by BCG vaccination (Christensen et al 2009). 
The adjuvant activity of DDA:TDB when combined with Ag85B-ESAT-6 was 
recently compared to aluminium hydroxide, an adjuvant approved for human use 
(Davidsen et al 2005). CD4+ T cells in mice secreted high levels of IFN-γ  and low 
levels of interleukin-5 (IL-5) in response to DDA:TDB whereas the opposite pattern 
was observed for aluminium hydroxide (Davidsen et al 2005; Christensen et al 2009). 
Although high levels of IgG1 antibody titres were seen with both DDA:TDB-
adjuvated vaccine and aluminium hydroxide-adjuvated vaccine, higher levels of IgG2 
antibody titres were seen with DDA:TDB (Davidsen et al 2005; Agger et al 2008b). 
Recent studies have identified DDA:TDB to induce a multi-functional CD4+ T-cell 
populations expressing several cytokines, mainly tumour necrosis factor-alpha (TNF-
α)+, IL-2+, and IFN-γ+, TNF-α+, IL-2+. In mice such a population is maintained for at 
least 1 year and thus are long-lived (Lindenstrom et al 2009). Additionally, a depot 
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formed at the site of injection by DDA:TDB has been shown to retain antigen in 
recent biodistribution studies (Henriksen-Lacey et al 2009). This could be a possible 
function of strong repulsive charges.  
 
4.1.3 Improving immunogenicity through modification of the liposomes composition 
Modifying the liposome composition in delivery systems has been attempted so as to 
improve immunogenicity (Christensen et al 2009). Delivery systems combined with 
non-ionic lipids and cholesterol, such as Ag85B-ESAT-6, was shown to decrease 
IFN-γ and IgG2
 
levels (Vangala et al 2006). However IgG1 titers remained relatively 
unchanged in the presence or absence of non-ionic lipids and cholesterol (Vangala et 
al 2006). A similar pattern emerged when DDA and TDB were incorporated into 
poly(D,L-lactic-co-glycolic acid) microspheres (PLGA), a decrease in IFN-γ and 
IgG2 levels and no difference in IgG1 levels, when compared to DDA:TDB (Kirby et 
al 2008a). DDA:TDB was also consistently better at initiating a diverse immune 
response encompassing both cell mediated immunity (CMI) and humoural immune 
responses, when compared to other types of microspheres than PLGA (Kirby et al 
2008b; Christensen et al 2009).  
 
Yet despite a range of studies, the mechanism behind the immunostimulatory effect 
obtained with the cationic liposomal vaccine adjuvant DDA:TDB remains unclear. 
One of the proposed hypotheses is the ‘depot effect’ in which the liposomal carrier 
helps to retain the antigen at the injection site thereby increasing the time of vaccine 
exposure to the immune cells (Henriksen-Lacey et al 2010). The depot effect has been 
suggested to be primarily due to electrostatic forces between the net negatively 
charged protein and the positively charged liposomes i.e. aggregation between the 
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cationic liposomes and serum proteins, thereby causing a liposomal net which retains 
the antigen (Henriksen-Lacey et al 2010). The aim of this current study was to further 
test this hypothesis by investigating whether sterically stabilising the DDA:TDB 
system with polyethylene glycol (PEG) reduces aggregation, and subsequently 
influences the formation of a depot at the site of injection and the immune response.  
 
4.1.4 Steric stabilisation using polyethylene glycol (PEG) 
Poly (ethylene glycol) (PEG) is the most widely used hydrophilic polymer for the 
steric stabilisation of liposome drug delivery systems. PEG is a linear polyether diol 
with many useful properties, such as biocompatibility, solubility in aqueous and 
organic media (Powell 1980), very low toxicity, immunogenicity and antigenicity 
(Dreborg & Akerblom 1990), and good excretion kinetics (Yamaoka et al 1994). 
These properties allow its use in a variety of applications (Harris 1992), including its 
application in therapeutic products such as Caelyx, which is a PEGylated liposomal 
delivery system for doxorubicin. PEG can be incorporated on the liposomal surface in 
different ways, but the most widely used method at present is to anchor the polymer in 
the liposomal membrane via a cross-linked lipid (i.e. PEG-
distearoylphosphatidylethanolamine (DSPE) as schematised in Figure 4.3) (Allen et al 
1991b, 2002). PEG has been used to derivatise therapeutic proteins and peptides, 
increasing drug stability and solubility, lowering toxicity, increasing half-life (Caliceti 
& Veronese 2003), decreasing clearance and immunogenicity. 
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Figure 4.3 Chemical structures of distearolylphosphatidylcholine (DSPC), 
distearoylphosphatidyl-ethanolamine after conjugation with poly (ethylene glycol) (PEG) (DSPE-
PEG).  
 
 
PEG provides a strong interbilayer repulsion on the surface of liposomes (Needham et 
al 1992; Immordino et al 2006). These act to stabilise liposome preparations by 
overcoming the attractive van der Waals forces and thus avoid aggregation. When 
bilayers that are combined with PEG1900-lipid are analysed by x-ray, from the lipid 
surface it is revealed the grafted polymer extends around 50 angstroms and produces 
strong inter-membrane repulsive forces (Needham et al 1992; Immordino et al 2006). 
The conformational flexibility together with molecular mass of the bound polymer 
and its uniformity (molecular cloud) enables the hydrophilic shell of PEG to avoid 
liposomal particle aggregation and decreases the particle-protein interaction 
(Torchilin et al 1994). By contrast liposome-protein interactions are not decreased 
when dextran, a more rigid polymer, is grafted to liposomes even when it is used at 
comparable quantities (Needham et al 1992). Many studies have focused on 
elucidating the optimal concentration of PEG that should be incorporated in the 
liposomal membrane. For example, Levchenko et al (2002) demonstrated that PEG 
concentrations of more than 6 mol% shield the electric surface potential of cationic 
liposomes, while higher concentrations (more than 15 mol%) were found to cause 
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unfavourable structural changes in the liposomal bilayer, and thus enhance the rapid 
clearance of liposomes from circulation, whilst other studies (Carstens et al 2007) 
suggested higher levels are required to mask cationic surfaces. For this reason, in this 
study lower concentrations i.e. 5, 10 mol% and higher concentration i.e. 25 mol% 
were included in the preparation of PEG-coated cationic liposomes.  
 
4.2 Aims and objectives 
The aim of this work was to see whether sterically stabilising DDA:TDB with PEG 
reduces aggregation in the presence of proteins and serum and whether it has an 
influence on the biodistribution, adjuvant properties and the formation of a depot at 
the site of injection. To do this the objectives were: 
1. To look at the effect of PEG on the DDA:TDB system, i.e. characterisation of 
the systems in terms of size, charge, loading, release and aggregation in the 
presence and absence of serum.   
2. To look at the effect of entrapping antigens within the liposomes rather than 
surface adsorption i.e. characterisation of the systems in terms of size, charge, 
loading and release. 
3. To look at the effect of PEGylation on biodistribution i.e. investigating whether 
different methods of antigen entrapment can alter the biodistribution of the antigen 
and liposomes. 
4. Finally, to look at the effect of adsorbing and entrapping antigens on vaccine 
efficacy using the subunit Ag85B-ESAT-6 antigen. 
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4.3 Materials and methods 
4.3.1 Materials 
Chemicals 
[3H] thymidine 
2,2’-azino-bis (3-ethylbenzthiazoline-6-
sulfonic acid)  
Acetic acid 
Bicinchoninic acid (BCA) 
Citric acid 
Chloroform (HPLC grade) 
Concanavalin A 
Coomasie (Brilliant Blue) 
Dimethyl sulphoxide (DMSO) 
DuoSet® capture ELISA  
ELISA plates (flat bottom, high binding) 
Foetal bovine serum (Heat-Inactivated) 
Glycine 
Heparin  
Horseradish peroxidise-conjugated goat anti-
mouse immunoglobulin IgG, IgG1 & IgG2b 
subclasses 
Hydrogen peroxide 
I125(NaI in NaOH solution) 
IODO-GEN® pre-coated iodination tubes 
Supplier 
Perkin Elmer (Waltham, MA) 
Sigma-Aldrich, Poole, Dorset, UK 
 
 
Fisher Scientific (Leicestershire, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Fisher Scientific (Leicestershire, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
R&D systems, UK 
Greiner Bio-One Ltd, UK 
Invitrogen, Paisley, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
AbD serotec, Oxford, UK 
 
 
 
Sigma-Aldrich, Poole, Dorset, UK 
Perkin Elmer (Waltham, MA) 
Pierce Biotechnology (Rockford, IL) 
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Incomplete Freund’s adjuvant  
Marvel 
Methanol (HPLC grade) 
Ovalbumin (OVA) 
Penicillin-streptomycin-glutamine (100X) 
Phosphate buffer saline tablets (PBS) 
Plain filter mats 
Potassium chloride 
Potassium phosphate 
Protein molecular weight standard  
RPMI 1640 cell culture medium 
SDS-PAGE 12% Tris-Glycine gels  
Sephadex G-75 
Sodium chloride 
Sodium dodecyl sulphate  
Sodium phosphate dibasic 
Solvable  
Tetramethylbenzidine  
Tris-base 
Trypan blue 
Tween-20  
Ultima Gold scintillation fluid 
 
 
 
Sigma-Aldrich, Poole, Dorset, UK 
Premier Int. Foods Ltd, Lincs, UK  
Fisher Scientific (Leicestershire, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Invitrogen, Paisley, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Molecular Devices Ltd., Wokingham, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Invitrogen, Paisley, UK 
Biosera Ltd, UK 
Invitrogen, Paisley, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Perkin Elmer (Waltham, MA). 
Sigma-Aldrich, Poole, Dorset, UK 
IDN Biomedical, Inc (Aurora, Ohio) 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Perkin Elmer (Waltham, MA) 
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Lipids 
1,2-dipalmitoyl (3H-DPPC) 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy-poly(ethylene 
glycol) 2000 (DSPEPEG2000) 
Dimethyldioctadecylammonium bromide 
(DDA) 
Trehalose 6,6′-dibehenate (TDB) 
Supplier 
Perkin Elmer (Waltham, MA) 
Avanti Polar Lipids, Inc. (Alabaster, AL) 
 
 
 
 
Avanti Polar Lipids, Inc. (Alabaster, AL) 
 
Avanti Polar Lipids, Inc. (Alabaster, AL) 
Non-His-tagged protein Ag85B-ESAT-6 was produced as described previously 
(Olsen et al 2001) and were provided by Staten Serum Institute, Denmark. Tris-base, 
obtained from IDN Biomedical, Inc (Aurora, Ohio) was used to make Tris buffer and 
adjusted to pH 7.4 using HCl; unless stated otherwise Tris buffer was used at 10 mM, 
pH 7.4. Double distilled water was used in the preparation of all solutions. 
 
4.3.2 Method  
4.3.2.1 Lipid-hydration method 
MLV were prepared using the previously described lipid-film hydration method 
(Bangham et al 1965) (Figure 4.4). Briefly, weighed amounts of DDA, TDB and PEG 
(Table 4.1) were dissolved in chloroform/methanol (9:1, by volume) and the organic 
solvent was removed by rotary evaporation followed by flushing with N2 to form a 
thin lipid film on the bottom of a round-bottom flask. The lipid film was hydrated in 
10 mM Tris-buffer at pH 7.4, to a final concentration of 1.98 mM DDA with 0.25 mM 
TDB added in the case of DDA:TDB, by heating for 20 min at 60 °C. The Ag85B-
ESAT-6 antigen was added post-hydration of the lipid film. 
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Figure 4.4 Schematic representation of the lipid-hydration method. (A) Weighed amounts of lipids 
were first dissolved in chloroform/methanol (9:1, by volume), (B) followed by removal of the solvent 
under vacuum to leave a thin lipid film, which was then purged with a gentle stream of N2 to remove 
any residual solvent. (C) Vesicles were subsequently formed by simply hydrating the lipid film with an 
aqueous phase for 20 minutes, at a temperature 10 °C above the main phase transition of DDA (Tc ≈ 47 
°C), with the final concentrations of DDA and TDB corresponding to 1.25 mg/mL and 0.25 mg/mL 
respectively. (D) Finally, the solution was allowed to cool before addition of Ag85B-ESAT-6, followed 
by vortex mixing. 
 
4.3.2.2 Small unilamellar vesicles (SUV) 
To generate SUV, the MLV produced in section 4.3.2.1 were disrupted using sonic 
energy to fracture large liposomes into smaller structures (< 100 nm). In this instance, 
a probe sonicator (Soniprep 150) was used to produce SUV. The tip of the sonicator 
probe was placed onto the liposome surface of the MLV mixture. The milky MLV 
suspension transforms into a clear SUV suspension.   
 
4.3.2.3 Dehydration-rehydration method 
The dehydration-rehydration method (Kirby & Gregoriadis 1984a) was used for 
incorporation of Ag85B-ESAT-6 into liposome vesicles (Figure 4.5). In brief, MLV 
prepared according to the lipid hydration method outlined above was sonicated to 
produce SUV. These SUV composed of 1.98 mM DDA with 0.25 mM TDB in the 
presence or absence of PEG (0.112, 0.223, 0.558 mM) were mixed with Ag85B-
ESAT-6, frozen at -70 °C and freeze dried overnight (-40 °C, vacuum to 40 mbar). 
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Controlled rehydration of the dried powder led to the formation of antigen containing 
DRV. Controlled rehydration was achieved by addition of 10 % of the final volume, 
which was standardised at 1 ml. Therefore 100 µl was added initially to these 
formulations, which were vortexed and left at room temperature for 30 minutes. A 
further 100 µl was added and formulations again were incubated for 30 minutes at 
room temperature and subsequently made up to 1 ml. DRV preparations were then 
centrifuged twice at 125,000 ×g for 20 minutes to remove non-entrapped antigen and 
resuspended in distilled water, to the appropriate volume. 
 
 
 
 
 
 
 
 
Figure 4.5 Schematic representation of the dehydration-rehydration method. In brief, MLV 
prepared according to the lipid hydration method outlined above was sonicated to produce SUV. These 
SUV were mixed with Ag85B-ESAT-6, frozen at -70 °C and freeze dried overnight (-40 °C, vacuum to 
40 mbar). Controlled rehydration of the dried powder led to the formation of antigen containing DRV 
vesicles.  
 
 
 
During freeze-drying the liposomes flatten and on 
rehydration they fuse and entrap the antigen  
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Table 4.1 Weight (mg) and moles of DDA:TDB and 5 %, 10 % and 25 % PEG. 
 
4.3.2.4 Determination of vesicle size and zeta potential 
The vesicle size and zeta-potential was determined using the photon correlation 
spectroscopy (PCS) technique. The measurements were performed at 25 oC using a 
ZetaPlus (Brookhaven Instrument Corporation, USA). Polystyrene size standard 220 
± 6 nm (Duke scientific corp, Duke, NC) was used as a control. The samples were 
diluted with 10 mM Tris-buffer at pH 7.4 to achieve the optimal vesicle concentration.  
 
4.3.2.5 Sodium dodecyl sulphate polyacrylamide gel-electrophoresis (SDS page) 
Cationic formulations were mixed with OVA (either 100 µg/ml or 1 mg/ml) and ultra-
centrifuged twice at 125,000 ×g, for 60 minutes at room temperature in order to pellet 
the liposomes. Supernatant was then removed and pellets were re-suspended back into 
their original volume, using the corresponding buffer solution. Upon heating at 90 °C 
for 3 minutes, 10 µl samples of pellet and supernatant from each of the formulations 
were analysed via SDS-PAGE for semi-quantification of the protein concentrations 
present.    
 
 
 
DDA:TDB 
Formulation 
DDA 
Weight (mg)/Moles 
TDB 
Weight (mg)/Moles 
PEG 
Weight (mg)/Moles 
DDA:TDB only 
+ 5 % PEG 
+ 10 % PEG 
+ 25 % PEG 
1.25 / 1.98x10-6 
1.19 / 1.94x10-6 
1.125 / 1.78x10-6 
0.94 / 1.49x10-6 
0.25 / 2.53x10-7 
0.24 / 2.40x10-7 
0.22 / 2.28x10-7 
0.19 / 1.90x10-7 
0 / 0 
0.314 / 1.12x10-7 
0.63 / 2.23x10-7 
1.57 / 5.58x10-7 
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4.3.2.6 Quantification of non-adsorbed antigen via the BCA Assay 
The BCA assay has a working range of 5 to 25 µg of protein. To test non-adsorbed 
concentrations of OVA, triplicate 25 µl supernatant samples were tested. OVA protein 
concentrations present within the supernatants were quantified by the BCA Protein 
Assay in accordance with the associated protocol (Sigma-Aldrich Co. Ltd. Dorset, 
UK). The principle of the assay is that it relies on the formation of Cu2+ protein 
complex under alkaline conditions followed by the reduction of the Cu2+ to Cu1+. The 
amount of reduction is proportional to the protein present. An OVA standard curve 
was formed at concentrations of 0 - 1 mg/ml with 25 µl of sample and 225 µl of 
reagent added per well of a 96 well plate. 
 
4.3.2.7 Radiolabeling of Ag85B-ESAT-6 antigen 
Known volumes of Ag85B-ESAT-6 (0.8 mg/ml) and I125 were added to the IODO-
GEN® tube and left for 1 hour with intermittent swirling. Typical volumes for the 
production of 1 ml radiolabelled Ag85B-ESAT-6 would require the mixing of 100 µl 
Ag85B-ESAT-6 (0.8 mg/ml) with 6 MBq I125. A gel filtration column containing 
Sephadex-G75 was prepared using double distilled water and equilibrated using Tris 
buffer. The I125-Ag85B-ESAT-6 solution was added to the column and elucidated 
using Tris buffer, maintaining a steady flow through the column. Aliquots (0.25 ml) 
were collected and analysed for I125 content using a Cobra™ CPM Auto-Gamma® 
counter (Packard Instruments Company inc, IL, USA). Verification of Ag85B-ESAT-
6 presence was undertaken using the BCA assay in which protein presence resulted in 
a visual colour change from green to purple. The samples with the highest protein 
content and highest γ-counts were then collected and pooled for subsequent use as 
radiolabelled protein. The final sample was diluted accordingly with Tris buffer. 
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4.3.2.8 Ag85B-ESAT-6 antigen adsorption / entrapment to cationic liposomes 
To assess the degree of antigen adsorption, I125-labeled Ag85B-ESAT-6 was added to 
the liposomes and left for 1 hour with intermittent shaking. For antigen entrapment 
I125-labeled Ag85B-ESAT-6 was added to the SUV liposomes, frozen at -70 °C and 
freeze dried overnight (-40 °C, vacuum to 40 mbar). Controlled rehydration of the 
dried powder led to the formation of Ag85B-ESAT-6 containing DRV. Due to their 
relatively small size and highly cationic nature, DDA-based liposomes do not pellet 
efficiently during centrifugation, even at high speeds. Therefore to aid sedimentation 
during centrifugation, liposomes were subsequently placed in a solution of OVA 
(1 mg/ml) and centrifuged (125,000 ×g, 4 °C, 1 hour), resuspended in Tris buffer and 
centrifuged again to ensure removal of all non-bound Ag85B-ESAT-6. The I125 
recovery in the pooled supernatant after two washes (unbound antigen) and the pellet 
(bound antigen) was measured. The percentage of Ag85B-ESAT-6 adsorbed and 
entrapped was calculated as a percentage of the total radioactivity recovered from 
both supernatant and pellet. 
 
Radioactivity of washed sample    x 100% 
                                          Radioactivity of unwashed sample 
 
To ensure reliability of entrapment values, the total recovery of protein antigen was 
also calculated using the following equation (including any dilutions) 
 
Radioactivity of washed sample + Radioactivity of supernatant    x 100% 
                                          Radioactivity of unwashed sample 
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4.3.2.9 Ag85B-ESAT-6 antigen retention in simulated in vivo conditions 
Antigen release from liposomes stored in simulated in vivo conditions was determined 
using liposomes adsorbing and entrapping I125-labelled Ag85B-ESAT-6. Aliquots of 
each formulation were diluted (1:5) using 50 % FCS in Tris buffer and incubated in a 
shaking water bath at 37 °C for 96 h. At time intervals, samples were centrifuged 
twice and Ag85B-ESAT-6 release was calculated as a percentage of the recovered 
radioactivity. 
 
4.3.2.10 Biodistribution of cationic liposomes adsorbing and entrapping Ag85B-ESAT-6 antigen 
Inbred female Balb/C (6-10 weeks of age) mice were housed in cages within a 
laminar flow safety enclosure and provided with irradiated food and filtered drinking 
water. Experimentation strictly adhered to the 1986 Scientific Procedures Act (UK). 
All protocols have been subject to stringent ethical review and were carried out in a 
designated establishment. Four to six days prior to injection, mice were injected 
subcutaneously (s.c.) with 200 µl pontamine blue (0.5 % w/v). Liposomes containing 
the tracer molecule H3-DPPC were produced as described in sections 4.3.2.1-2. To 
obtain isotonicity, trehalose was added to the hydrating buffer to a final concentration 
of 10 % w/v. Each immunisation dose contained 2 µg Ag85B-ESAT-6 with 25 ng 3H-
DPPC, 250 µg DDA and 50 µg TDB ± 12.6 µg/31.5 µg PEG. Mice were injected 
intramuscularly (i.m; 50 µl) into the left quadricep. At time-points 1 day, 4 days and 
14 days post injection (p.i) (Figure 4.6) mice were terminated by cervical dislocation. 
Spleen, injected muscle site and popliteal lymph nodes were removed and weighed 
into plastic γ-vials to which 1.5 ml SOLVABLE™ was added. Samples were assessed 
for I125 content using a Cobra™ CPM Auto-Gamma® counter. Fully digested tissue 
samples were bleached using hydrogen peroxide (200 µl) and transferred to glass 
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scintillation vials followed by the addition of Ultima Gold (10 ml) for H3 
quantification. 
 
 
 
 
 
 
 
Figure 4.6 Time-points for the biodistribution study, days 1, 4 and 14 post injection (p.i)   
 
4.3.2.11 Immunological analysis of liposome formulations 
Nine groups of five female C57BL/6 mice (6 - 10 weeks of age), received doses of 
liposome vaccine formulations containing 2 µg of Ag85B-ESAT-6 in a 50 µl volume. 
A second group received 2 µg of Ag85B-ESAT-6 in a 50 µl volume. Naïve groups 
received the appropriate volume of PBS. Vaccine formulations were administered 
intramuscularly, and each mouse received three doses at intervals of two weeks. 
Serum samples were taken at 12 days after the first administration and at two week 
intervals thereafter. 
 
4.3.2.12 Analysis of Ag85B-ESAT-6 specific antibody isotypes 
Sera samples obtained at different time intervals after immunisation were analysed for 
the presence of anti-Ag85B-ESAT-6 IgG, IgG1 and IgG2b antibodies by enzyme-
linked immunosorbent assay (ELISA) (Figure 4.7). ELISA plates (flat bottom, high 
binding) were coated with 50 µl of Ag85B-ESAT-6 per well (3 µg/well) in PBS and 
incubated at 4 ºC overnight. Unbound antigen was aspirated and residual washings 
were removed by blotting firmly onto paper towel. Plates were blocked with 100 µl 
per well of 4 % w/v Marvel (dried skimmed milk powder) in PBS. Serum samples 
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were serially diluted to washed plates and incubated for 1 hour at 37 ºC. Anti-Ag85B-
ESAT-6 antibodies were detected by addition of horseradish peroxidase conjugated 
anti-mouse isotype specific immunoglobulin (goat anti-mouse IgG, IgG1, or IgG2a), 
and subsequent addition of substrate solution, 2,2’-azino-bis (3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) in citrate buffer incorporating 5 µl of 30 % H2O2/50 ml 
following repeated incubation and washing steps. Absorbance was measured at 405 
nm (Bio-Rad, Herts, UK).  
 
 
 
Figure 4.7 Schematic representation of analysis of antibody production by enzyme-linked 
immunosorbent assay (ELISA).  Serially diluted serum samples are added to 96-well microplates 
coated with antigen and blocked with Marvel (4 % (w/v)) in PBS. Serum antibodies recognise antigen 
adsorbed to wells. Antibodies are then detected using secondary antibody conjugate, which recognises 
antibody bound to antigen adsorbed to wells, following repeated incubation and washing steps. 
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4.3.2.13 Spleen cell culture preparation 
Upon termination of experiments, mice were humanely culled and their spleens 
aseptically removed and placed into ice-cold sterile PBS. Spleens were treated as 
follows: a crude suspension of spleen cells in 10 ml working media (RPMI 1640 cell 
culture medium supplemented with 10 % (v/v) foetal bovine serum, 2 mM L-
glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml)) was prepared by 
gently grinding the spleen on a fine wire screen. After allowing the cell suspension to 
settle for approximately 5 minutes the liquid was transferred to sterile 20 ml ‘Falcon’ 
tubes, without disturbing the cellular debris at the bottom. The cell suspension was 
centrifuged at 1200 rpm for 10 minutes at 15 oC. After centrifugation the supernatant 
was removed, the cell pellet resuspended in 10 ml fresh working media and the 
centrifugation procedure was repeated.  
 
4.3.2.14 Analysis of spleen cell proliferation 
For study of antigen specific proliferative responses, aliquots of 100 µl volumes of 
sterile media or antigen in sterile media (at the concentrations stated (0.05, 0.5, 5 and 
25 µg/ml)) were seeded onto 96 well suspension culture plates  and 100 µl volumes of 
viable splenocytes (approximately 8 × 106 cells/ml) added to each well (Figure 4.8). 
As a positive control, cells were co-cultured with concanavalin A at a concentration of 
3 µg/ml. Covered plates were incubated in a humid, 5 % CO2 environment at 37 ºC 
for 72 hours. After 72 hours incubation, half a microcurie of [3H] thymidine in 40 µl 
volumes of freshly prepared sterile working media was added to each well, and the 
incubation continued for a further 24 hours. The well contents were harvested onto 
plain filter mats using a cell harvester (Titertek). After drying, the discs representing 
each well were punched from the filter mats into 5 ml volumes of scintillation fluid 
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and the incorporation of [3H] thymidine into the cultured cells was measured using 
standard counting procedures (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Schematic representation spleen cell proliferation analysis.  Antigen is seeded onto 96 
well suspension culture plates and incubated with viable splenocytes at 37 °C (5 % CO2) for 72 hours. 
Cells are then pulsed with 3H thymidine, incubated, and harvested onto filter mats, which are counted 
for 3H using standard counting procedures. 
 
 
4.3.2.15 Analysis of cytokine production 
Splenocytes were isolated and cells were plated onto 96-well plates. Cells were 
incubated for 40 hours at 37 oC, in a humid (5 % CO2) environment, after which 
supernatants were removed and stored at -70 oC for later analysis. Cytokine levels of 
IL-2, IL-5, IL-6, IL-10 and IFN-γ in the cell culture supernatants were quantified 
using the DuoSet® capture ELISA kits according to the manufacturer’s instructions 
(Figure 4.9). Briefly, ELISA plates were first coated with capture antibody, followed 
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by washing and blocking. Samples of cell culture supernatants were then added and 
cytokines detected by addition of a detection antibody, enzyme marker (Streptavidin-
HRP) and substrate solution following repeated incubation and washing steps. 
Absorbance was measured at 405 nm (Bio-Rad, Herts, UK) (Figure 4.9). 
 
 
 
 
Figure 4.9 Schematic representation of cytokine detection using DuoSet® capture ELISA kits. 
Spleen cell culture supernatants are added to 96 well microplates coated with capture antibody. 
Addition of detection antibody and enzyme marker, followed by activation with substrate solution, 
allows determination of cytokine secretion by optical density measurements. 
 
4.3.2.16 Freeze-fracture microscopy  
A drop of each incubation mixture (approximately 5 µl) was placed on a ridged, gold 
specimen support or was sandwiched between two copper plates for fracture in a 
double replica device. Samples were frozen by rapid plunging into a constantly stirred 
mixture of propane:isopentane (3:1) cooled by liquid nitrogen. Fracture was 
performed on a Balzers BAF 400D apparatus at a temperature of -110 ◦C. Replicas 
were floated free on distilled water and cleaned in 40 % chromic acid. Images were 
viewed using a transmission microscope. 
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4.3.2.17 Statistical analyses 
For all experiments, means and standard deviations were calculated. To determine 
statistical significance the one way analysis of variance (ANOVA) was performed on 
all data, with the statistical significance determined to 0.05 confidence intervals 
(p<0.05). Tukey’s post hoc test was conducted to determine which conditions differ 
significantly from each other.  
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4.4 Results and discussion 
4.4.1 The effect of PEGylation DDA:TDB MLV characteristics  
DSPEPEG2000 (PEG) is an amphiphilic molecule composed of a hydrophobic 
phospholipid and hydrophilic PEG chain. Here the PEGylated lipid was incorporated 
into ‘empty’ (i.e. no antigen present) DDA:TDB systems at 5, 10 and 25 mol%. The 
size and zeta-potentials were measured (Figures 4.10A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 (A) Vesicle size (nm) (bars) and polydispersity (values) and (B) zeta-potential (mV) of 
DDA:TDB 5, 10, 25 % PEG liposomes. Size and zeta-potential measured in Tris buffer (1 mM) using 
a Brookhaven ZetaPlus instrument. Results represent mean ± SD of triplicate experiments. 
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From Figure 4.10, it can be seen that the incorporation of PEG to the DDA:TDB 
MLV influenced the size, polydispersity and zeta-potential of the liposomes. As the 
amount of PEG increased there is a decrease in vesicle size, with liposomes prepared 
from DDA:TDB alone being around 446.3 ± 3.3 nm, whilst formulations containing 
5, 10 and 25 % PEG being 365.1 ± 22.2 nm (p<0.01) for 5 %, 360.5 ± 18.6 nm 
(p<0.01) for 10 % and 287.7 ± 43.3 nm (p<0.001) for 25 % PEG formulation 
respectively (Figure 4.10). This may be due to PEG in the formulation influencing the 
lipid packaging within the systems and/or reducing the number of bilayers within the 
MLV system which would subsequently reduce the vesicle size. Since the attachment 
of PEG molecules to the surface of liposomes both strongly reduces the attractive 
forces (van der Waals), and increases the repulsive forces (steric, electrostatic, and 
hydration) (Kenworthy et al 1995; Lasic & Martin 1995), increasing PEG 
concentration causes disaggregation of liposome assemblies and a gradual reduction 
of liposome size. It is important to note that replacement of similar amounts of DDA 
with a zwitterionic lipid (DSPE) did not have the same effect (unpublished data from 
our lab). 
 
The zeta potential, which is related to the charge on the surface of the particle and is 
important for interactions of liposomes with biological systems in vivo (Scherphof et 
al 1997; Scherphof & Kamps 1998), was also measured for these systems. From the 
results (Figure 4.10B), it can be seen that as the amount of PEGylation increased there 
was a drop in zeta potential from 58 ± 1.5 mV when no PEG is present to around 19.4 
± 1.9 mV when the bilayer contains 25 % PEG (p<0.001) (Figure 4.10B). This 
gradual reduction in zeta potential is possibly due to the hydrophilic chains of the 
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PEG grafted onto the DSPE extending out from the surface of the liposomes masking 
the cationic charge of the DDA.  
 
4.4.2 The effect of antigen adsorption onto MLV DDA:TDB 
A range of procedures for the preparation of the liposomes can be employed. 
However, preparation of liposomes by addition of aqueous solution of antigens to 
dried lipid films, resulting in multilamellar vesicles (MLV), is generally the most 
convenient method of liposome preparation for vaccine formulations. Yet, the 
addition of an anionic antigen to cationic MLV will result in electrostatic interactions, 
influencing the physico-chemical properties of the vesicles. To investigate and 
initially characterise the interaction of anionic subunit antigens with the various MLV 
systems, ovalbumin (OVA) was used as the model protein. However, for later loading 
and release studies Ag85B-ESAT-6, a novel tuberculosis subunit antigen, was used. 
Ovalbumin (OVA), a glycoprotein consisting of 385 amino acids, has a molecular 
mass of 43 kDa (Nisbet et al 1981; Huntington & Stein 2001) and has a negative 
charge at neutral pH so will adsorb to DDA:TDB similar to Ag85B-ESAT-6. Due to 
its low cost and characteristics which generally map to common subunit antigens, it is 
often used as a model antigen of low immunogenicity in assessment of novel 
adjuvants (Stewart-Tull 1991).  
 
The effect of OVA adsorption at various ratios (10 µg/ml, 100 µg/ml and 1000  
µg/ml) with various PEGylated DDA:TDB MLV (5 %, 10 % and 25 % PEG) was 
determined on the size and zeta-potential (Figure 4.11). The size and the zeta-
potential of ‘empty’ systems (where no OVA is present) were initially measured and 
compared to formulations containing OVA (Figure 4.11). For all four formulations, 
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the addition of 10 µg of OVA had no measurable effect on the size and the zeta-
potential of the liposomes (Figure 4.11). On the addition of 100 µg of OVA to 
DDA:TDB, 5 % and 10 % PEG formulation a significant (p<0.05) increase in size 
was found compared to their OVA free counterparts with the size being 755.6 ± 77.8 
nm for DDA:TDB, 542.8 ± 55.9 nm for 5 % and 515.4 ± 5.5 nm for 10 % PEG 
respectively compared to 446.3 ± 3.3 nm, 365.1 ± 22.3 nm and 360.5 ± 18.6 nm for 
the OVA free formulations respectively (Figure 4.11A). For the 25 % PEG 
formulation there was no significant increase in size (p>0.05) (403.2 ± 33.7 nm 
compared to 401.7 ± 43.3 nm with OVA free formulations). In terms of zeta-potential, 
the addition of 100 µg of OVA resulted in a reduction in measured potential with the 
DDA:TDB formulation. However, for the remaining three pegylated formulations, no 
significant change in zeta potential was found (Figure 4.11B). Following the addition 
of 1000 µg of OVA, all four formulations were found to aggregate with sizes between 
1-2 microns; this increase in size was also associated with a drop in zeta-potential 
with all formulations having a neutral charge after the addition of OVA (Figure 
4.11B).  
 
These results suggest that at low OVA concentrations, the liposomes are able to 
adsorb the antigen without notable influence to the physico-chemical characteristics 
measured. As the concentration of OVA increases, surface neutralisation and 
aggregation of the vesicles is promoted due to electrostatic interactions between the 
anionic protein and the cationic liposomes, as is commonly reported with anionic 
nucleic acids and cationic liposomes (e.g. McNeil & Perrie 2006). Similarly the 
aggregation of protein to cationic liposomes has been previously reported by Brgles et 
al (2008) where by using 2.5 mg OVA or greater, the systems aggregated (and 
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sedimented) due to saturation of the liposomes. The concentration at which this occurs 
will be due to the binding capacity of the liposomes at a higher concentration (1000 
µg) of OVA the liposomes will become saturated and a large fraction of antigen will 
not be bound to the vesicles, and therefore will remain free in solution (Korsholm et al 
2007). However liposomes with higher concentrations of PEGylated surface coating, 
already display a reduced cationic zeta potential due to the hydrophilic PEG coating 
prior to the addition of OVA (Figure 4.11B). Therefore this will limit the interaction 
of the OVA with the liposomes due to both the reduced cationic nature of the system, 
and due to steric hindrance which will prohibit the OVA interacting with the liposome 
surfaces. Steric hindrance is where the tightly bound water molecules form a hydrated 
film around the particle and repel the protein interactions (van Vlerken et al 2007). In 
turn, this will limit the changes in liposome size and zeta potential (Figure 4.11) as 
vesicle-OVA interactions are blocked.  
 
4.4.3 Adsorption of antigen to MLV DDA:TDB 
4.4.3.1 Adsorption of OVA 
To confirm if PEGylation was limiting protein-binding, the degree of adsorption of 
various concentrations of OVA to the various DDA liposome formulations was 
investigated. Adsorption was evaluated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and BCA assay following ultra-centrifugation.  
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Figure 4.11 (A) Vesicle size (nm) and (B) zeta-potential (mV) of DDA:TDB, 5, 10, 25 % PEG 
liposomes following the addition of OVA at 10 µg/ml, 100 µg/ml and 1000 µg/ml. Size and zeta-
potential measured in Tris buffer (1 mM) using a Brookhaven ZetaPlus instrument. Results represent 
mean ± SD of triplicate experiments. 
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SDS is an anionic detergent that binds quantitatively to proteins, giving them linearity 
and uniform charge, so that they can be separated solely on the basis of their size 
(Caprette 2010). The SDS has a high negative charge that overwhelms any charge the 
protein may have, imparting all proteins with a relatively equal negative charge. The 
SDS has a hydrophobic tail that interacts strongly with protein (polypeptide) chains. 
The polyacrylamide gel electrophoresis separates protein molecules according to their 
size. An electric current is used to move the protein molecules across a 
polyacrylamide gel. The negatively charged protein molecules are pulled to the 
positive end by the current. The smaller molecules are able to navigate faster than 
larger ones, so they make it further down the gel allowing SDS-PAGE to separate 
different protein molecules according to their size (Caprette 2010). 
 
The BCA assay was used to measure free protein present in the supernatants as lipids 
present in the resuspended pellet interfered with the assay components. However, one 
of the limitations of the BCA assay is that for protein samples it has a linear range of 
100 - 1000 µg/ml. Therefore, samples containing 10 µg/ml of protein were not tested 
as the concentration would be out of the linear range, whereas 100 µg/ml, although 
being below the linear range, and 1000 µg/ml concentrations were tested (Figure 
4.12A). From Figure 4.12A, it can be seen that for the 0, 5 and 10 % PEG 
formulations no free OVA was detected in the supernatants when 100 µg/ml was 
added, whereas for the 25 % PEG formulation 4.9 % (4.9 µg) of free OVA was found. 
With the addition of 1000 µg of OVA, the levels of non-adsorbed OVA increased for 
all four of the formulations, and the amount of non-adsorbed protein increased with 
increasing PEG concentrations, from ~25 % with DDA:TDB formulations up to ~80 
% when 25 % PEG was present in the formulation (Figure 4.12A). These results were 
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confirmed using SDS page. From Figure 4.12B, it can be seen that no protein bands 
were detected in the supernatants of all formulations incubated with 100 µg/ml, 
whereas protein bands were present for the pelleted samples confirming antigen 
adsorption to the liposomes. Figure 4.12C shows the SDS page analysis of 
formulations prepared with 1000 µg/ml. Again in line with the results in 4.12A, 
higher levels of protein are detected in the supernatant with formulations containing 
increasing PEG concentrations. This coincides with decreasing levels of protein 
associated with the pelleted liposomes. These findings are summarised in Table 4.2. 
In line with these studies, Korsholm et al (2007) also found that the majority of the 
protein was found to be associated with liposomes at concentrations of OVA less than 
1 mg/ml. Therefore taken together these findings (Figures 4.11 and 4.12) demonstrate 
that cationic liposomes are able to bind anionic proteins such as OVA, and the binding 
of OVA to these liposomes results in decreased zeta potential and increased vesicle 
size, presumably due to the electrostatic interactions promoting vesicle aggregation. 
With increasing concentration of PEG on the surface of the liposomes, the protein 
binding capacity of the liposomes is reduced due to the hydrophilic coating produced 
by the PEG. Therefore the steric coating of the DDA:TDB liposome reduces 
electrostatic interactions of the liposomes with proteins thereby limiting their ability 
to carry sub-unit antigens on their surface. 
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Figure 4.12 Adsorption of OVA. (A) Percentage (%) of non-adsorbed OVA (100 µg/ml and 1000 
µg/ml) present within the supernatants of DDA:TDB 5, 10 and 25 % PEG formulations were quantified 
by the BCA protein assay. These results of the BCA protein assay were confirmed by SDS page (B) 
100 µg/ml and (C) 1000 µg/ml of OVA. Lane 1 = DDA:TDB, lane 2 = 5 % PEG, lane 3 = 10 % PEG, 
lane 4 = 25 % PEG. P = pelleted liposomes; S = supernatant. Results represent mean ± SD of triplicate 
experiments. 
 
  
Table 4.2 Description table of the bands and corresponding formulations including the result of 
the BCA assay for the % protein non-adsorbed. 
 
 
Lane 
P = pellet 
S= supernatant 
Formulation % Protein non-adsorbed 
100 µg/ml 
% Protein non-adsorbed 
1000 µg/ml 
1P DDA:TDB   
1S DDA:TDB None detected 27.6 ± 0.03% 
2P 5 % PEG    
2S 5 % PEG None detected 21.3 ± 7.2% 
3P 10 % PEG   
3S 10 % PEG None detected 50.6 ± 1.1% 
4P 25 % PEG   
4S 25 % PEG 4.9 ± 1.5% 66.9 ± 2.9% 
Marker  1P    1S    2P    2S     3P    3S     4P    4S Marker  1P     1S     2P     2S    3P     3S    4P     4S 
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4.4.3.2 Adsorption of Ag85B-ESAT-6 antigen  
To further confirm the binding efficiency of antigens to DDA based liposomes, the 
adsorption capacity of the systems for the mycobacterial Ag85B-ESAT-6 fusion 
protein was investigated. This protein has been identified as a promising vaccine 
antigen against TB in several studies (e.g. Olsen et al 2001; Langermans et al 2005); a 
disease for which a Th1 type immune response is required for protection. The degree 
of adsorption of antigen (% of total used; 0.01 mg) to DDA:TDB liposomes in the 
presence and absence of PEG was determined using 125I-labelled Ag85B-ESAT-6 to 
both validate previous studies and allow lower antigen concentrations to be tested. 
Again the addition of PEG was found to have an effect on protein adsorption, with 
DDA:TDB adsorbing around 97 % of Ag85B-ESAT-6 (Figure 4.13), in line with 
previous studies (Davidsen et al 2005), whilst the loading was reduced to ~ 80 % for 
the 25 % PEG formulation. The ability of tracking radio-labelled protein allows 
adsorption studies to be conducted with higher sensitivity than is the case with BCA 
and SDS page assays. As can be seen from Figure 4.13, that even at low subunit 
antigen concentrations, the presence of PEG on the surface of the cationic liposomes 
influences the electrostatic binding of the antigen to the MLV surface. However, to a 
much lesser extent than that seen when higher protein concentrations are used (Figure 
4.12).  
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Figure 4.13 Quantification of antigen adsorption of DDA:TDB, 5, 10, 25 % PEG liposomes using 
125I-labelled Ag85B-ESAT-6. MLVs were prepared by the lipid-hydration method. Non-adsorbed 
antigen was removed via centrifugation. Results represent mean ± SD of triplicate experiments. 
 
4.4.4 Interactions of MLV liposomes with serum proteins 
4.4.4.1 Particle size and zeta potential 
Due to their surface charge, cationic liposomes are known to interact with biological 
media and aggregate into larger constructs (McNeil & Perrie 2006). To investigate 
possible electrostatic interactions of the DDA with biological media and the effect 
pegylation of these liposomes has on these interactions, the various DDA:TDB 
liposomes were placed into a solution containing 50 % FCS (aiming to mimic the 
protein environment found in vivo that the liposomes may encounter upon injection).  
 
Upon exposure to 50 % FCS, an immediate visible aggregation of DDA:TDB cationic 
liposomes occurred, with particles sizes increasing from 482 nm to over 700 nm after 
exposure for 60 minutes (Figure 4.14A). Similarly formulations containing 5 % PEG 
also showed a significant (p<0.05) increase in size post-exposure to 50 % FCS. In 
contrast, with the 10 % or 25 % PEG formulation (Figure 4.14A), no significant 
difference in size and zeta potential was observed (Figure 4.14B).  
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For cationic liposomes, interactions with serum proteins in vivo results in aggregation 
and quick clearance from the circulation. For example, Opanasopit et al (2002) found 
that cationic particles are particularly susceptible to forming aggregates after binding 
of negatively charged plasma proteins, which are then either entrapped in the 
pulmonary capillary bed or taken up by the MPS. However, it is also well documented 
that pegylated liposomes have excellent stability in body fluid environments 
(Moghimi & Szebeni 2003). The use of PEG to provide a hydrophilic shield over the 
surface of the particle is the most usual means of minimising these interactions with 
plasma proteins (Fattal & Barratt 2009). For cationic liposomes, although the high 
zeta potential value of 48.0mV should generate enough electrostatic repulsion to keep 
the particles stable in colloidal systems, the highly cationic surface will promote 
interaction with serum proteins or opsonins in the body fluid leading to aggregation. 
However, the pegylated formulations (in particular those containing 10 % and 25 % 
PEG) were stabilised against such aggregation due to the presence of the flexible 
polymer preventing protein-liposome interactions (both the loading of antigens and 
serum proteins). A neutral zeta potential and steric outer layer appears to create a 
physical barrier between protein and liposome carrier. A study by Huang et al (2008) 
also showed that PEG stabilised cationic niosomes in serum condition. The authors 
found that turbidity of cationic niosomal suspensions increased to relatively high 
levels, indicating an increase in particle size induced by aggregation or protein 
absorption on the particle surface. Meanwhile, the turbidity of pegylated niosomes 
changed little in 6 hours and showed only a slight increase in 20 hours (Huang et al 
2008). 
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Overall, this work suggests that DDA:TDB liposomes can be prepared by the addition 
of PEG to be resistant to aggregation in the presence of biological media whilst still 
being able to carry significant levels of adsorbed antigen. This offers the potential to 
investigate a cationic liposome formulation which may not aggregate after 
intramuscular injection, and offer a different pharmacokinetic profile where a depot 
may not be formed, thus allowing the role of vaccine delivery systems biodistribution 
to be further investigated.   
 
4.4.4.2 Antigen retention in the presence of biological moieties  
It has been previously reported that association of antigen with the adjuvant delivery 
system can improve vaccine efficacy (Holten & Andersen 2004). To look at the 
potential of these systems to retain their antigen after injection, antigen release from 
liposomes incubated in either Tris buffer or simulated in vivo conditions (50 % FCS 
as previous) and antigen retention measured using I125-labelled Ag85B-ESAT-6. Each 
formulation was diluted (1:5) using 50 % FCS in Tris buffer and incubated in a 
shaking water bath at 37 °C for 96 hours. Over the 96 h period of the study a high 
degree of I125-Ag85B-ESAT-6 adsorbed to DDA:TDB liposomes was maintained 
(Figure 4.15) with only 2 % loss in the initial 24 hour period  and no significant loss 
following in the next 24 h (Figure 4.15). 
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Figure 4.14 (A) Vesicle size (nm) and (B) zeta-potential (mV) of DDA:TDB, 5, 10, 25 % PEG 
liposomes upon exposure to stimulated in vivo conditions (represented by storage at 37 oC in 50 
% FCS). Results represent mean ± SD of triplicate experiments. 
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A similar result was found for the 5 % PEG formulation. However, over time antigen 
loss was noted for both of these formulations and at 96 hours around 83 - 88 % 
antigen remained with the liposome formulation suggesting these formulations offer a 
sustained and prolonged release (Figure 4.15). However, whilst the presence of PEG 
on the surface of liposomes had been shown to inhibit liposome aggregation in 
simulated in vivo conditions, these systems were less able to retain antigen under such 
conditions with increasing levels of PEG resulting in a higher release of antigen from 
the system. For the 10 % PEG formulation, the initial antigen adsorption was 89 % 
respectively and a steady release was seen over time to around 69 % after 96 hours of 
incubation. For the formulation containing 25 % PEG, the release rate was 
significantly (p<0.05) greater again with only 31% of the antigen remaining adsorbed 
after 96 hours (Figure 4.15). From these results, it is apparent that with increasing 
amount of PEG there was a greater release of antigen from the liposome systems over 
time, in particular with the 10 % and 25 % PEG formulations.  
 
These results suggest that the addition of PEG to the liposomes is limiting 
electrostatic interactions therefore reducing binding and resulting in increased loss of 
adsorbed antigen over time. A similar result has been reported by Huang et al (2008). 
The authors used bovine serum albumin to evaluate the protein/gene carrier binding 
efficiency of serum albumin with PEG niosomes and found that it was significantly 
lower than that of cationic niosomes. In particular the authors noted that a neutral 
zeta-potential and steric outer layer, due to PEG modification, appeared to create a 
physical barrier between protein and gene carrier. Control studies in which fetal calf 
serum (FCS) was mixed with I125-Ag85B-ESAT-6 without liposomes did not result in 
aggregates which could be pelleted by the same centrifugation method, therefore 
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dismissing the possibility that dissociated antigen may have given false positives due 
to an association with serum proteins. Overall this suggests that protein from the FCS 
adds cumulatively to the vaccine antigen rather than competitively displacing the 
vaccine antigen from the surface of the liposomes. 
 
Figure 4.15 Adsorbed Ag85B-ESAT-6 antigen retention profile. DDA:TDB 5, 10, 25 % PEG MLV 
liposomes stored under simulated in vivo conditions with antigen (represented by storage at 37 oC in 50 
% FCS). Results represent mean ± SD of triplicate experiments. 
 
 
4.4.5 Entrapment of antigen within DRV cationic liposomes  
Given the advantages of PEGylation in inhibiting liposome aggregation in the 
presence of biological moieties but the disadvantage that its presence reduces antigen 
surface-loading, a method to entrap the antigen within liposomes were considered. 
The preparation of dehydration-rehydration vesicles (DRV) was first established by 
Kirby and Gregoriadis (1984a) and was developed to promote higher entrapment 
within vesicles than could be achieved with other methods such as the lipid hydration 
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method or the reverse-phase evaporation method. With the DRV method, a process of 
dehydration followed by rehydration has been employed to entrap material inside the 
liposomes. The starting point is the preparation of ‘empty’ aqueous filled SUV. To 
this SUV suspension the solute to be entrapped within the liposomes is added, such 
that the solute is outside the liposomes in the external medium. Lyophilisation of the 
mixture, followed by subsequent rehydration with an initial low volume of water 
brings about a reorganisation of the lipid membranes such that after fusion they 
reform liposomes in which a considerable proportion of the aqueous solute is now 
located within the vesicles. The liposomes obtained are larger than the original SUV 
and oligolamellar in nature. The advantages of employing this method include 
(Gregoriadis et al 1999): 
• High entrapment of a range of solutes including small drugs, DNA, peptides 
and proteins. 
• Large scale production of SUV can be undertaken in a range of ways prior to 
addition of the solute to be entrapped. 
• No exposure of the drug to be entrapped to solvents. 
• Prior to rehydration the product is in a freeze-dried state offering longer term 
stability. 
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4.4.5.1 Comparison of size and zeta potential of pegylated DRV 
The DRV method has shown to promote greater humoural and cell-mediated immune 
responses against the encoded antigen in immunised mice in contrast to naked DNA 
or DNA complexed to preformed liposomes (Gregoriadis et al 1997; Perrie et al 
2001). Previously in section 4.4.2, the effect of OVA (0 µg, 10 µg, 100 µg and 1000 
µg) on the size and zeta-potential of MLV prepared from DDA:TDB with (5, 10 and 
25 %) and without PEG was investigated. To consider the potential of entrapping 
antigen within the liposomes, similar formulations were also prepared by the DRV 
method.  
 
The sizes of the various DRV constructs are shown in Figure 4.16. It can be seen that 
the incorporation of PEG to ‘empty’ DDA:TDB, 5 %, 10 % and 25 % DRV 
formulations resulted in vesicle sizes of around 450 nm for DDA:TDB, 370 nm for 5 
%, 365 nm for 10 %, which were similar in size to their MLV counterparts, however 
the 25 % PEG formulation was somewhat smaller in size compared to the MLV 
counterparts (120.9 nm versus 287.7 nm respectively).  
 
As with MLV based systems (Figure 4.11) following the addition of 10 µg of OVA, 
there was no significant increase in size for the DRV DDA:TDB, 5 %, 10 % and 25 % 
PEG formulation (Figure 4.16A). The addition of 100 µg/ml of OVA did have a 
significant effect on the size of the DDA:TDB (p<0.05) and the 5 % PEG 
formulations (p<0.01), where an increase in size was found due to the incorporation 
of the protein within the DRV vesicles. However, this was not the case for the 10 % 
and 25 % PEG formulations where no significant change in size was measured 
compared to their equivalent ‘empty’ DRV. On further increases in antigen 
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concentration to 1000 µg, all 4 of the DRV formulations show major increases in 
vesicle size suggesting at high protein/cationic lipid concentrations larger vesicle 
constructs are formed in all cases. This is supported by the zeta-potential studies 
(Figure 4.16B), which assist to evaluate the extent of cationic lipid and anionic 
antigen interactions. In the instance of no protein and 10 µg and 100 µg (with the 
exception of 25 % PEG at the latter concentration) the zeta-potential does not change, 
suggesting that a considerable amount of antigen is not interacting with the vesicle 
surface and is either not surface bound or located within the liposomes presumably 
bound to the cationic charges of the inner bilayers. However, as the concentration of 
antigen is increased to 1000 µg a significant (p<0.05) reduction in cationic charge was 
found for all formulations compared to their empty liposomal counterparts. Again this 
suggests a high protein/lipid ratios may result in the inner vesicle core of the DRV 
become full with more protein being complexed on the vesicle surface, thus causing 
neutralisation of the vesicles cationic charge.  
 
It has previously been reported that by employing the DRV procedure, consistently 
high entrapment values for a range of antigens and solutes can be achieved, depending 
on the liposome composition and the moiety being entrapped (Gregoriadis et al 1996). 
The 25 % PEG formulation did not form DRV vesicles and remained as SUV. It could 
be that due to the high PEG content, which is known to have unfavourable structural 
changes in the liposomal bilayer and the neutral charge, may have resulted in the 
formulation remaining as SUV.  
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Figure 4.16 (A) Vesicle size (nm) and (B) zeta-potential (mV) of DDA:TDB, 5, 10, 25 % PEG 
liposomes following the entrapment of OVA at 10 µg/ml, 100 µg/ml and 1000 µg/ml. Size and zeta-
potential measured in Tris buffer (1 mM) using a Brookhaven ZetaPlus instrument. Results represent 
mean ± SD of triplicate experiments. 
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4.4.5.2 The effect of PEGylation DDA:TDB SUV characteristics  
In order to investigate if vesicle size had an effect, smaller vesicles were prepared by 
sonicating the MLV to produce SUV prior to the addition of antigen. The liposomes 
produced were in the range of 100 - 250 nm in size (Table 4.3).  
 
Table 4.3 Characterisation data for the SUV based liposomes with 2 µg of Ag85B-ESAT-6.  
 
 
Results represent mean ± SD of triplicate experiments.  
 
 
From Table 4.3, it can be seen that the incorporation of PEG to the DDA:TDB SUV 
influenced the size, polydispersity and zeta-potential of the liposomes. As the amount 
of PEG increased there is a decrease in vesicle size, with liposomes prepared from 
DDA:TDB alone being around 250.2 ± 43.3 nm whilst formulations containing 10 %, 
and 25 % PEG being 144.1 ± 9.3 nm (p<0.001) for 10 %, and 120.0 ± 12.2 nm 
(p<0.001) for 25 % PEG formulation respectively (Figure 4.3). In terms of the zeta-
potential, it can be seen that as the amount of PEGylation increased there was a drop 
in zeta potential from 45.6 ± 1.8 mV when no PEG is present to around 2.9 ± 1.0 mV 
when the bilayer contains 25 % PEG (p<0.001). These results showed a similar trend 
to that found with the MLV based liposomes (section 4.4.1) 
 
 
 
 
Formulation Size (nm) Polydispersity (PI) Zeta-potential (mV) 
DDA:TDB 250.2 ± 43.3 0.384 ± 0.05 45.6 ± 1.8 
10 % PEG 144.1 ± 9.3 0.279 ± 0.05 20.8 ± 1.0 
25 % PEG 120.0 ± 12.2 0.255 ± 0.04 2.9 ± 1.0 
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4.4.5.3 Comparison of MLV, SUV and DRV antigen loading and retentions  
From the results obtained above from sections 4.4.1 - 4.4.5.2 on the basis of 
adsorption, release, and serum stability data for the MLV systems and the initial 
characterisation data for the SUV and DRV systems, it was decided that in addition to 
the DDA:TDB formulation, the 10 % and 25 % PEG formulations would be taken 
forward for the biodistribution studies based on:  
1. The MLV 10% PEG formulation having an initial antigen adsorption of 89 % 
and a steady release to around 69 % after 96 hours. The results obtained for the 
5 % PEG were similar to that of DDA:TDB and for the 25 % PEG a less initial 
antigen adsorption and greater release was found.  
2. The 10 % and the 25 % formulations were found to be stable in the presence 
of serum proteins compared to the 5 % and DDA:TDB formulations which were 
found to aggregate. 
 
Further characterisation work involving quantifying and determining release of 
entrapped (DRV) and adsorbed antigen (SUV) was carried out on the DDA:TDB, 10 
%, and the 25 % PEG formulations.  
        
To quantify the amount of associated antigen with the different liposome types (MLV, 
SUV and DRV), 125I-labelled Ag85B-ESAT-6 was used (Figure 4.17). The 
DDA:TDB DRV based formulation had 98 % of the antigen associated with the 
pellet, a similar result to that of MLV and SUV based formulations (Figure 4.17). 
However compared to the MLV and SUV systems, the entrapment for the 10 % PEG 
DRV formulation was higher at ~98 % (similar to that of the DDA:TDB DRV) 
compared with 89 % for the MLV and 88 % for SUV systems of the same 
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composition (Figure 4.17). When the PEG content was increased to 25 % in the 
systems there was no significant difference between the MLV, DRV and SUV 
formulations with all three showing antigen association of 80-82 % (Figure 4.17). 
 
The DRV method is reported to promote entrapment of solutes (Kirby & Gregoriadis 
1984a) however in the case of systems where there is electrostatic interactions 
between the solute and the liposomal membrane, as is the case with anionic protein 
and cationic liposomes, it is not always clear where the antigen is located (adsorbed 
on the surface versus entrapped within the liposomes). From the data in Figure 4.17, 
there is no evidence of differences between the three types of formulations that the 
antigen is entrapped within the DRV compared with surface adsorbed. However, to 
confirm that the antigen is entrapped and not surface adsorbed further experiments 
were carried out as described in detail in section 5.3.1.   
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Figure 4.17 Quantification of antigen entrapment of DDA:TDB, 5, 10, 25 % PEG liposomes using 
125I-labelled Ag85B-ESAT-6. DRVs were prepared by the dehydration-rehydration method. Non-
adsorbed antigen was removed via centrifugation. Results represent mean ± SD of triplicate 
experiments. 
 
The ability of these systems to retain the associated antigen when incubated in either 
Tris buffer or simulated in vivo conditions (50 % FCS as previous) was also tested 
(Figure 4.18). In terms of antigen retention profiles of the various formulations 
(Figure 4.18), after 24 hours significant differences in the level of antigen retention 
was measured. For the MLV based formulations DDA:TDB had an antigen retention 
of 89 %, whereas for 10% and 25 % PEG a retention of 70 % and 38 % was found. A 
similar pattern of antigen retention was found for the SUV based liposomes (Figure 
4.18A). Thereafter, all six formulations investigated showed no further significant 
release. For the DRV based liposomes, the DDA:TDB DRV formulation had a 
slightly higher retention profile compared to the MLV formulation with antigen 
entrapment of 93 % compared with 89 % after four days of incubation for the DRV 
and MLV respectively (Figure 4.18A). A similar higher retention over time was found 
for the 10 % PEG DRV formulation around 80 % entrapment compared to 69 % 
antigen adsorption for the equivalent MLV after 96 hours (Figure 4.18B). For the 25 
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% formulations, again a better release profile was found when the antigen was 
entrapped with 54 % antigen retention compared to 31 % and 35 % for MLV and 
SUV formulations after 96 hours (Figure 4.18C). These results suggest generally the 
DRV systems were able to retain their associated antigen compared to their equivalent 
MLV and SUV counterparts. This finding is supported by Perrie and Gregoriadis 
(2000b). The authors found that interaction of DNA with preformed cationic SUV or 
with cationic SUV made of DOPE and DOTAP (1:1 molar ratio) leads to the 
formation of large complexes with externally bound DNA. However, dehydration of 
the DNA-SUV complexes and subsequent rehydration generates submicron liposomes 
incorporating most of the DNA in a fashion that prevents DNA displacement.
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Figure 4.18 Ag85B-ESAT-6 antigen release profile. (A) DDA:TDB, (B) 10 % PEG and (C) 25 % PEG MLV, DRV and SUV (to allow comparison) liposomes when stored 
under simulated in vivo conditions (50 % FCS, 37 °C). Results represent mean ± SD of triplicate experiments. 
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4.4.5.4 Addition of cryoprotectant: a modified DRV procedure for the formation of 
small liposomes  
Liposomes entrapped antigen vesicles prepared by the DRV procedure (Gregoriadis et 
al 1999) produce liposomes of relatively large size (> 200 nm) and subsequently Zadi 
and Gregoriadis (2000) developed a novel and non-destructive method of producing 
small liposomal vesicles, which are still able to retain a high percentage of entrapped 
solutes. It is a modification of the DRV procedure, where a disaccharide is utilised as 
a cryoprotectant during freeze-drying. The method is an extension of Crowe and 
Clegg’s (1973) suggestion that disaccharides added to vesicles could replace water 
that normally surrounds the polar groups of the lipids.  
 
When liposomes are subjected to the DRV procedure, the freeze-drying process 
removes the water content of the vesicles. With water removal, the vesicles fuse due 
to the physical changes in the bilayers structure, with a transition from the gel to 
liquid phase, creating larger liposomes than those prior to the process (i.e. SUV). The 
disaccharides interact with the polar groups of the phospholipids by hydrogen bonds 
and as a consequence stabilise the vesicles during freeze-drying (Crowe et al 1988).   
 
To utilise this method to produce smaller DDA:TDB with entrapped antigen, sucrose 
was used as the cryoprotectant added during the freeze-drying stage at a sucrose to 
lipid mass ratio of 1:1, based on previous studies, reporting this as the optimal 
sucrose/lipid mass ratio (Zadi & Gregoriadis 2000).  
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Figure 4.19 Effect of sucrose on (A) vesicle size (nm) (B) zeta potential (mV) within DRV 
liposomes. Results represent mean ± SD of triplicate experiments. 
 
 
From Figure 4.19A, it can be seen that vesicle sizes reduced considerably when 
sucrose was added to the liposome suspension, in the case of DDA:TDB from 400 nm 
to 179 nm, and for the 10 % PEG from 500 nm to 251 nm. The zeta-potential for 
DDA:TDB, 58.0 mV versus 50.1 mV with sucrose and for 10 % PEG, 28.5 mV 
versus 20.1 mV, was unaffected by the addition of sucrose (Figure 4.19B). The initial 
antigen loading was not affected by the addition of the cryoprotectant with the 
percentage of antigen entrapment being around 95 - 97 % for DDA:TDB and 85 - 90 
% for the 10 % PEG formulation (Figure 4.20). During the DRV procedure, the 
liposomes endure two distinct stresses, freezing and drying (Allison et al 2000). Upon 
rehydration, the liposomal bilayer membranes lose functionality and become 
disrupted, causing the membrane to fuse and aggregate and resulting in the production 
of large vesicles in which the antigen becomes entrapped. However, in the presence of 
sugars this disruption does not occur (Crowe et al 1985).  
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Figure 4.20 Quantification of antigen entrapment of DDA:TDB and 10 % PEG liposomes with 
addition of sucrose using 125I-labelled Ag85B-ESAT-6. DRVs were prepared by the dehydration-
rehydration method. Non-adsorbed antigen was removed via centrifugation. Results represent mean ± 
SD of triplicate experiments.  
 
4.4.6 Biodistribution studies of liposomes and their associated antigens 
The biodistribution of liposomes depends on the physicochemical properties of the 
liposomes such as liposome size, surface charge and composition as well as on other 
factors such as dose and route of administration. Previous biodistribution studies 
(Henriksen-Lacey 2010) have found that DDA:TDB forms an efficient depot of 
antigen at the injection site. The ‘depot effect’ is when the antigen is retained at the 
injection site, thereby increasing the time of vaccine exposure to the immune cells. 
With the DDA:TDB formulation this has been suggested to be due to the strong 
electrostatic charges i.e. aggregation between the cationic liposomes and serum 
proteins, thereby causing a liposomal depot to form which retains the antigen. 
Therefore, the PEGylated formulations were prepared to address whether the 
aggregation between the liposomes and serum proteins is responsible for the depot 
effect. Since pegylated liposomes have excellent stability in the presence of serum 
proteins due to the hydrophilic shield over the surface (Immordino et al 2006), this 
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will offer the potential to investigate cationic liposome formulations which may not 
aggregate after intramuscular injection of the particle. In addition the ability to entrap 
antigen within the liposomes, rather than surface adsorb, may promote enhanced 
retention of the antigen with the liposomes. Therefore within biodistribution studies 
the effect of PEGylation on various liposome systems (MLV, SUV and DRV) was 
considered. 
 
To follow the fate of the liposomes and the antigen, mice were vaccinated i.m. with 
I125-labelled Ag85B-ESAT-6 with H3-labelled liposomes in order to analyse the fate 
of injected antigen in the presence and absence of a pegylated liposomal carrier. On 
days 1, 4 and 14 post vaccination, major organs/tissues (spleen, non-injected and 
injected muscle site and popliteal lymph node (PLN)) were isolated and I125 and H3 
content was determined. No other organs were tested based on previous studies 
(Henriksen-Lacey et al 2010) which demonstrated these to be the major site of interest 
after i.m. immunisation. 
 
4.4.6.1 The effect of PEGylation on MLV retention at the site of injection 
From Figure 4.21, it can be seen that for the DDA:TDB formulation the levels of 
liposomes retained at the injection site after four days had not decreased significantly 
compared to day 1, and more than 40 % of the original dose was still present even 
after 14 days (Figure 4.21A; Table 4.4). Considering the effect of PEG, on days 1 and 
4 there was no significant difference between the DDA:TDB and the 10 % PEG 
formulation, with the percentage liposome retention being similar for both 
formulations but by day 14 there was significantly more (p<0.01) DDA:TDB 
liposomes present compared to the 10 % PEG formulation. In contrast, the 25 % PEG 
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liposomes were removed faster than the DDA:TDB with significantly lower levels 
found at the injection site on day 1 (p<0.05) and day 14 (p<0.001). Simultaneously, 
Ag85B-ESAT-6 detection showed that more than 70 % of the initially co-
administered antigen dose was found at the SOI 1 day p.i. when administered with 
DDA:TDB liposomes, and the presence of 10 % PEG in the formulation made no 
significant difference (Figure 4.21B Table 4.4), whereas only 7 % of the initial 
antigen dose was detected when administered together with 25 % PEG formulation at 
the same time-point (Figure 4.21B). By day 4, DDA:TDB retained significantly 
higher levels at the injection site compared to both PEGylated formulations but by day 
14 there was no significant difference. 
 
These results suggest that higher levels of PEG are able to significantly inhibit the 
formation of a liposome depot at the injection site and also severely limit the retention 
of antigen at the site. This suggests that the presence of PEG on the surface of the 
liposomes may allow the faster drainage of the liposomes from the site of injection. 
Previous biodistribution studies (Henriksen-Lacey et al 2010) demonstrated the 
requirement of a cationic vesicle for the formation of a depot at the site of injection 
which promoted antigen retention. The authors compared neutral DSPC liposomes 
with DDA:TDB liposomes and found that the level of both liposomes and antigen at 
the SOI were significantly lower in the case of the DSPC formulation at all time 
points and by day 14 p.i. is undetectable. It was hypothesised that the decrease in 
antigen retention at the SOI for DSPC liposomes when compared to DDA based 
liposomes, is due to the non-aggregating nature of DSPC liposomes in the presence of 
biological components. However, in this case the opposite was true for the 10 % PEG 
formulation as it was found from the characterisation work that although the 10 % 
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PEG formulation did not aggregate in the presence of serum proteins, the formulation 
still formed a depot of antigen at the site of injection.  
 
4.4.6.2 The effect of PEGylation on SUV retention at the site of injection 
In order to investigate if vesicle size had an effect on the liposome depot effect, 
smaller vesicles were prepared by sonicating the MLV to produce SUV prior to the 
addition of antigen. From Figure 4.21C, 61 % of DDA:TDB SUV liposomes 
remained at the site of injection after day 1, which dropped to 52 % on day 4, and 15 
% by day 14. The addition of 10 % PEG had no significant effect on day 1 with the 
percentage of liposomes at the site of injection being around 50 % compared to 61 % 
found with the DDA:TDB liposomes. However, a significant difference was found 
compared to DDA:TDB on day 4, and 14 with only 14 % versus 55.9 % on day 4, and 
1.8 % versus 15.0 % liposomes on day 14. Following the addition of 25 % PEG, 
similar to the MLV based formulation the liposomes were removed faster than the 
DDA:TDB with significantly lower levels found at the injection site on day 1 
(p<0.05) and day 14 (p<0.001). 
 
Simultaneously, Ag85B-ESAT-6 detection showed that more than 78 % of the 
initially co-administered antigen dose was found at the SOI 1 day p.i. when 
administered with DDA:TDB liposomes. Furthermore, the presence of 10 % PEG 
made a significant difference to the amount of antigen present (p<0.05) which was 
around 43.4 % (Figure 4.21D Table 4.4), whereas only 5 % of the initial antigen dose 
was detected when administered together with 25 % PEG formulation at the same 
time-point (Figure 4.21D). By day 4 and 14, DDA:TDB retained significantly higher 
levels at the injection site compared to both PEGylated formulations. 
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When comparing the MLV and the corresponding SUV liposomes (summarised in 
Table 4.4), there was no significant difference in the liposome retention for 
DDA:TDB at the site of injection on days 1 and 4. However on day 14, a significantly 
higher (p<0.05) percentage of liposome retention was found for the MLV liposomes 
compared to the SUV liposomes (~30 % versus ~15 % respectively). For the 10 % 
PEG formulation, there was no significant difference in the liposome retention at the 
site of injection on days 1 and 14. However, a significant difference in the liposome 
retention was found at the site of injection on day 4, with a significantly higher 
(p<0.05) percentage of liposome retention found for the MLV liposomes compared to 
the SUV liposomes (48 % versus ~14 % respectively). For the 25 % PEG formulation, 
there was no significant difference in the percentage of liposome retention at the site 
of injection between the MLV and the SUV formulations at all time-points (Table 
4.4).  
 
In terms of antigen retention for the DDA:TDB formulation, no significant difference 
was found between the MLV and SUV formulations on day 1 and 14 (Table 4.4). 
However, a higher % of antigen retention was found on day 4 (47 % compared to the 
MLV formulation around 24 %).  
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Figure 4.21 Pharmacokinetic profile of (A) liposome and (B) antigen for MLV and (C) liposome and (D) antigen for SUV following i.m. injection. Liposomes and 
Ag85B-ESAT-6, radiolabelled with H3 and I125 respectively, were detected at the site of injection using γ-counting and scintillation counting techniques. The proportion of 
each radionucleotide as a % of the initial dose was calculated. Results represent mean ± SD of five mice.  
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This higher level of antigen retention suggests that perhaps the SUV based liposomes, 
due to their small size, aggregate more extensively with serum proteins thereby 
causing the antigen to retain at the site of injection longer. For the 10 % PEG, a 
significant difference (p<0.05) was found on day 1 with a higher percentage of 
antigen retention found with the MLV formulation, however by day 4 and 14 there 
was no significant difference. Furthermore, the percentage of antigen retention for the 
25 % PEG formulation MLV and SUV was similar at all time-points with no 
significant difference (p>0.05).  
 
From these results, it was found that higher levels of PEG in both the MLV and SUV 
liposomes is able to significantly inhibit the formation of a liposome depot at the 
injection site. In spite of this when comparing the MLV and SUV liposomes a higher 
percentage of liposome retention was found with the MLV based liposomes. Although 
a higher level of PEG severely limits the retention of antigen at the site of injection, 
from this data it was found that size has an effect as well, with a faster drainage of the 
antigen from the site of injection found with the smaller 10 % pegylated liposomes on 
day 1 compared to the MLV counterpart. At higher PEG concentrations, there was no 
difference, however since the 25 % PEG MLV liposomes are considerably smaller 
than the other MLV systems (362 nm versus 454 nm with the DDA:TDB formulation) 
size may again be playing a role. On the other hand, in the absence of PEG, liposome 
size had no effect on the liposome retention at the SOI at all time points and had little 
effect on the depot effect at early time points. However a significantly higher 
percentage of antigen was found with the SUV based formulation at the SOI on day 4, 
and slightly more on day 14. Thus a larger group size would be required to elucidate if 
this small difference is indeed significant. 
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Table 4.4 Summary of the percentage (%) of liposome and antigen retention at the SOI for the 
MLV and SUV formulations on days 1, 4 and 14.  
Results represent mean ± SD of five mice. 
 
Previous studies (Henriksen-Lacey et al 2010) have compared the biodistribution 
profile of sonicated and non-sonicated DSPC:TDB liposomes and found no 
significant difference in the amount of antigen and liposome present at the site of 
injection. Although these were neutral based liposomes, in this work a similar result 
was found with the cationic DDA:TDB liposomes suggesting that cationic 
interactions with serum proteins can promote a depot effect with both small and large 
cationic systems.  
 
4.4.6.3 The effect of entrapping antigen within the liposomal systems on their biodistribution 
In order to investigate whether depot formation of antigen could be further improved, 
Ag85B-ESAT-6 was entrapped within DRV liposomes rather than surface adsorbed to 
MLV. Previous studies have found that the development of DRV made possible high-
yield entrapment of macromolecules in liposomal formulations and was initially 
applied to proteins (Factor VIII) (Kirby & Gregoriadis 1984b). In subsequent studies, 
DRV liposomes were shown to be immunogenic for entrapped tetanus toxoid. This 
was comparable with tetanus toxoid covalently linked to multilamellar vesicles (Davis 
& Gregoriadis 1987).  
Formulation  MLV 
      Size (nm)                 Liposomes                 Antigen 
SUV 
      Size (nm)                Liposomes               Antigen 
DDA:TDB Day 1 
                  Day 4 
                  Day 14 
 
454.3 ± 11.0 nm 
 
65.7 ± 29.6% 
52.3 ± 12.0% 
29.8 ± 7.0% 
73.5 ± 12.0% 
23.5 ± 4.4% 
0.80 ± 0.6% 
 
250 ± 43.3 nm 
 
61.1 ± 23.0% 
55.9 ± 16.0% 
15.0 ± 4.9% 
78.0 ± 20.2% 
46.8 ± 11.1% 
2.1 ± 1.3% 
10 % PEG Day 1 
                    Day 4 
                  Day 14 
 
375.0 ± 4.2 nm  
63.9 ± 2.2% 
42.6 ± 4.9% 
13.9 ± 6.0% 
68.4 ± 3.6% 
6.2 ± 1.8% 
0.16 ± 0.05% 
 
144.1 ± 9.3 nm 
 
47.8 ± 18.8% 
14.0 ± 6.9% 
1.8 ± 0.8% 
43.4 ± 10.4% 
8.6 ± 5.5% 
0.14 ± 0.3% 
25 % PEG  Day 1 
                    Day 4 
                  Day 14 
 
362.0 ± 6.4 nm 
18.7 ± 6.3% 
5.3 ± 0.95% 
1.06 ± 0.44% 
5.1 ± 0.92% 
0.65 ± 0.2% 
0.32 ± 0.13% 
 
120.2 ± 12.2 nm 
 
15.9 ± 8.4% 
10.9 ± 4.3% 
0.27 ± 0.07% 
4.97 ± 2.3% 
0.56 ± 0.1% 
0.13 ± 0.03% 
 186 
 
The clearance of the DDA:TDB DRV and modified DRV (mDRV) (both with and 
without PEG) was also investigated using radio-label to track them as previously 
described for MLV and SUV. From the results (Figure 4.22A), around 64 % of 
DDA:TDB DRV liposomes remained at the site of injection after 24 hours, which 
dropped to 47 % on day 4, and 29 % by day 14. The addition of 10 % PEG had a 
significant (p<0.05) effect on liposome retention initially (52 % liposome retention 
compared to 64 % found with the DDA:TDB formulation). However, longer term no 
significant effect on clearance was noted with the presence of 10 % PEGylation of the 
DRV (Figure 4.22A). Further increases in the PEG content to 25 % further increased 
liposome clearance rates, with significantly lower liposome levels found at the 
injection site on day 1 (p<0.01) and day 14 (p<0.01) (Figure 4.22A).  
 
For the smaller modified DRV formulations, formulated as DDA:TDB and 
DDA:TDB:10% PEG, there was no significant difference between the two 
formulations at each of the time points measured (Figure 4.22A). On comparing the 
DRV and mDRV for DDA:TDB, there was no significant difference at day 1 and 4, 
however by day 14 significantly higher (p<0.05) levels of the smaller vesicles had 
been cleared from the injection site (29 % for the DRV compared to 15 % found with 
the mDRV formulation; Figure 4.22A). For the 10 % PEG formulations, no 
significant difference was found at any of the time points.        
 
In terms of antigen retention, a significant (p<0.05) higher percentage of antigen was 
found with the DDA:TDB DRV compared with the 10 % PEG formulation on day 1 
(67 vs 54 % respectively) and day 4 (24 % compared to 10 %), however by day 14 
there was no significant difference (Figure 4.22B). With the 25 % PEG formulation, 
antigen was cleared from the site of injection faster than DDA:TDB with significantly 
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lower levels of antigen at the injection site on day 1 (p<0.01) and day 14 (p<0.01) 
(Figure 4.22B). A similar pattern of antigen retention was found with the 
corresponding mDRV formulations and comparing DRV and mDRV of the same 
formulation showed no significant difference in antigen retention. These studies 
suggest that reducing the size of DRV liposomes with or without 10 % surface PEG 
had no effect on the retention of liposomes and antigen at the SOI (Table 4.5). 
 
Table 4.5 Summary of the percentage (%) of liposome and antigen retention at the SOI for the 
DRV and mDRV formulations on days 1, 4 and 14. 
 
Results represent mean ± SD of five mice. 
 
 
 
 
 
 
 
 
 
 
 
Formulation  DRV 
Size (nm)                Liposomes            Antigen 
mDRV 
        Size (nm)               Liposomes           Antigen 
DDA:TDB Day 1 
                   Day 4 
                  Day 14 
 
560.1 ± 13.3 nm 
 
64.5 ± 3.7% 
47.0 ± 3.7% 
28.6 ± 6.0% 
67.1 ± 8.3% 
24.2 ± 4.8% 
2.4 ± 2.1% 
 
179.0 ± 82 nm 
 
52.0 ± 25.3% 
45.8 ± 25.3% 
14.6 ± 3.9% 
54.4 ± 26.1% 
26.0 ± 5.9% 
1.2 ± 0.7% 
10 % PEG  Day 1 
                   Day 4 
                  Day 14 
 
502.2 ± 128.0 nm  
 
51.6 ± 10.6% 
42.0 ± 10.2% 
26.3 ± 14.9% 
54.1 ± 7.6% 
9.98 ± 6.2% 
3.7 ± 3.4% 
 
251.0 ± 95.1 nm 
 
65.9 ± 15.9% 
30.2 ± 14.9% 
19.1 ± 8.7% 
62.6 ± 17.6% 
7.5 ± 6.0% 
2.12 ± 1.43% 
25 % PEG  Day 1 
                   Day 4 
                  Day 14 
 
132.45 ± 8.9 nm 
 
24.5 ± 7.9% 
5.9 ± 7.8% 
2.1 ± 0.1% 
6.6 ± 2.2% 
1.05 ± 0.22% 
0.62 ± 0.12% 
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Figure 4.22 Pharmacokinetic profile of (A) liposome and (B) antigen for DRV and mDRV 
following i.m. injection. Liposomes and Ag85B-ESAT-6, radiolabelled with H3 and I125 respectively, 
were detected at the site of injection using γ-counting and scintillation counting techniques. The 
proportion of each radionucleotide as a % of the initial dose was calculated. Results represent mean ± 
SD of five mice. 
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When comparing the MLV with DRV formulations (Table 4.4 and 4.5 respectively), it 
was found that comparable liposome compositions had a similar percentage of 
liposome retention at the site of injection at all three time-points, irrespective of their 
preparation method. More importantly, in terms of antigen retention, again there was 
no significant difference between the two preparations methods, with a similar 
percentage of antigen retention at the site of injection, for DDA:TDB, 10 % and 25 % 
PEG compositions at each of the three time points (Table 4.4 and 4.5). Similarly, 
comparison of SUV with mDRV shows no significant difference in antigen retention 
for both compositions. This suggests that regardless of whether the antigen is 
entrapped within the vesicle or adsorbed onto the outer surface, it has no effect on the 
retention of antigen and liposomes.  
 
The aim of the biodistribution study was to see whether the aggregation between the 
liposomes and serum proteins is responsible for the depot effect. Pegylated liposomes 
were employed to provide the hydrophilic shield over the surface (Immordino et al 
2006), to investigate cationic liposome formulations which may not aggregate after 
intramuscular injection of the particle. From the results, it was found for the various 
liposome systems, MLV, SUV and DRV, higher levels of PEG, i.e. 25 % PEG, were 
able to significantly inhibit the formation of a liposome depot at the injection site. The 
inclusion of 25 % of PEG also severely limited the retention of antigen at the site of 
injection. With the 10 % PEG formulations, although from the characterisation studies 
it was found that this formulation did not aggregate in the presence of serum proteins, 
it was found that this formulation formed a depot of liposomes and antigen at the site 
of injection. The 10 % PEG has a zeta-potential of around 20 mV as opposed to 50 - 
60 mV usually found with the DDA:TDB formulation. This suggests that it is not 
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entirely the cationic charge responsible for the depot formation. In addition, there was 
no significant difference on whether the antigen is entrapped (DRV) or adsorbed 
(MLV) on the surface on the retention of the antigen and the liposomes.  
 
4.4.7 Detection of vaccine components in the popliteal lymph nodes 
The left popliteal lymph node (PLN) is the local lymph node to which the lymph from 
the SOI (the left quadriceps) drains. Therefore, it will be the primary site at which the 
antigen will be presented to the T cells. The presence of both liposome and antigen 
vaccine components to the PLN was therefore analysed. The distribution of vaccine 
components to the draining PLN is shown in Figure 4.23. With the pegylated 
formulations, in particular, the 25 % PEG MLV and DRV liposomes although not 
significant, a marked increase in liposomes was found compared to the DDA:TDB 
liposomes suggesting that the liposomes drain quickly to the PLN when depot is not 
obtained. This was significant (p<0.05) in the case of 25 % PEG SUV liposomes on 
day 4 (Figure 4.23D).  
 
In terms of antigen retention, all three MLV formulations had a similar percentage of 
antigen retention on days 1 and 4, however, on day 14 the 25 % PEG formulation had 
a slightly higher level of antigen draining to the lymph nodes (0.02 % compared to 
0.01 % found with the DDA:TDB formulation; Figure 4.23B). A similar result was 
found for the 25 % PEG SUV (Figure 4.23D). For the DRV based formulation again a 
higher percentage of antigen drainage was found with the 25 % PEG DRV 
formulation 0.16 % compared to 0.009 % found with the DDA:TDB formulation 
(Figure 4.23B and F). From the initial biodistribution results, it was found that 25 % 
PEG formulation cleared from the site of injection significantly faster compared to the 
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DDA:TDB formulation which formed a depot of antigen. From this data, it appears 
that the 25 % PEG formulation drained quickly to the PLN with significantly higher 
levels found with the SUV formulation. It has previously been suggested (Mann et al 
2009) that a formulation that is able to get around the body would be able to stimulate 
a strong antibody mediated response, whereas one that forms a depot could likely aid 
a cell mediated response. DDA:TDB forms a depot at the site of injection and has 
been previously found to stimulate a Th1 type immune response (Davidsen et al 
2005).  
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Figure 4.23 Draining of liposomes and Ag85B-ESAT-6 to the PLN after i.m injection. DDA:TDB, 
10% PEG and 25% PEG (A) liposomes (B) antigen of MLV, (C) liposomes (D) antigen of SUV and 
(E) liposomes (F) antigen of DRV and mDRV. The proportion of each radionucleotide as a percentage 
of the initial dose and divided by the mass of the tissue (mg) was calculated. Results represent mean ± 
SD of 5 mice. 
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4.4.7.1 Monocyte influx to the SOI as determined by pontamine blue staining 
In accordance with previous studies (Henriksen-Lacey et al 2010), pontamine blue 
dye was used as a marker for infiltrating monocytes to the SOI. Using this method, it 
was found that mice injected with antigen alone showed little/no blue staining at the 
site of injection whereas mice injected with cationic liposomes showed localised blue 
staining at the injection site (Henriksen-Lacey et al 2010). Furthermore, the authors 
found a noticeable increase in the intensity of blue staining at the site of injection in 
mice injected with DDA:TDB liposomes as compared to DDA liposomes suggesting a 
role for TDB in the activation of the innate immune system, notably in the recruitment 
of circulating monocytes to the site of injection (Henriksen-Lacey et al 2010). 
 
Considering the different PEGylated and non-PEGylated formulations all of the 
liposome formulations tested induced monocyte infiltration, however the kinetics and 
intensities were varied (Figure 4.24): at day 14, higher level of monocyte infiltration 
can be seen with the DDA:TDB and 10 % PEG formulations compared with the 25 % 
PEG formulations (Figure 4.24). It is interesting that on day 14 p.i, the presence of 
DDA:TDB MLV liposomes at the SOI was equal to that of 10 % PEG liposomes and 
this was comparable with the DRV based formulations. Korsholm et al (2010) found 
that intraperitoneal injection of DDA based liposomes resulted in a significant 
recruitment of neutrophils, monocytes, mature macrophages and activated natural 
killer cells (Korsholm et al 2010) correlating nicely with the large monocyte 
infiltration observed in this and previous studies (Henriksen-Lacey et al 2010). 
However, with the SUV based liposomes all three liposome formulations induced a 
slower monocyte influx to the SOI suggesting that perhaps size of the liposome 
influences the recruitment of circulating monocytes to the site of injection. 
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Figure 4.24 Pontamine blue staining at the site of injection (quadriceps) after 14 days injection. 
DDA:TDB, 10 %, 25 % PEG liposomes MLV, SUV and DRV. A higher level of monocyte infiltration 
can be seen with the DDA:TDB and 10 % PEG formulations compared with the 25 % PEG 
formulations for all three MLV, SUV and DRV based liposomes.  
 
 
 
 
 
 
 
 
 
 
25% PEG DRV 10% PEG DRV DDA:TDB DRV 
10% PEG MLV DDA:TDB MLV 25% PEG MLV 
25% PEG SUV 10% PEG SUV DDA:TDB SUV 
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4.4.8 Synopsis of the biodistribution data  
Previous biodistribution studies (Henriksen-Lacey 2010) have found that DDA:TDB 
forms an efficient depot of antigen at the injection site. With the DDA:TDB 
formulation this has been suggested to be due to the strong electrostatic charges i.e. 
aggregation between the cationic liposomes and serum proteins, thereby causing a 
liposomal depot to form which retains the antigen. Therefore, the PEGylated 
formulations were prepared to address whether the aggregation between the liposomes 
and serum proteins is responsible for the depot effect. It has been demonstrated that 
higher levels of PEG i.e. 25 % was able to significantly inhibit the formation of a 
liposome depot at the injection site and also severely limit the retention of antigen at 
the site therefore resulting in a faster drainage of the liposomes from the site of 
injection.  
 
4.4.9 Testing the potential of the various formulations as vaccine adjuvants 
To test the potential of the various formulations as vaccine adjuvants, immunological 
analysis was carried out in order to determine the efficacy of the liposome 
formulations in achieving the desired immune response, encompassed quantification 
of Ag85B-ESAT-6 specific IgG antibody production, cytokine secretion and spleen 
cell proliferation (the ability of spleen cells to respond to re-stimulation with antigen). 
In terms of antibody responses, IgG is the most obvious choice for detection from 
blood samples. It can activate both the complement system and mediate opsonisation, 
thus leading to enhanced phagocytosis (Goldsby et al 2003). Further, the analyses will 
encompass the measuring of both the IgG1 and IgG2a subsets. Production of IgG1 
generally follows activation of Th2 type cells, whereas IgG2a is produced following 
secretion of Th1 type cytokines such as IFN-γ (Zhu et al 2007). Therefore, these 
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investigations will give an indication of both the level and type of humoural response 
initiated by the formulations tested. Cell proliferation analysis will provide an 
indication of both B cell and T cell activation in response to the antigen, giving 
further insight into the type and level of immune response achieved by each 
formulation. Cytokine ELISAs can be used as assay markers of both Th1 (IFN-γ and 
IL-2) and Th2 (IL-5 and IL-6) responses, providing further elucidation into the method 
of action of each formulation. IFN-γ is considered the key cytokine marker for anti-
mycobacterial immunity (Agger & Andersen 2001), being the major macrophage 
activator element, indicative of CD4+ recruitment, whilst also playing a role in B cell 
differentiation (Playfair & Bancroft 2004), therefore vital for cell mediated immunity 
(Mosmann & Sad 1996). IL-2 is a growth factor secreted by T-cells, thus indicative of 
T-cell activation, which in turn can lead to B-cell proliferation and differentiation. IL-
2 is therefore another essential signal in directing cell mediated immunity (Playfair & 
Bancroft 2004), whilst also playing a role in the humoural response. In terms of the 
Th2 cytokine markers, IL-5 promotes B-cell proliferation and differentiation, and also 
leads to eosinophil production and activation, whereas IL-6 is key in differentiation to 
plasma cells (Playfair & Bancroft 2004), an important facet in memory responses and 
innate immunity, and therefore useful in vaccines. 
 
4.4.9.1 Antibody production 
Antibody ELISAs were performed at regular intervals (see section 4.3.2.12) to 
determine the antigen specific antibody production initiated by each formulation 
(Figure 4.25). In terms of IgG, Figure 4.25A shows there was no significant difference 
at all time-points. Ag85B-ESAT-6 alone did not give detectable levels of IgG at the 
first time point, whereas all liposome formulations were able to induce measurable 
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levels of IgG. A comparison between the formulations at the first time point show a 
trend of increasing IgG levels with higher levels of PEG, but no notable differences 
between MLV, SUV and DRV. At the subsequent time-points, free antigen was able 
to induce IgG levels of log end point serial dilutions of around 3.0 (Figure 4.25A). In 
comparison, all liposome formulations were able to induce significantly (p<0.05) 
higher levels of IgG relative to free antigen, however there was no significant 
difference between the various liposome formulations. At the next two time-points a 
similar story in terms of IgG levels was noted. 
 
Considering the IgG1 and IgG2b (Figures 4.25B and C respectively) antibody isotype 
immune responses, the responses were similar to those of IgG with the exception of 
25 % PEG MLV and DRV formulation where Ag85B-ESAT-6-specific IgG2b levels 
were comparable to the free Ag85B-ESAT-6, even at the later time point. In contrast, 
the DDA:TDB MLV and DRV formulations appeared to show the highest and most 
enhanced IgG2b responses compared to the free Ag85B-ESAT-6 from 35 days 
onwards (Figure 4.25C). Interestingly there were no significant differences (p<0.05) 
in antibody responses from mice immunised with 10 % PEG DRV formulations with 
entrapped antigen compared with the group which received antigen adsorbed to 10 % 
PEG SUV. However, from the data it can be seen that the DDA:TDB MLV and DRV 
are able to elicit high titres of all three antibody isotypes, and also show strong 
Ag85B-ESAT-6-specific IgG2b mediated immune responses.  
 
Previous studies (Vangala et al 2007b) have shown that DDA:TDB was superior in 
inducing a cell mediated immune response as well as an IgG2 antibody response, 
compared to other cationic liposome systems in a hepatitis B study using hepatitis B 
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surface antigen (HBsAg). As discussed previously, there have been a number of 
attempts to optimise the DDA:TDB immune response by modification of the 
composition of the delivery system. Vangala et al (2006) incorporated non-ionic 
lipids and cholesterol, which resulted in a significant reduction of Ag85B-ESAT-6-
specific IFN-γ and IgG2 levels, while the induction of IgG1 titers was comparable 
between the formulations with and without non-ionic lipids and cholesterol (Vangala 
et al 2006). Incorporation of the two lipid components, DDA and TDB, into 
poly(D,L-lactic-co-glycolic acid) microspheres (PLGA) also resulted in a decrease 
in IFN-γ and IgG2 levels and no difference in IgG1 levels, when compared to 
DDA:TDB (Kirby et al 2008a). The results presented here suggest that following the 
addition of PEG, whilst the IgG1 titer was comparable between the formulations, a 
reduction of Ag85B-ESAT-6-specific IgG2 levels was found.    
 
4.4.9.2 Cytokine production 
Following on from the antibody ELISA, the next immunological investigation of this 
study was determining cytokine production induced by each formulation. The 
cytokines assayed encompassed indicators for both Th1 and Th2 immune responses. 
For Th1, IFN-γ (considered the key cytokine marker for tuberculosis immunity) and 
IL-2 were measured, and for Th2, IL-5 and IL-6 were measured (Figure 4.26). In 
terms of IFN-γ (Figure 4.26A), PEGylation of the formulations was seen to reduce 
responses for MLV, SUV and DRV formulations, with DDA:TDB systems being 
significantly (p<0.05) higher than their 25 % PEG formulation equivalents. 
Comparison between all the formulations shows that DDA:TDB MLV gave the 
highest levels. The results for the IL-2 cytokine were similar to those of IFN-γ 
(Figures 4.26A and B), with the presence of PEG in the formulations reducing IL-2 
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levels. IL-5 which is an indicator of a Th2 type immune response was significantly 
higher (p<0.05) for the 10 % PEG MLV compared to the DDA:TDB. Although not 
significant, a higher level of IL-5 was produced for the corresponding 10% PEG SUV 
formulation (Figure 4.26C). IL-6 is a pro-inflammatory cytokine and a significant 
higher level of this cytokine was produced for the DDA:TDB MLV (p<0.05) and 
DRV (p<0.001) formulations compared to the pegylated liposomes (Figure 4.26D).  
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Figure 4.25 Ag85B-ESAT-6 specific antibody titres. Groups of five female BALB/c mice, 
approximately six weeks old, received doses of vaccine formulations containing 2 µg of Ag85B-ESAT-
6 in a 50 µl volume. Vaccine formulations were administered intramuscularly, and each mouse 
received three doses at intervals of two weeks. Serum samples were taken at 12 days after the first 
administration and at two week intervals thereafter. Sera samples obtained at different time intervals 
after immunisation were analysed for the presence of anti-Ag85B-ESAT-6 IgG (A), IgG1 (B) and (C) 
IgG2b antibodies by enzyme-linked immunosorbent assay (ELISA). 
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It has been reported that an important mechanism of the ability of DDA (present in all 
formulations) to act as an adjuvant in the delivery of antigen is the immediate 
electrostatic interaction with the cell surface, followed by induction of active uptake 
(Smith Korsholm et al 2007). This observation implicates the loss of DDA molecules 
from the 25 % PEG formulation, thus leading to inefficient antigen uptake and lack of 
immunological effect. For the DRV based formulation, significantly higher levels of 
IFN-γ were found and this is comparable to the MLV based formulation 
demonstrating high levels of cell-mediated immunity with the addition of PEG having 
no effect. With the DDA:TDB DRV based formulation, a significantly higher level of 
IL-2 was produced compared to the pegylated formulations suggesting that the 
formulations containing PEG perhaps stimulate a Th2 type immune response. This 
was confirmed from the IL-5 cytokine results, where a significantly higher level of 
this cytokine was produced for the 10 % and 25 % PEG formulations. For the SUV 
based formulations, a similar trend was found with the pegylated formulations having 
a higher level of IL-5.  
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Figure 4.26 Ag85B-ESAT-6 specific cytokine production. Cytokines were detected using DuoSet® capture ELISA kits (mouse IFN-γ (A), IL-2 (B), IL-5 (C), IL-6 (D)) 
purchased from R&D systems, Abingdon, UK, according to the manufacturers instructions. Filled diamonds represent the mean of three measurements for each individual 
spleen. Horizontal lines represent average group values (n = 5) and are shown numerically on the chart. ** denotes significantly increased levels in comparison to naïve 
controls (n=5, p<0.01) *** denotes significantly increased levels in comparison to naïve controls (n=5, p<0.001) n.s. denotes no statistical difference between groups (n=5, 
p>0.05). 
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 4.4.9.3 Cell proliferation  
Following on from the cytokine work, each formulation was also investigated for its 
ability to initiate antigen specific spleen cell proliferation (Figure 4.27) In comparison to 
the DDA:TDB MLV formulation (the previously studied system; Davidsen et al 2005), a 
significant (p<0.01) increase in cell proliferation was found with the 10 % PEG 
formulation. The 25 % PEG MLV, SUV and DRV reduced cell proliferation compared to 
their non-pegylated counterparts, however this was not significant (p>0.05). The cytokine 
results taken in conjunction with the cell proliferation results seem to indicate that the 
increased cell proliferation for the 10 % PEG formulation may be due to B cell 
proliferation, since IFN-γ was increased for DDA:TDB, and IL-5 was increased for 10 % 
PEG. It is likely that PEG formulations stimulate a Th2 type immune response and this 
increase in cell proliferation is due to B cell proliferation since an antibody mediated 
immune response is mediated by B-cells.  From the biodistribution studies (Figures 4.21 
and 4.22), it was found that 25 % PEG formulations, regardless of the method of 
preparation, did not form a depot at the site of injection.  
 
It is likely that a vaccine formulation that is able to get circulate around the body would 
be able to stimulate a strong antibody mediated response such as the pegylated 
formulation, whereas one that forms a depot could likely aid a cell mediated response 
such as the DDA:TDB formulation. In an antibody mediated response, antibody is 
produced primarily in order to neutralise disease threats such as tetanus and diphtheria 
toxins, or free virus likely to infect host cells. Conversely, the cell mediated side acts 
against infected cells that are (generally) restricted in their ability to migrate, that are 
 204 
 
present within tissues, and dealt with more effectively by a cell mediated type response 
that will isolate and destroy infected cells. Any adjuvants / co-adjuvants will also have an 
input on the type of response. This therefore might not be as straightforward, and the 
antibody and cell mediated responses will have significant overlap in any case. 
Furthermore, there have been studies that have found that hydrophilic surfaces, such as 
those of pluronic-coated nanoparticles, activate the alternative pathway rather than the 
classical pathway of the complement cascade (Reddy et al 2007). The authors have 
suggested that the activation of the alternative pathway may be due to the OH groups on 
the polyhydroxylated nanoparticles binding to the exposed thioester of C3b to activate 
complement by the alternative pathway. 
Figure 4.27 Spleen cell proliferation in response to stimulation/re-stimulation with Ag85B-ESAT-6 
antigen. Cell proliferation was measured by incorporation of 3H into cultured splenocytes. * denotes 
significantly increased levels in comparison to naïve controls (n=5, p<0.05), ** denotes significantly 
increased proliferation in comparison to naïve controls (n=5, p<0.01). *** denotes significantly increased 
proliferation in comparison to naïve controls (n=5 p<0.001).   
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4.5 Conclusion  
PEG is the most widely used hydrophilic polymer for the steric stabilisation of liposome 
drug delivery systems. The aim of this study was to see whether by sterically stabilising 
DDA:TDB with PEG reduces aggregation and whether it has an influence on the 
biodistribution, adjuvant properties and the formation of a depot at the site of injection. 
Table 4.6 summarises the results of this chapter. From the initial characterisation studies, 
it was found that incorporating increasing amount of PEG 5 %, 10 % and 25 % resulted in 
a decrease in vesicle size due to PEG in the formulation influencing the lipid packaging 
within the systems and/or reducing the number of bilayers which would subsequently 
reduce the vesicle size. A reduction in zeta potential was found due to the hydrophilic 
chains of the PEG extending out from the surface of the liposomes therefore masking the 
cationic charge of the DDA. In terms of antigen loading, the addition of PEG to the 
liposomes was found to limit electrostatic interactions, thereby reducing binding and 
resulting in increased loss of antigen over time. From the biodistribution studies, it was 
found that higher levels of PEG i.e. 25 %, was able to significantly inhibit the formation 
of a liposome depot at the injection site. PEG also severely limited the retention of 
antigen at the site, thus resulting in a faster drainage of the liposomes from the site of 
injection. This was reflected by the immunisation study where lower levels of IgG2b 
antibody, IFN-γ and IL-2 was found compared to the DDA:TDB formulation and a higher 
level of IL-5 cytokine suggested that the pegylated formulations stimulate a Th2 type 
immune response. 
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Table 4.6 Summary table of the effect of PEG, on a number of characteristics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Effect of PEGylation Effect of vesicle size Effect of antigen 
entrapment within 
DRV 
Particle size Increasing PEG, reduced 
vesicle size 
MLV ≈ DRV ≈ SUV Particle size increased 
with increasing amount 
of antigen entrapment 
Particle zeta 
potential 
Increasing PEG, reduced 
vesicle zeta-potential 
MLV ≈  DRV ≈ SUV Zeta-potential reduced  
with increasing amount 
of antigen entrapment 
Antigen Loading Increasing PEG, reduced 
antigen loading 
MLV ≈  DRV > SUV Increasing antigen 
loading reduced antigen 
entrapment 
Biodistribution High PEG concentration 
reduced antigen and 
liposome retention at the 
SOI 
MLV ≈  DRV > SUV Similar biodistribution 
profile found to that of 
MLV liposomes 
Antibody responses Increasing PEG resulted 
in higher levels of IgG 
and IgG1 and lower levels 
of  IgG2b 
MLV ≈  DRV ≈  SUV No effect 
Cytokine responses Increasing PEG reduced 
IFN-γ and IL-2 but 
increased IL-5 levels 
MLV ≈  DRV > SUV No effect 
Cell proliferation Increasing PEG resulted 
in a B-cell proliferation 
MLV ≈  DRV ≈  SUV No effect 
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Chapter 5  
Incorporation of immunostimulatory components to the 
DDA:TDB adjuvant delivery system  
 
 
Graphical Abstract: 
 
 
 
 
 
 
 
Small unilamellar vesicles (SUVs) are more potent at inducing anti-OVA T-cell 
responses than multilamellar vesicles (MLVs) whereas incorporating OVA within the 
liposomal vesicle has no effect on CD8+ T-cell IFN-γ spleen responses and a small non-
significant effect on CD4+ IFN-γ responses. 
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5.1 Introduction 
The immune system is divided into two parts, innate immunity and adaptive immunity. B 
and T lymphocytes are the key players of the adaptive immune system and recognise 
pathogens through high affinity receptors. Activation of the adaptive immune system is 
delayed, and thus in order to eradicate microorganisms the rapidly responding innate 
immune system plays a major role in host defense during the early stages of infection 
(Werling & Jungi 2003). To initiate an innate immune response, pathogens exhibit 
conserved molecular patterns that are recognised by germline-encoded receptors, namely 
the toll-like receptor (TLR) family (Werling & Jungi 2003; Kaisho & Akira 2002).      
 
5.1.1 Toll-like receptors (TLR) 
TLRs are pattern recognition receptors present on diverse cell types that recognise 
specific molecular patterns present in pathogens like bacteria, virus or fungi (Takeda et al 
2003). There are currently 10 TLRs in the human gene database which are mainly 
transmembrane proteins with an extracellular domain having leucine rich repeats (LRR) 
and a cytosolic domain called the Toll/IL-1 receptor (TIR) domain (Lahiria et al 2008). 
The ligands for these receptors are highly conserved microbial molecule like 
lipopolysaccharides (LPS) (recognised by TLR 4), lipopeptides (recognised by TLR 2 in 
combination with TLR 1 or TLR 6), flagellin (by TLR 5), single or double stranded (ds) 
RNA (by TLR 7 with TLR 8 and by TLR 3 respectively), and CpG motif containing 
DNA (recognised by TLR 9) (Lahiria et al 2008). The activation of TLRs by their cognate 
ligands leads to production of inflammatory cytokines, up-regulation of MHC molecules 
and co-stimulatory signals. This links innate recognition with adaptive immune responses 
namely T and B cell activation and memory response after the host encounters any 
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pathogen (Akira & Takeda 2004). Thus, this profound property of TLRs to link innate 
and adaptive immunity can be used extensively by adding microbial components in 
experimental vaccines to evoke robust and durable immune response (Iwasaki & 
Medzhitov 2004; van Duin et al 2006). The various TLR agonists that are being used as 
adjuvants are listed in Table 5.1. However, a weakness of many vaccine adjuvants is the 
limited induction of CD8+ T-cell responses against protein antigens. Using CD8-inducing 
Toll-like receptor 3 and 9 agonists in vaccine adjuvants might overcome this limitation. 
Here we are interested in the versatility of cationic liposomes based on DDA:TDB in 
combination with different immunostimulatory ligands, including polyinosinic-
polycytidylic acid (poly(I:C), TLR 3 ligand), and CpG (TLR 9 ligand) in combination 
with DDA:TDB using ovalbumin (OVA) protein as a model antigen.  
 
5.1.1.1 Poly(I:C) - TLR 3 agonist 
TLR 3 recognises viral double-stranded RNA and thus is important in antiviral responses. 
Poly(I:C) is the synthetic analogue of dsRNA and although this was used in a phase I and 
II trial in the treatment of leukemia patients, its toxicity resulted in withdrawal from the 
market (Robinson et al 1976). The TLR 3 signaling pathway has therefore been studied 
extensively to make a better adjuvant in order to control the toxicity exerted by poly(I:C) 
(Salem et al 2006; Asahi-Ozaki et al 2006; Lahiria et al 2008). A study by Asahi-Ozaki et 
al (2006) reported that that co-administration of vaccine prepared from recombinant a 
virulent avian influenza virus with both poly(I:C) and chitin microparticles (CMP) as 
mucosal adjuvants elicits protective immunity against highly pathogenic influenza virus 
H5N1 infection. Unfortunately, the use of poly(I:C) has been associated with side effects 
as a result of the induction of pro-inflammatory cytokines (Lahiria et al 2008). 
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Table 5.1 Adjuvants and their corresponding TLR receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.1.2 Unmethylated CpG DNA - TLR 9 agonist 
TLR 9 is located on the inner endosomal membrane and recognises CpG DNA (Wagner 
2004; Lahiria et al 2008). Synthetic CpG DNA has shown promising therapeutic potential 
in a range of pathophysiological conditions (Kreig 2006) and was further shown by Waag 
et al (2006) to mediate protection against lung infection or death in BALB/c mice 
challenged with Burkholderia mallei. In an experimental model of murine toxoplasmosis 
(a parasitic disease caused by the protozoan Toxoplasma gondii), CpG DNA improved 
the immune response resulting in increased survival and a decrease in parasite burden in 
the central nervous system (CNS) of mice after weeks (Zimmermann et a 2008). A 
number of studies however argue the conjugation of CpG to plasmid protein antigens or 
TLR Adjuvants 
TLR 1 + TLR 2 Pam3Cys 
 MALP2 
 
TLR 2 + TLR 6 Pam3Cys 
 
TLR 2 BCG peptidoglycan 
 
TLR 3 
 
Poly(I:C) 
Poly (I):poly (C12U) 
 
TLR 4 
 
 
 
 
 
TLR 5 
 
TLR 7/8 
 
 
 
 
 
TLR 9 
 
MPL A 
E6020 
BCG peptidoglycan 
LPS analogues 
Aminoalkyl glucosaminide phosphates 
 
Flagellin 
 
Resiquimod 
Imiquimod 
3M-019 
R-848 
3M compound 008 
 
CpG 
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formulations with delivery systems maximises the adjuvant effect of CpG (Singh et al 
2001).  
 
5.2 Aims and objectives 
The aim of the study was to evaluate the adjuvanting capacity of cationic liposomes based 
on DDA:TDB in combination with immunostimulatory ligands, including TLR ligands. 
Polyinosinic-polycytidylic acid, poly(I:C) TLR 3 ligand), and CpG (TLR 9 ligand) were 
evaluated in combination with DDA:TDB.  
 
The objectives of the study were: 
• To evaluate how incorporation of immunostimulatory components affect the physico-
chemical properties of the liposomes. Several modification of the DDA:TDB 
liposomes, including size either as multilamellar vesicles (MLV), small unilamellar 
vesicles (SUV), antigen association and addition of TLR agonist either entrapped 
within the vesicles or adsorbed onto the liposome surface was investigated for 
immunogenic capacity as vaccine adjuvants.   
• To identify a formulation with the ability to induce cell-mediated responses, 
characterised by IFN-γ cytokine production by CD8+ T-cells.  
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5.3 Materials and Methods 
5.3.1 Materials  
Chemicals 
Acetic acid 
Bicinchoninic acid (BCA) 
Chloroform (HPLC grade) 
Coomasie (Brilliant Blue) 
CpG-ODN type C 
DuoSet® capture ELISA  
ELISA plates (flat bottom, high binding) 
Foetal bovine serum (Heat-Inactivated) 
Horseradish peroxidise-conjugated goat anti-
mouse immunoglobulin IgG, subclasses 
I125(NaI in NaOH solution) 
IODO-GEN® pre-coated iodination tubes 
Methanol (HPLC grade) 
OliGreen quantification reagent 
Ovalbumin (OVA) 
Poly(I:C) synthetic analog of dsRNA 
Protein molecular weight standard  
SDS-PAGE 12 % Tris-Glycine gels  
Sephadex G-75 
Tris-base 
Supplier 
Fisher Scientific (Leicestershire, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Fisher Scientific (Leicestershire, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Invivogen, San Diego, USA  
R&D systems, UK 
Greiner Bio-One Ltd, UK 
Invitrogen, Paisley, UK 
AbD serotec, Oxford, UK 
 
Perkin Elmer (Waltham, MA) 
Pierce Biotechnology (Rockford, IL) 
Fisher Scientific (Leicestershire, UK 
Molecular Probes-Invitrogen, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Invivogen, San Diego, USA  
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
Sigma-Aldrich, Poole, Dorset, UK 
IDN Biomedical, Inc (Aurora, Ohio) 
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Trypsin 
 
Lipids  
Trehalose 6,6′-dibehenate (TDB) 
Dimethyldioctadecylammonium bromide 
(DDA) 
 
Sigma-Aldrich, Poole, Dorset, UK 
 
Supplier 
Avanti Polar Lipids, Inc. (Alabaster, AL) 
Avanti Polar Lipids, Inc. (Alabaster, AL) 
 
5.3.2 Methods  
5.3.2.1 Lipid hydration method 
MLV were prepared using the previously described lipid-film hydration method 
(Bangham et al 1965) (Figure 4.4). Briefly, weighed amounts of DDA and TDB were 
dissolved in chloroform/methanol (9:1 by volume) and the organic solvent was removed 
by rotary evaporation followed by flushing with N2 to form a thin lipid film on the bottom 
of a round-bottom flask. The lipid film was hydrated in 10 mM Tris-buffer at pH 7.4 by 
heating for 20 minutes at 60 °C. In all formulations the final OVA concentration in a 50 
µl dose was 20 µg, and the final concentration of DDA and TDB was 250 µg and 50 µg, 
CpG was at 20 µg/dose and poly(I:C) at 50 µg/dose. 
 
5.3.2.2 Small unilamellar vesicles 
To generate SUV, the MLV produced in section 5.3.2.1 were disrupted using sonic 
energy to fracture large liposomes into smaller structures (< 100 nm). In this instance, a 
probe sonicator (Soniprep 150) was used to produce SUV. The tip of the sonicator probe 
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was placed onto the liposome surface of the MLV mixture. The milky MLV suspension 
transforms into a clear SUV suspension.   
 
5.3.2.3 Dehydration-rehydration method 
For the preparation of DRV, the MLV prepared according to the lipid hydration method 
outlined above was sonicated to produce SUV were mixed in the presence and absence of 
OVA, CpG and poly(I:C), frozen at -70 °C and freeze dried overnight (-40 °C, vacuum to 
40 mbar). Controlled rehydration of the dried powder led to the formation of antigen 
containing DRV. Controlled rehydration was achieved by addition of 10 % of the final 
volume, which was standardised at 1 ml. Therefore 100 µl was added initially to these 
formulations, which were vortexed and left at room temperature for 30 minutes. A further 
100 µl was added and formulations again incubated for 30 minutes at room temperature 
and subsequently made up to 1 ml. DRV preparations were then centrifuged twice at 
125,000 ×g for 20 minutes to remove non-entrapped antigen and/or components and 
resuspended in distilled water, to the appropriate volume. 
 
5.3.2.4 Determination of vesicle size and zeta potential 
The vesicle size and zeta-potential was determined using the photon correlation 
spectroscopy (PCS) technique. The measurements were performed at 25 oC using a 
ZetaPlus (Brookhaven Instrument Corporation, USA). Polystyrene size standards 220 ± 6 
nm (Duke scientific corp, Duke, NC) was used as a control. The samples were diluted 
with 10 mM Tris-buffer at pH 7.4 to achieve the optimal vesicle concentration.  
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5.3.2.5 Trypsination experiment  
Cationic formulations were mixed with OVA (100 µg/ml) and ultra-centrifuged twice at 
125,000 ×g, for sixty minutes at room temperature in order to pellet the liposomes. 
Supernatant was then removed and pellets were re-suspended back into their original 
volume, using the corresponding buffer solution. The protein and liposome were 
incubated in trypsin at 0 µg/ml, 100 µg/ml, 200 µg/ml and 400 µg/ml for 2 hours at 37 oC 
(this would remove any adsorbed protein) and then after this treatment, the formulations 
were ultra-centrifuged at 125,000 ×g, for 60 minutes at room temperature. Supernatant 
was then removed and pellets were re-suspended back. Upon heating at 90 °C for 3 
minutes, 10 µl samples of pellet and supernatant from each of the formulations were 
analysed via SDS-PAGE for semi-quantification of the protein concentrations present. 
For the radiolabelled experiments, OVA was radiolabelled with I125 and the procedure 
above was repeated but rather than carrying out SDS page, I125 activity was measured.  
 
5.3.2.6 OVA antigen adsorption / entrapment to cationic liposomes 
To assess the degree of antigen adsorption, I125-labeled OVA was added to the liposomes 
and left for 1 hour with intermittent shaking. For antigen entrapment, I125-labeled OVA 
was added to the SUV liposomes, frozen at -70 °C and freeze dried overnight (-40 °C, 
vacuum to 40 mbar). Controlled rehydration of the dried powder led to the formation of 
OVA containing dehydration-rehydration vesicles (DRV). Formulations were centrifuged 
(125,000 ×g, 4 °C, 1 hour), resuspended in Tris buffer and centrifuged again to ensure 
removal of all non-bound OVA. The I125 recovery in the pooled supernatant after two 
washes (unbound antigen) and the pellet (bound antigen) was measured. The percentage 
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of OVA adsorbed and entrapped was calculated as a percentage of the total radioactivity 
recovered from both supernatant and pellet. 
 
Radioactivity of washed sample    x 100% 
                                           Radioactivity of unwashed sample 
 
To ensure reliability of entrapment values, the total recovery of protein antigen was also 
calculated using the following equation (including any dilutions) 
 
Radioactivity of washed sample + Radioactivity of supernatant    x 100% 
                                          Radioactivity of unwashed sample 
 
5.3.2.7 OVA antigen retention in simulated in vivo conditions 
Antigen release from liposomes stored in simulated in vivo conditions was determined 
using liposomes adsorbing and entrapping I125-labelled OVA. Aliquots of each 
formulation were diluted (1:5) using 50 % FCS in Tris buffer and incubated in a shaking 
water bath at 37 °C for 96 hours. At time intervals, samples were centrifuged twice and 
OVA release was calculated as a percentage of the recovered radioactivity. 
 
5.3.2.8 Oligreen assay 
Quantification of the CpG content was determined according to the manufacturer's 
instructions. Briefly, aliquots of encapsulated oligonucleotide were diluted in TE assay 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). A 10 µl aliquot of the diluted sample 
was added to 100 µL of a 1:200 dilution of Oligreen™ reagent. An oligonucleotide 
standard curve was prepared using the 2 µg/ml oligonucleotide stock solution. 
Fluorescence of the OLIGREEN™-antisense complex was measured using excitation and 
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emission wavelengths of 485 nm and 520 nm, respectively. Surface associated antisense 
was determined by comparing the fluorescence measurements in the absence and 
presence of detergent. 
 
5.3.2.9 Immunisation studies 
C57BL/6 mice (6 mice per group) were injected with the liposomal formulations into the 
tibial muscle (25 µl per leg) in a triple homologous vaccination regimen, with 2 week 
intervals between immunisations. Tail bleeds for serum samples were performed at 
indicated time-points (days 14, 28, 42, 70 and 128). Spleens were removed at the sacrifice 
time-point and used for measuring IFN-γ production by ELISpot. 
Figure 5.1 Immunisation study timeline. C57BL/6 mice (6 mice per group) were injected with the 
liposomal formulations into the tibial muscle (25 µl per leg) in a triple homologous vaccination regimen, 
with 2 week intervals between immunisations. Tail bleeds for serum samples were performed at indicated 
time-points (days 14, 28, 42, 70 and 128). Spleens were removed at the sacrifice time-point and used for 
measuring IFN-γ production by ELISpot. 
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5.3.2.10 Analysis of anti-OVA antibody production following vaccination with the 
liposomal formulations 
 
Total IgG antibodies against whole OVA protein were measured in a standard end-point 
titre ELISA. Briefly, immunosorbent plates were coated with OVA protein 2 µg/ml in 
PBS. Mouse sera were diluted to 1:100, added in duplicate wells, and serially diluted in 
threefold steps. Absorbance at 405 nm was measured using a microplate reader (BioTek, 
UK). The endpoint titers were taken as the x axis intercept of the dilution curve at an 
absorbance value three standard deviations greater than the optical density at 405 nm for 
naïve mouse sera.  
 
5.3.2.11 Spleen ELISpot assay 
IFN-γ production in total mouse splenocytes was measured using ex vivo IFN-γ ELISpot, 
using coating and detecting antibodies from Mabtech. Splenocytes were isolated from 
immunised C57/BL6 mice and restimulated overnight with peptides corresponding to two 
CD4+ and one CD8+ OVA epitopes at 1 µM final concentration. Plates were developed 
and analysed using AID ELISpot (AID Diagnostika GmbH) reader system and software. 
 
5.3.2.12 Statistical analyses 
For all experiments, means and standard deviations were calculated. To determine 
statistical significance the one way analysis of variance (ANOVA) was performed on all 
data, with the statistical significance determined to 0.05 confidence intervals (p<0.05). 
Tukey’s post hoc test was conducted to determine which conditions differ significantly 
from each other.  
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5.4 Results and discussion 
5.4.1 Quantification of entrapped protein 
To determine the fraction of liposome-bound OVA exposed on the outer liposomal 
membrane, the DDA:TDB with OVA both surface adsorbed and entrapped was incubated 
in a solution of the proteolytic enzyme trypsin. Trypsin does not pass through the 
liposomal bilayer and, therefore, the encapsulated protein is protected from enzymatic 
digestion. Briefly, the liposomal OVA formulation was incubated in 0, 100, 200 and 400 
µg/ml trypsin. After 2 hours of incubation at 37 oC, samples were centrifuged to remove 
adsorbed protein. The fraction of remaining entrapped OVA, protected from enzymatic 
digestion, was determined by SDS page and confirmed by radiolabelled work. The results 
of the SDS page are shown in Figure 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 SDS page of DDA:TDB MLV and DRV liposomes exposed to trypsin at (0, 100, 200 and 
400 µg/ml). Lane 1 - OVA no trypsin, lane 2 - OVA 100 µg/ml trypsin, lane 3 - OVA 200 µg/ml trypsin, 
lane 4 - OVA 400 µg/ml trypsin, lane 5 - DDA:TDB MLV no trypsin, lane 6 - DDA:TDB MLV 100 µg/ml 
trypsin, lane 7 - DDA:TDB MLV 200 µg/ml trypsin, lane 8 -  DDA:TDB MLV 400 µg/ml trypsin, lane 9 - 
DDA:TDB DRV no trypsin, lane 10 - DDA:TDB DRV 100 µg/ml trypsin, lane 11 - DDA:TDB DRV 200 
µg/ml trypsin, lane 12 - DDA:TDB DRV 400 µg/ml trypsin. 
 
1        2     3     4     5       6       7        8         9     10     11     12   
180kDa 
 
115kDa 
 
 
82kDa 
 
 
64 kDa 
 
49kDa 
 
 
 
 
37kDa 
 
 
 
 
26kDa 
 
 
19kDa 
 
6kDa 
 220 
 
From the SDS page results in lane 1, which is the non-trypsin exposed OVA control, a 
very strong band could be seen, whereas lanes 2, 3 and 4 which are trypsin exposed 
samples no bands suggesting that trypsin has digested the protein. Whereas for the 
liposomal formulations, firstly the DDA:TDB MLV formulation so this is where the 
protein is adsorbed to the surface of the liposome it can be seen that lane 5 the non-
trypsin exposed sample strong band whereas with increasing concentration of tryspin in 
lanes 6, 7 and 8 the bands become lighter suggesting tryspin digestion with increasing 
concentration. Trypsin degrades proteins by cleaving lysyl and arginyl bonds. Lanes 9, 
10, 11 and 12 are the DRV based formulations, so this is where the protein is entrapped 
and it is found that at all concentrations of trypsin the bands are the same. This suggests 
that the protein is in fact entrapped within the lipid bilayer and not surface adsorbed. A 
study by van Slooten et al (2001) investigated the fraction of surface-exposed human 
interferon gamma (hIFN-γ) present on the external surface of the liposomes. The authors 
used a similar trypsination experiment. The authors found that liposome-entrapped hIFN-
γ molecules, which are not exposed on the liposome surface, were protected from 
enzymatic degradation, as the enzyme is unable to cross bilayers.  
 
To confirm the results of the SDS page, the above experiment was repeated with I125OVA 
and the activity of OVA adsorbed to the liposomes or entrapped within the lipid bilayers 
was measured. Figure 5.3A shows DDA:TDB MLV liposomes with OVA adsorbed to the 
surface. It can be seen that the non trypsin exposed sample had an initial adsorption of 
OVA around 65%, but with increasing concentration of trypsin there is less protein 
adsorbed to the surface. Figure 5.3B, shows DDA:TDB DRV liposomes with OVA 
entrapped within the lipid bilayers. Similar to the results of the SDS page, at all 
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concentrations of trypsin, the percentage of OVA entrapped is the same around 65 to 70% 
suggesting protein is entrapped within the liposomes and not surface adsorbed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Percentage (%) of OVA (A) adsorption and (B) entrapment following exposure to trypsin. 
Results represent mean ± SD of triplicate experiments. 
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5.4.2 Incorporation of immunostimulating compounds 
5.4.2.1 Multilamellar vesicles (MLV) 
Incorporation of certain immunostimulating compounds into DDA:TDB liposomes may 
affect the immunological properties, as well as the physico-chemical properties, of the 
adjuvant formulation. We have looked at the characterisation of the physico-chemical 
properties since this is important for issues such as formulation with antigen and stability. 
Incorporation of immunostimulatory components was found to affect the particle size and 
surface charge of MLV based liposomes (Figure 5.4A). Empty DDA:TDB liposomes 
were found to be 572.6 ± 50.4 nm in size with a positive surface of 59.9 ± 10.5 mV. The 
adsorption of OVA resulted in an increase in size to 1047.1 ± 135.8 nm, whereas with the 
addition of CpG and poly(I:C) to the DDA:TDB OVA liposomes made no further 
significant difference in the size (1116.9 ± 176.0 nm). However, a significant difference 
(p<0.05) in the zeta potential was found after the addition of the immunostimulatory 
components (Figure 5.4B). This drop in surface charge may be due to poly I:C being 
negatively charged resulting in strong electrostatic interactions between the opposite 
charged components and hence increase in size.  
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Figure 5.4 (A) Vesicle size (nm) and (B) zeta-potential (mV) of DDA:TDB MLV liposomes prepared 
by the lipid-hydration method with OVA and immunostimulatory components CpG and poly(I:C). 
Results represent mean ± SD of triplicate experiments. 
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5.4.2.2 Dehydration-rehydration vesicles (DRV) 
When the dehydration-rehydration method was used to incorporate the OVA within the 
liposomes (Figure 5.5A), the size of the liposomes was 546 ± 23.7 nm that was 
significantly smaller than vesicles prepared with surface complexed OVA. In contrast, 
with the entrapment of only CpG within the DDA:TDB DRV the size of the liposomes 
significantly increased to 1010 ± 235 nm and zeta potential significantly reduced to near 
neutral (3.4 ± 1.3 mV). This suggests a reconfiguration of the system compared to the 
DDA:TDB entrapping OVA. However, the addition of poly(I:C) in combination with 
CpG resulted in vesicles of a similar size (1101.9 ± 55.8 nm) but with a negative zeta 
potential (-39.9 ± 11.1 mV) (Figure 5.5B). Finally the addition of the three components 
OVA, CpG and poly:IC resulted in a no further significant change in zeta potential but a 
slight increase in size to 1399.2 ± 172.5 nm. The reversal in measured zeta potential 
suggests a neutralization of the cationic nature of the liposomes in the presence of the 
various anionic components such that they are present on the outer surfaces of the 
vesicles and not fully incorporated within the DRV vesicles.  
 
5.4.2.3 Small unilamellar vesicles (SUV) 
Following the sonication of MLV liposomes the addition of OVA to the SUV based 
liposomes resulted in an increase in size from 150 nm to 591.9 nm (Figure 5.6A) and a 
drop in zeta-potential from 50.1 mV to 33.9 mV (Figure 5.6B). The addition of 
immunostimulatory components to the DDA:TDB SUV liposomes, firstly the TLR 9 CpG 
and secondly CpG and poly(I:C), also resulted in an increase in size of the liposomes, to 
around 785.8 nm and 978.6 nm, with a drop in surface charge to around -43.9 and -50.1 
mV.  
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Figure 5.5 (A) Vesicle size (nm) and (B) zeta-potential (mV) of DDA:TDB DRV liposomes prepared 
by the dehydration-rehydration method with OVA and immunostimulatory components CpG and 
poly(I:C). Results represent mean ± SD of triplicate experiments. 
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Figure 5.6 (A) Vesicle size (nm) and (B) zeta-potential (mV) of DDA:TDB SUV liposomes prepared 
by the lipid-hydration method with OVA and immunostimulatory components CpG and poly(I:C). 
Results represent mean ± SD of triplicate experiments. 
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5.4.2.4 Quantification of OVA adsorption and entrapment 
Figures 5.7A, B and C show OVA retention measured in simulated in vivo conditions i.e. 
in 50 % FCS in Tris buffer and compared to formulations in Tris buffer. The percentage 
of OVA incorporation was calculated as a percentage of the total radioactivity recovered 
from both supernatant and pellet in both conditions. For the MLV liposomes (Figure 
5.7A), although in the tris condition a difference in release was found between the two 
formulations, with a greater release with the formulation containing the 
immunostimulatory components, in a serum condition a similar sustained release profile 
was found. For the SUV liposomes (Figure 5.7B), an initial burst release was found with 
the formulation containing poly(I:C) to around 45 % OVA retention after 96 hours of 
incubation, whereas DDA:TDB and DDA:TDB with CpG had similar release profiles, 
around 60 % antigen retention after 96 hours. Previous studies (Henriksen-Lacey et al 
2010) have found that the strong repulsive charges between positively charged liposomes 
and negatively charged serum proteins are responsible for the slow release of antigen. 
However, the greater release with this formulation maybe due to the positively charged 
quaternary ammonium head groups of the DDA molecule binding to the negatively 
charged phosphate groups in the backbone of the nucleic acid structure. This results in an 
overall negative charge as found with the characterisation studies and the greater release 
compared to the other formulations. For the formulation containing the TLR 3 agonist 
poly(I:C), a similar result is found with the DRV based formulations (Figure 5.7C) 
suggesting that regardless of the nature of the liposome-antigen association, the release of 
46 - 50 % after 96 hours is equal between the liposomal preparations However, the rate of 
release over time varies to some extent. Protein release from the DRV (protein) liposome 
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formulations was slow and controlled over time. With sustained release, the DRV based 
formulations may act as an effective depot (Storm & Crommelin 1998) from which the 
protein antigen can slowly leak from the liposome and maintain therapeutic levels of 
antigen for presentation to APC.   
 
5.4.2.5 Quantification of CpG using the OliGreen assay 
Synthetic oligonucleotides are used in a number of different molecular biology 
techniques, including DNA amplification (PCR), DNA sequencing, site directed 
mutagenesis, and in situ hybridisation. These techniques require that precise 
concentrations of ssDNA oligonucleotide are present in the reactions. OliGreen is an 
intercalating cyanine dye that selectively binds to oligonucleotides within a linear 
detection range extending over more than four orders of magnitude with a single dye 
concentration. There are very low variations between signals (Singer et al 1997) and it is 
considered as a sensitive practical alternative to other methods such as detecting 
oligonucleotides on electrophoretic gels stained with ethidium bromide (Ahn et al 1996). 
In this case, OliGreen ssDNA quantitation reagent was used to quantify CpG adsorption 
and entrapment. The results are shown in Table 5.2.  
 
Table 5.2 Quantification of CpG using the OliGreen assay. 
Results represent mean ± SD of triplicate experiments. 
Formulation Incorporation of CpG  
 MLV SUV DRV 
DDA:TDB:CpG N/A 69 ± 9.2% 66 ± 2.9% 
DDA:TDB:CpG:poly(I:C) 55 ± 6.5% 51 ± 3.0% 59 ± 6.2% 
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From the OliGreen results, it can be seen that the incorporation of CpG for the MLV, 
SUV and the DRV based liposomes was between 51 - 69 %. When CpG alone was added 
to DDA:TDB liposomes, a higher adsorption and entrapment was found for SUV 
liposomes around 69 % and for DRV liposomes around 55 %. However, following the 
addition of poly(I:C) less incorporation of CpG was found. It may be that poly(I:C) 
displaces the surface bound or entrapped CpG and therefore reduces CpG content within 
the liposomes. Studies by Beaudette et al (2009) also looked at the co-encapsulation of 
CpG DNA and antigen in acid-degradable microparticles. The authors also used an 
OliGreen assay as a method of quantification and found an incorporation of CpG into the 
particles with efficiencies of up to 60 - 70 %.     
 
 
Following these initial characterisation studies, the effect of entrapping the OVA antigen 
within the liposomes, as opposed to adsorbing it to the liposome surface, on protein 
immunogenicity was evaluated.   
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Figure 5.7 OVA retention profile. (A) MLV (B) SUV (C) and DRV liposomes which were stored in tris and under simulated in vivo conditions (50% FCS, 37 
°C). Results represent mean ± SD of triplicate experiments. 
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5.4.3 Immunisation studies 
As described above, cationic DDA:TDB liposomes, prepared as either MLV, SUV and 
DRV were combined with OVA protein with and without the TLR agonists CpG 
oligonucleotide (TLR 9 ligand) and poly(I:C) (TLR 3 ligand). The aim was to identify a 
formulation with the ability to induce cell-mediated responses, characterised by IFN-γ 
cytokine production by CD8+ T-cells. Work described in here was done in collaboration 
with Dr. Anita Milicic and Professor Adrian Hill at the Jenner Institute, University of 
Oxford. 
 
5.4.3.1 Antigen-specific CD8+ T cells in the spleen and peripheral blood 
CD8+ T-cell responses are initiated during infection when peptide antigens are presented 
by dendritic cells in the lymph nodes or in the spleen if the infection is blood-borne. 
Following their activation, antigen-specific CD8+ T-cell clones undergo a process of rapid 
proliferation in the secondary lymphoid tissue to give rise to effector cells that migrate to 
the periphery to resolve the infection. Thus, the progeny of the stimulated naive CD8+ T 
cell may be engaged either in clonal expansion or in the killing of infected target cells 
(Bannard et al 2009). In the present work, splenocytes were isolated from immunised 
C57BL/6 mice and restimulated overnight with peptides corresponding to two CD4+ and 
one CD8+ OVA epitope at a 1 µM final concentration. IFN-γ secretion in the spleen and 
peripheral blood by CD4+ and CD8+ T cells was measured using ex vivo IFN-γ ELISpot. 
As shown in Figure 5.8A, in the spleen it was found that SUV based liposomes were 
more potent at inducing anti-OVA CD8+ T-cell responses (p<0.01) than MLVs, since 350 
spot forming units (SFU) per million peripheral blood mononuclear cells (PBMC) were 
found with SUV based liposomes compared to 50 SFU per million PBMCs for the MLV 
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liposomes. In terms of CD4+ a higher level of IFN-γ was produced with the SUV based 
formulations, with a SFU per million PBMCs of around 200 compared to 50 and 90 with 
the MLV and DRV based formulations although this was not significant (Figure 5.8B and 
C). In terms of IFN-γ secretion in the peripheral blood (Figure 5.9), again a statistically 
significant increase in CD8+ response was found with the DDA:TDB SUV together with 
the TLR 9 ligand CpG (p<0.01).  
 
The results presented here suggest that liposome uptake by DCs is dependent on the size 
of the vesicles, with the SUV based liposomes inducing higher anti-OVA CD8+ T-cell 
responses therefore stimulating a Th1 immune response. A study by Mann et al (2009) 
found that smaller vesicles (~ 250 nm) enhanced Th2 responses whilst larger liposomes (~ 
980 nm) induced high levels of IFN-γ and IgG2 antibodies characteristic of a Th1 
response. In addition, the larger liposomes also gave better protection in an influenza 
challenge model in ferrets (Mann et al 2009). Thus, particle size has also been shown to 
have a significant effect on vesicle trafficking to lymph nodes (Oussoren et al 1997), 
antigen uptake (Foged et al 2005) and processing by APCs (Brewer et al 2004). 
Furthermore, in the present work it was also found that the incorporation of OVA within 
the liposomal vesicle had no effect on CD8 T-cell IFN-γ spleen and peripheral blood 
responses as no significant difference (p>0.05) was found between the MLV and DRV 
formulations (Figure 5.9).  
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Figure 5.8 Spleen T-cell responses. (A) CD8+ IFN-γ responses (B) CD4+ epitope 1 IFN-γ responses (C) CD4+ epitope 2 IFN-γ responses. Splenocytes from 
C57BL/6 mice (n=6 per group) vaccinated with 3 homologous injections were analysed for IFN-γ production 14 weeks after the last injection. Experiment 
conducted at the Jenner Institute, University of Oxford. 
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Figure 5.9 Peripheral blood T-cell responses. (A) CD8+ IFN-γ responses (B) CD4+ epitope 1 IFN-γ 
responses. Experiment conducted at the Jenner Institute, University of Oxford. 
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5.4.3.2 Antibody responses 
To test the potential of the various formulations as vaccine adjuvants, immunological 
analysis was carried out in order to determine the efficacy of the liposome formulations in 
achieving the desired immune response, encompassed quantification of OVA specific IgG 
antibody production. In terms of antibody responses, IgG is the most obvious choice for 
detection from blood samples. It can activate both the complement system and mediate 
opsonisation, thus leading to enhanced phagocytosis (Goldsby et al 2003). Antibody 
ELISAs were performed at regular intervals (days 14, 28, 42, 70 and 128) to determine 
the antigen specific antibody production initiated by each formulation. From the results it 
was found that the highest IgG titres were obtained after vaccination with SUVs with 
adsorbed OVA, as well as SUVs and MLVs associated with OVA and CpG  (p<0.05 - 
0.001 at day 42 (Figure 5.10A) and p<0.05 - 0.01 at day 126 (Figure 5.10B)). 
 
The results presented here suggest that CpG can be combined with cationic liposomes and 
antigen to produce a high level of antibody response. Previous studies (Kinman et al 
1999) have found that TLR 9 ligands such as CpG stimulate and cause a signaling 
cascade that culminates in the maturation, differentiation and proliferation of T-cells, 
monocytes/macrophages and natural killer cells. With regards to targeting TLR 3, some 
liposomal formulations containing the TLR 3 agonist poly(I:C) have the ability to cross-
present antigen and therefore stimulate CD8+ T cell responses (Zaks et al 2006; Mastelic 
et al 2010). However, in this case it was found that poly(I:C) did not increase antigen-
specific antibody responses (Figure 5.10). 
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Figure 5.10 Total IgG antibody responses. Responses measured in the sera of vaccinated mice at various 
time-points. Titres measured at days (A) 42 and (B) 126 (2 weeks and 14 weeks post last vaccination, 
respectively) are shown. Experiment conducted at the Jenner Institute, University of Oxford. 
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5.5 Conclusion  
Many of the novel subunit vaccines require adjuvants in order to induce immune 
responses to vaccine antigens and enhance their protective efficacy. However, many of 
the potent immunogenic adjuvants also display unacceptable local or systemic 
reactogenicity. Liposomes, in particular cationic DDA:TDB vesicles, have been shown in 
animal models to induce strong humoural responses to the associated antigen without 
increased reactogenicity, and are currently being tested in human clinical trials. Several 
modifications of DDA:TDB liposomes including size, antigen association and addition of 
TLR agonists for immunogenic capacity as vaccine adjuvants using OVA as a model 
protein vaccine were explored. Cationic DDA:TDB liposomes, prepared as either MLVs, 
SUVs or DRVs were combined with OVA protein and TLR agonists CpG oligonucleotide 
(TLR 9 ligand) and poly(I:C) (TLR 3 ligand). OVA and TLR agonists were either 
entrapped within the vesicles or adsorbed onto the liposome surface. C57BL/6 mice were 
given three homologous vaccinations two weeks apart, and cellular and humoural 
responses measured at several time points up to ten weeks post last immunisation. SUVs 
showed significantly increased capacity for inducing IFN-γ CD8+ responses in peripheral 
blood and spleen, compared to larger MLV liposomes. The peak antigen-specific 
antibody responses were also higher with SUVs and the adsorption of TLR 9 agonist 
increased the adjuvanticity of MLVs but not SUVs.  
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Chapter 6 
Preparation, characterisation and entrapment of a non-glycosidic 
threitol ceramide into liposomes for presentation to invariant natural 
killer T cells 
 
Graphical Abstract: 
 
 
 
 
 
 
 
 
Very few compounds have been found that stimulate iNKT cells and of these the best-
characterised is the glycolipid α-galactosylceramide (α-GalCer) and the αGalCer 
analogue, threitol ceramide (ThrCer). Within this chapter ThrCer is incorporated into 
liposomal systems. 
 
 
 
 
 
 
 
Some of the results presented in this chapter have been published in the paper;  
Kaur, R., Chen, J., Dawoodji, A., Cerundolo, V., Garcia-Diaz, Y. R., Wojno, J., Cox, L. 
R., Besra, G. S., Moghaddam, B., Perrie, Y. (2011) Preparation, characterisation and 
entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to 
invariant natural killer T cells. Journal of Pharmaceutical Sciences. Accepted. 
 239 
 
6.1 Introduction  
Invariant natural killer T (iNKT) cells are unique lymphocytes defined by their co-
expression of surface markers associated with NK cells along with a T-cell antigen 
receptor (Schmieg et al 2005). They recognise amphipathic ligands such as glycolipids or 
phospholipids presented in the context of the non-polymorphic, major histocompatibility 
complex (MHC) class I-like molecule CD1d (Godfrey et al 2000). To date, relatively few 
compounds have been found that stimulate iNKT cells. Of these, α-galactosylceramide 1 
(α-GalCer) (Figure 6.1) is one of the most potent agonists, and has the ability to induce 
CD1d-restricted NKT cells specifically to produce high levels of both IL-4 (Th2) and 
IFN-γ (Th1) in vitro and in vivo once αGalCer binds with the CD1d protein (Kawano et al 
1997; Spada et al 2000; Matsuda et al 2000). 
 
iNKT cells in different situations display both tolerogenic and immunostimulatory 
functions in vivo following αGalCer administration. Unfortunately for therapeutic 
applications, αGalCer leads to overstimulation of iNKT cells; more specifically, it has 
been shown that a single injection of mice with 1 - 2 µg of αGalCer induces long-term (> 
30 days) anergy of iNKT cells (Parekh et al 2009; Silk et al 2008). During this 
hyporesponsive state, further activation of iNKT cells with αGalCer is unsuccessful. The 
production of both Th1 and Th2 cytokines and the “unresponsive state” of iNKT cells, 
after activation with αGalCer renders this glycolipid of limited therapeutic use as a direct 
activator of iNKT cells, and has encouraged the development of αGalCer analogues that 
circumvent some of these problems. It has been demonstrated that the αGalCer analogue, 
threitol ceramide (ThrCer) (Figure 6.1), successfully activates iNKT cells and overcomes 
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the problematic iNKT cell activation-induced anergy associated with αGalCer (Silk et al 
2008). ThrCer is a promising agonist for iNKT cells and may have therapeutic 
application. It has been previously demonstrated that this glycolipid, whilst preventing 
αGalCer-dependent iNKT cell over-stimulation, ensures effective dendritic cell (DC) 
maturation, minimises iNKT cell-dependent DC lysis, and promotes optimal expansion of 
antigen-specific T cell responses (Silk et al 2008). Thus, by minimising iNKT cell over-
stimulation and iNKT cell-dependent DC lysis, ThrCer rectifies some of the deficiencies 
of αGalCer. ThrCer also possesses the advantage over αGalCer, that the polar head group 
is bound to the ceramide base via an ether bond, which is more stable towards acidic 
hydrolysis and biodegradation than the glycosidic bond of αGalCer. This increased 
stability should extend the time that ThrCer persists in the cell compartments, increasing 
the chances of it being loaded on to CD1d for presentation.  
 
 
 
 
 
 
Figure 6.1 CD1d agonists αGalCer and ThrCer.  
 
ThrCer is lipid-based with a molecular weight of 800 g/mol; it displays poor water 
solubility.  Based on the ability of liposomes to be taken up and stimulate antigen 
presenting cells (APC), e.g. macrophages, the potential of using liposomes as a delivery 
system of ThrCer was investigated in an effort to both formulate this low solubility 
moiety and hence improve the delivery of this immunostimulatory agent, ThrCer.  
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6.1.1 Incorporation of ThrCer into liposomes 
As noted previously liposomes are generally described as phospholipid vesicles 
consisting of one or several concentric lipid bilayers, enclosing many aqueous 
compartments (Bangham et al 1965). Liposomes based on dimethyldioctadecylammonium 
bromide (DDA) as discussed previously in chapter 5 have been evaluated as carriers for 
drugs (Carmona-Ribeiro et al 1997), as antimicrobial agents (Lincopan et al 2003) and as 
adjuvants (Dzata et al 1991) for a range of vaccines for both parenteral and mucosal 
delivery. In recent years, they have been used as part of more complex adjuvant systems 
for experimental subunit vaccines (e.g. Hilgers & Snippe 1992; Kirby et al 2008a).  
 
Recent studies provide support for this notion by showing that if DDA is replaced with a 
neutral lipid such as 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), the 
neutralisation of the surface charge of the liposomes diminishes their immunogenicity 
(Henriksen-Lacey et al 2010). Whilst the effect of cationic liposomes on dendritic cells 
(DCs) is not well characterised in the literature it is however, well known that cationic 
amphiphiles can be used as liposome carriers for nucleic acids and thus enhance the 
transfection efficiency of cells in general (Dass 2004).  
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6.2 Aims and objectives 
Within this chapter, the aim of the studies was to incorporate ThrCer into the bilayers of 
liposomes composed of the cationic lipid DDA or the zwitterionic lipid DSPC. These 
systems were prepared both as multilamellar vesicles (MLV) and small unilamellar 
vesicles (SUV). To achieve this, the objectives were: 
• To initially look at the physiochemical characterisation i.e. vesicle size, 
entrapment efficiency and stability of incorporated ThrCer. 
• To carry out release studies; ThrCer release from liposomes stored in simulated in 
vivo conditions was determined using liposomes entrapping 14C-radiolabelled 
ThrCer. 
• To investigate the packaging of ThrCer with the DDA or DSPC using surface 
pressure/area isotherms of monolayers of the lipids on their own or in 
combination. 
• To investigate the uptake of the immunostimulatory agent, ThrCer by DCs, and 
presentation on CD1d molecules to iNKT cells. 
• Finally, in vivo studies were carried out to assess DC maturation in vivo. 
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6.3 Materials and Methods 
6.3.1 Materials 
Chemicals     Supplier  
Threitol ceramide (ThrCer) and radiolabelled ThrCer, 14C-ThrCer, was prepared as 
previously described (Garcia-Diaz et al 2009) and were supplied by Professor Besra, 
Birmingham University. 
 
 
 
Chloroform (HPLC grade) 
Ethanol (HPLC grade) 
Foetal bovine serum (Heat-Inactivated) 
Hydrochloric acid 
Methanol (HPLC grade) 
Tris-base 
Ultima Gold scintillation fluid 
 
Lipids  
1,2-distearoyl-sn-glycero-3-phosphocholine  
     (DSPC) 
Dimethyldioctadecylammonium bromide 
(DDA) 
 
Fisher Scientific (Leicestershire, UK) 
Fisher Scientific (Leicestershire, UK) 
Invitrogen, Paisley, UK 
Fisher Scientific (Leicestershire, UK 
Fisher Scientific (Leicestershire, UK 
IDN Biomedical, Inc (Aurora, Ohio) 
Perkin Elmer (Waltham, MA) 
 
Supplier 
Avanti Polar Lipids, Inc. (Alabaster, AL) 
 
Avanti Polar Lipids, Inc. (Alabaster, AL) 
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6.3.2 Methods 
6.3.2.1 Preparation of liposomes 
DDA and DSPC liposomes with and without the addition of ThrCer were prepared by the 
lipid hydration method (as described previously in Figure 4.4) (Bangham et al 1965). 
Briefly the lipids and ThrCer used in these experiments were dissolved in 
chloroform:methanol (2:1 v/v).  DDA or DSPC (30 µL of a 10 mg ml-1 solution) and 
ThrCer (60 µL of a 1 mg ml-1 solution) were placed in a 50 ml round-bottom Quick-fit 
flask and the organic solvent was removed by rotary evaporation at about 37 oC to yield a 
thin lipid film on the walls of the flask, which was flushed with oxygen-free nitrogen (N2) 
in order to ensure complete removal of solvent. The vesicles were formed by hydrating 
the lipid film in Tris buffer at pH 7.4 (600 µl of a 10 mM solution). The lipid film was 
hydrated for 20 minutes at a temperature of 10 oC above the main phase transition of 
either DDA (Tc ~47 oC) or DSPC (Tc ~55 oC) respectively to ensure complete hydration.  
 
For the generation of small unilamellar vesicles (SUV), the multilamellar vesicles (MLV) 
produced were disrupted by sonication using a probe sonicator (Soniprep 150), to fracture 
the large liposomes into smaller structures. The DSPC liposomes were sonicated for 1 
minute, whereas the DDA liposomes were sonicated for 30 seconds to produce SUV.  
 
6.3.2.2 Measuring entrapment of ThrCer in DSPC and DDA liposomes  
The degree of ThrCer incorporated in the liposomes was determined by tracking 14C-
labelled ThrCer. 14C-Radiolabelled ThrCer (10 µl of a 1 mg ml-1 solution) was added to 
liposomes prepared as described above. The DSPC or DDA 14C-ThrCer liposomes (400 
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µl) were placed into dialysis tubing (molecular weight cut off (MWCO) of 12,000 daltons 
or greater), and transferred into tris buffer (500 ml of a 10 mM solution, pH 7.4). At 
various time-points up to 28 days, ThrCer incorporation and release from the liposome 
formulations was determined by removing 1 ml sample from liposome suspension, which 
was subsequently replaced with 1 ml Tris buffer, in order to maintain sink conditions. 
Incorporation of ThrCer was determined on the basis of 14C-labelled ThrCer remaining in 
the liposome suspension after dialysis.  
 
6.3.2.3 ThrCer retention in simulated in vivo conditions 
ThrCer release from liposomes stored in simulated in vivo conditions was determined 
using liposomes entrapping 14C-radiolabelled ThrCer prepared as described in Section 
6.3.2.1. Aliquots of each formulation were diluted (1:5) using 50 % FCS in Tris buffer 
and incubated in a shaking water bath at 37 °C for 28 days. At time intervals, samples 
were centrifuged (125000 ×g, 4 °C, 1 h), resuspended in Tris buffer and centrifuged again 
to ensure removal of all non-incorporated ThrCer. The 14C-ThrCer recovery in the pooled 
supernatant after two washes (non-incorporated ThrCer) and the pellet (incorporated 
ThrCer) was measured. The percentage of ThrCer entrapped was calculated as a 
percentage of the total radioactivity recovered from both supernatant and pellet.  
 
6.3.2.4 Determination of liposome size  
The vesicle size of DDA and DSPC liposomes with and without the inclusion of ThrCer 
was determined using the photon correlation spectroscopy (PCS) technique. The 
measurements were performed at 25 oC using a ZetaPlus (Brookhaven Instrument 
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Corporation, USA). Polystyrene size standards 220 ± 6 nm (Duke scientific corp, Duke, 
NC) was used as a control. The samples were diluted with 10 mM Tris buffer at pH 7.4 to 
achieve the optimal vesicle concentration. 
 
6.3.2.5 Langmuir-Blodgett isotherms 
An automated controlled film balance apparatus (KSV Langmuir Mini-trough, KSV 
Instruments Ltd, Helsinki, Finland) equipped with a platinum Wilhemy plate and placed 
on a vibration-free table was used to collect the surface pressure-area isotherms as 
previously reported (Christensen et al 2008). The size of the trough was 24,225.0 mm2 
enclosing a total volume of approximately 220 ml; the subphase was composed of filtered 
double-distilled water. The compounds (at fixed total concentration of 1 mg ml-1) were 
dissolved in chloroform and 20 µl of each solution was spread onto the air/water interface 
with a Hamilton microsyringe, precise to ± 0.2 µl. After spreading, the monolayers were 
left for 10 minutes to allow the chloroform to evaporate. Thereafter, the molecules 
underwent constant compression (10 mm s-1) until the required surface pressure of less 
than 0.2 mN/m was attained. The spread monolayer was then compressed or expanded 
symmetrically with the two barriers until the desired surface pressure was reached with 
accuracy within 0.1 mN/m. The temperature of the subphase was kept constant at 20 ± 1 
°C by means of an external water bath circulation system. Each experiment was only 
compressed once and was performed three times with monolayers prepared from different 
solutions. KSV software (KSV Instruments Ltd, Helsinki, Finland) was used for data 
analysis. 
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6.3.2.6 Liposome presentation to invariant natural killer T cells  
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors’ buffy 
coats by density gradient centrifugation over Lymphoprep (Nycomed, Birmingham, UK). 
Monocytes were positively selected using anti-CD14 mAb-coated magnetic beads 
(MACS; Miltenyi Biotec, Surrey, UK) and were then cultured in 6-well plates in either X-
Vivo 15 + 2 % Human AB serum with 800 U ml-1 granulocyte monocyte colony 
stimulating factor (GM-CSF) and 500 U ml-1 IL-4 for 4 days to produce immature DCs. 
On day 4, liposomes (100 ng ml-1 or 1 µg ml-1), lab grade ThrCer (1 µg ml-1) and α-
GalCer (100 ng ml-1) were added to the immature DCs, followed by the addition of 
maturation cocktail (IL-1β, IL-6, TNF-α and PGE2) after 3 hours. DCs were harvested 
and assayed with iNKT cells overnight, the supernatants were taken and an IFN-γ ELISA 
performed. DCs were also analysed by FACS after addition of liposomes for expression 
of CD80 and CD86 to see whether there is any contamination of liposomes. 
 
6.3.2.7 IFN-γ ELISA   
ELISA plates were coated with 1D1K antibody (Mabtech, Nacka Strand, Sweden) and 
left overnight at 4 oC. Plates were washed with 0.05 % tween 20 in PBS (v/v). To 
eliminate any non-specific antigen binding, the plates were coated (i.e. blocked) with 200 
µl of 10 % FCS in PBS (v/v) and incubated for 2 hours at 37 oC. 100 µl of reaction 
supernatant was transferred to the ELISA plate and the standard was added starting at 50 
ng ml-1. The plate was then incubated at 4 oC overnight. The following day, the plates 
were washed with 0.05 % tween 20 in PBS and the biotinylated anti-cytokine detecting 
mAb was added at 50 µl/well and incubated at room temperature for 2 hours. After 
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incubation, the plates were washed eight times with 0.05 % tween 20 in PBS. 100 µl of 
working dilution of avidin-peroxidase was added per well after which the plates were 
incubated at room temperature for 2 hours. Plates were once again washed eight times 
with 0.05 % tween 20 in PBS. 100 µl of tetramethylbenzidine (TMB) agent was added 
per well. Reaction was stopped with 50 µl solution of 0.5 M H2SO4 and the optical 
density of each well was measured immediately using a microplate reader (Bio-Rad 
Laboratories, model 680) set to 450 nm. 
 
6.3.2.8 Phenotyping of APC 
The maturation status of APC in response to different liposomes was assessed 36 hours 
after addition of the liposomes. DCs were analysed on a FACS Calibur (Becton 
Dickinson). In brief, 100000 DCs were stained with CD80-PE and CD86-APC in FACS 
buffer (PBS, 1 % FCS) at 4 oC for 30 minutes. Cells were washed three times in ice-cold 
PBS / 1 % FCS and analysed by flow cytometry using CellQuest software. Dead cells 
were excluded by forward light scattering and propidium iodide staining.  
 
6.3.2.9 Injection of ThrCer liposome to assess DC maturation in vivo 
C57BL/6 female mice or B6-NKTKO female mice were immunised with 200 µl / mouse 
by the intravenous route of injection (IV). Stock solutions were made up at 5 µg/ml (1 µg 
/ mouse). Mice were immunised with either: 1 µg ml-1 lab-grade αGalCer, 1 µg ml-1 lab 
grade ThrCer, 1 µg ml-1 each of the liposome formulations, 10 µg ml-1 LPS (50 µg/ml in 
PBS). Spleens were removed the next day and blood taken by cardiac puncture to assess 
IFN-γ levels in the serum.  
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6.3.2.10 Statistical analysis  
For all experiments, means and standard deviations were calculated. To determine 
statistical significance the one way analysis of variance (ANOVA) was performed on all 
data, with the statistical significance determined to 0.05 confidence intervals (p<0.05). 
Tukey’s post hoc test was conducted to determine which conditions differ significantly 
from each other.  
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6.4 Results and discussion 
6.4.1 Characterisation of ThrCer liposomes 
As discussed previously, cationic liposomes based on DDA have been evaluated and have 
shown potential as an adjuvant system for vaccines against a wide range of diseases (e.g. 
Davidsen et al 2005). In this study, two liposomal delivery systems composed of DDA 
and DSPC (a neutral alternative) were tested for their ability to enhance ThrCer delivery 
to DCs. Table 6.1 provides size, polydispersity and ThrCer loading of the liposomal 
systems with and without the inclusion of ThrCer when formulated in both multilamellar 
vesicles (MLV) and small unilamellar vesicles (SUV).   
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Size (nm) of (A) DSPC liposomes and (B) DDA liposomes over time of sonication. Results 
represent mean ± SD of triplicate experiments. 
 
The time required for sonication was based on these results and is dependent on 
concentration of lipid and sonication power used (Figure 6.2). For the DSPC based 
liposomes, a sonication time of 60 seconds was chosen to produce liposomes of 121.1 nm 
in size, whereas for the DDA based liposomes the sonication time was 30 seconds. This 
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may be an outcome of the cationic lipids packing less tightly into the liposome 
membranes such that they are more sensitive to sonication. 
Table 6.1 Characterisation of MLV or SUV liposomes prepared from DSPC or DDA with and without the 
inclusion of ThrCer.  
 
Formulation MLV SUV 
 Size (nm) Polydispersity 
Index (PI) 
ThrCer 
loading (% of 
amount used) 
Size (nm) Polydispersity 
Index (PI) 
ThrCer 
loading (% 
of amount 
used) 
DSPC 1346.6 ± 267.0 0.378 ± 0.00 - 228.4 ± 3.2 0.302 ± 0.03 - 
DSPC:ThrCer 174.5 ± 3.1 0.324 ± 0.05 96 ± 2.5 % 121.1 ± 2.3 0.302 ± 0.00 94 ± 2.8 % 
DDA 408.7 ± 14.9 0.345 ± 0.03 - 103.1 ± 1.4 0.296 ± 0.07 - 
DDA:ThrCer 572.8 ± 18.3 0.327 ± 0.03 80 ± 1.2 % 121.2 ± 4.7 0.357 ± 0.00 74 ± 4.2 % 
 
Size (nm) and polydispersity (PI) were measured by photon correlation spectroscopy. Results represent 
mean ± SD of triplicate experiments. 
 
The addition of ThrCer to DSPC liposomes was found to significantly (p<0.05) reduce 
the size of both MLV and SUV liposomes (Table 6.1). However in contrast, for the DDA-
based liposomes a significant increase (p<0.05) in size was found for MLV liposomes but 
no significant change in size was noted for SUV liposomes (Table 6.1). The changes in 
size seen in both sets of formulations suggest that ThrCer promotes a re-organisation of 
surfactants within the bilayers, and in the case of the DSPC liposomes promoting smaller 
sized vesicles. A similar effect with small-molecule drugs was found by Lopes et al 
(2004), where sodium diclofenac, an amphiphilic molecule, interacted with the bilayers of 
liposomes composed of soya phosphatidylcholine, causing a decrease in liposome size. 
Several other studies have also suggested that a molecular association between 
amphiphilic drugs and phospholipids including anti-inflammatory compounds, results in a 
decrease in the size of liposome structures (Schreier et al 2000; Kriwet & Muller-
Goymann 1994; Stoye et al 1998). Interestingly, the effect of ThrCer on DDA liposomes 
 252 
 
was in contrast, with its addition promoting slightly larger vesicle sizes, suggesting the 
charge of the lipid headgroup was playing an influencing role.  
 
Incorporation of ThrCer was also influenced by the charge of the lipids employed, with 
cationic liposomes prepared from DDA having a reduced loading compared to their 
zwitterionic counterpart; both MLV and SUV liposomes prepared using DSPC 
incorporated more ThrCer than their cationic DDA counterparts (Table 6.1). This 
suggests that the zwitterionic lipid DSPC is better able to accommodate the ThrCer within 
the bilayer structure compared to DDA. This may be due to the larger head group of DDA 
inhibiting effective packaging of the molecules within the bilayer thereby inhibiting 
inclusion of ThrCer within the system. 
 
6.4.2 Determination of vesicle stability over time 
Stability was investigated in terms of changes in vesicle size over time and the 8 
formulations were prepared and stored at room temperature (25 oC) for 28 days (Figure 
6.3A and B). Whilst after the initial preparation, the DSPC MLV were 1346.6 ± 267.0 
nm, the size of these vesicles increased rapidly on storage to 1944.2 ± 102.2 nm after 14 
days and after 28 days storage visible aggregation became apparent (Figure 6.3A). In 
contrast, addition of ThrCer to these DSPC liposomes promoted enhanced stability with 
liposomes showing no significant change (p<0.05) in particle size over the 28 day period 
with sizes remaining around 296.1± 39.2 nm, indicating that the presence of ThrCer in the 
DSPC liposome bilayers leads to improved liposome stability potentially through 
promoting the reduced vesicle sizes which were less likely to sediment and aggregate 
(Figure 6.3A).  
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The MLV liposomes produced with DDA alone again showed instabilities in terms of 
particle size when stored at room temperature with a twofold increase in size being noted 
over the 28 day study (Figure 6.3A). However unlike the DSPC liposomes, the addition 
of ThrCer did not improve the stability of DDA liposomes with vesicle size increasing by 
59 % over the 28 days. These results could again suggest that the smaller vesicle size of 
the DSPC:ThrCer liposomes (~175 nm; Table 6.1) compared to the larger MLV DDA 
liposomes (~409 nm) was a factor in their improved stability. However this is not 
supported by stability studies of SUV formulations (Figure 6.3B). Of the four SUV 
formulations, again only the DSPC:ThrCer liposomes showed no significant change 
(p>0.05) in size over the 28 day period with sizes remaining around 177 nm, whilst 
DSPC only SUV increased by 57 % compared with their initial size (Figure 6.3B). The 
DDA SUV with and without ThrCer also showed size instability over time with particle 
sizes increasing from around 100 nm to 300 nm by day 14 with no further significant 
changes in size thereafter (Figure 6.3B). Therefore, whilst both liposome size and surface 
charge in general are known to have an influencing effect on the rate of sedimentation 
and potential aggregation, the change in lipid packaging with the addition of ThrCer to 
liposomes formulated as both MLV and SUV improved DSPC liposome stability but not 
those based on DDA. 
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Figure 6.3 Size (nm) of (A) MLV and (B) SUV of DSPC and DDA liposomes with and without the 
inclusion of ThrCer represented by storage at 25 °C. Size was measured in Tris buffer (1 mM) using a 
Brookhaven ZetaPlus instrument. Results represent mean ± SD of triplicate experiments. 
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6.4.3 ThrCer is retained in liposomes under simulated in vivo conditions 
For therapeutic application, it is important that drugs are retained within liposomes for an 
appropriate time, and release kinetics may vary depending on the drug delivered, the site 
of action and the therapeutic application. Among the various factors that dictate the 
liposomal release of a drug, the bilayer composition is a key factor (Devaraj et al 2002). 
ThrCer retention was measured in simulated in vivo conditions i.e. in 50 % FCS in Tris 
buffer and compared to formulations in Tris buffer. The percentage of ThrCer 
incorporation was calculated as a percentage of the total radioactivity recovered from 
both supernatant and pellet in both conditions. In the case of the MLV formulations 
(Figure 6.4A), the DSPC:ThrCer and DDA:ThrCer MLV retained over 88 % and 80 % 
respectively of the initial ThrCer loading over the period of the study (Figure 6.4A) and 
of this  7 % was lost over the initial 24 hour period.  
 
For the SUV-based formulations (Figure 6.4B), both the DSPC and DDA based vesicles 
gave significantly higher (p<0.05) ThrCer release in serum over time compared to the 
MLV, with DSPC vesicles having ThrCer retention of 63 % and DDA vesicles of 69 %. 
This increased instability of the SUV compared to the MLV maybe an outcome of the 
larger total surface area of the SUV which results in higher interactions of the lipids with 
the serum moieties. In general release in serum were higher than those measured for tris 
buffer (Figure 6.4) possibly due to the adsorption of serum proteins onto the liposomes 
resulting in greater release as it has been previously reported that the loss of lipids from 
liposomes through lipid exchange may be due to plasma high-density lipoproteins 
(Sulkowski et al 2005).  
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Figure 6.4 Entrapped ThrCer release profile of DSPC and DDA (A) MLV and (B) SUV. Liposomes 
were stored under simulated in vivo conditions with ThrCer (represented by storage at 37 oC in 50 % FCS). 
Results represent mean ± SD of triplicate experiments. 
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6.4.4 Langmuir-Blodgett isotherms 
To investigate the packaging of ThrCer with the DDA or DSPC surface pressure/area 
isotherms of monolayers of the lipids on their own or in combination were investigated.  
Such monolayer studies can be used to thermodynamically analyse interactions between 
components in mixed monolayers, allowing interactions between lipid components and 
their molecular arrangement at the air/water interface (Hac-Wydro et al 2007). It is clear 
that the structural differences of lipids influence the interactions among them and these 
interactions dominate the organisation of membranes (Andrade et al 2006). Many studies 
have been conducted on the behaviour of different lipids in mixed monolayers (e.g. Chou 
& Chang 2000; Gzyl & Paluch 2005), and these can be used to interpret interaction in 
liposome bilayers (e.g. Christensen et al 2008; Ali et al 2010). Surface properties of 
mixed monolayers are generally studied on the basis of surface pressure (pi)/mean 
molecular area (A) measurements in which bidimensional phases can be detected, each 
separated by a phase transition. The 2D phases in increasing pressure order are (1) 
bidimensional gas, (2) liquid (which can be further subdivided into expanded liquid, and 
condensed liquid), and (3) solid. In the gas phase, the molecules are not interacting with 
each other (Figure 6.5). When the surface area is decreased the molecules become more 
closely packed and start to interact with each other. At the solid phase, the molecules are 
completely organised and the surface pressure increases dramatically and collapse occurs, 
i.e. the monolayer breaks and aggregates or multilayers are formed. Importantly, the 
shape and location of the isotherms are indicative of the interactions both between 
molecules in the monolayer and of the subphase.  
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Figure 6.5 Surface pressure - area isotherm. The monolayer is formed by spreading the organic 
molecules on the water subphase. The molecules usually have hydrophilic (head) and hydrophobic (tail) 
parts, so when the film is formed the molecules stand on their heads. When the molecules first are spread on 
the water they are very loosely packed and form a so called gas phase. This means that the area on the water 
available for each molecule is rather large and the surface pressure is low. The surface pressure is usually 
measured using a Wilhelmy plate and a precision scale. The surface pressure can be increased by means of 
one or two sliding barriers. At a certain point the surface pressure starts to rise more rapidly indicating a 
transition to the liquid phase. As the barrier is moved even further the onset of the solid phase can be noted 
by an even steeper rise in the surface pressure. 
 
To investigate the geometrical interactions between DSPC or DDA with ThrCer at the 
air/water interface, surface pressure studies of the various surfactants and mixtures were 
investigated (Figure 6.6A and B, with calculations presented in Table 6.2). The isotherm 
of pure DSPC (one component system) shows the molecular area as 48.1 ± 2.7 A2 per 
molecule and the condensed phase collapsing at 58.5 ± 0.6 mN m-1 (Figure 6.6A; Table 
6.2), which are in agreement with results collated by Cardenas et al (2005). For DDA, 
monolayer collapse occurred at 44.8 ± 1.9 mN m-1, similar to literature reports of DDA on 
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pure water, which was found to be 45 mN m-1 (Hato et al 1993; Taylor et al 1996) (Figure 
6.6B; Table 6.2). Of the three pure molecules, ThrCer has a smallest area/molecule (A2) 
of 27.2 ± 1.3 and a collapse pressure similar to DSPC of 60.3 ± 2.4 mN m-1, which would 
be expected from this type of surfactant structure (a small headgroup and saturated tail 
groups; Figure 6.1). 
 
In both cases, the isotherms of the lipid mixtures were found to lie between the ranges of 
those of the pure components (Figure 6.6A and B) and for both the DSPC:ThrCer and 
DDA:ThrCer mixtures the measured extrapolated area per molecule was significantly 
higher than the predicted A2 per molecule (5 % deviation for the DSPC:ThrCer mix and 
14 % for the DDA:ThrCer mix; Table 6.2). It has been suggested (Hac-Wydro & Wydro 
2007) that positive deviation (which is when the experimental area is more than the ideal 
area) occurs with saturated lipids which stack co-operatively, and that there is no 
condensing effect as is noted when lipids such as DSPC are mixed with cholesterol (Ali et 
al 2010).  
 
Table 6.2 The experimental extrapolated area and area compressibility of mixed and pure 
monolayers at the air/water interface (at 20 ºC) by DSPC, DDA and ThrCer in ddH2O.  
Results represent mean ± SD of triplicate experiments. 
 
Formulation Extrapolated  
area at zero  
pressure (A2/Molecule) 
Ideal 
Extrapolated 
area at zero 
pressure 
(A2/Molecule) 
Deviation  
from  
ideality (%) 
Collapse pressure 
(mN m-1) 
DSPC 48.1 ± 2.7 - - 58.5 ± 0.6 
DDA 61.5 ± 2.7  - - 44.8 ± 1.9 
ThrCer 27.2 ± 1.3 - - 60.28 ± 2.4 
DSPC:ThrCer (1:1) 42.6 ± 2.6 37.65 + 4.95 57.1 ± 1.1 
DDA:ThrCer (1:1) 50.4 ± 2.6 44.35 + 13.64 63.5 ± 1.5 
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Figure 6.6 The surface pressure-area isotherms of mixed and pure monolayers at the air/water 
interface. The mixed and pure monolayers were of (A) DSPC, (B) DDA and ThrCer. The air/water 
interface was at 20 °C. Results represent mean ± SD of triplicate experiments. 
 
A 
B 
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In terms of monolayer collapse pressure, the addition of ThrCer to DSPC made no 
significant difference to the collapse pressure of the monolayer. In contrast, ThrCer was 
shown to significantly increase the surface pressure at which the monolayer collapsed 
compared to DDA alone (increasing the collapse pressure by 8.7 mN/m; Table 6.2). 
Recent surface pressure studies of DDA, in combination with trehalose 6,6’dibehenate 
(TDB) (Christensen et al 2008), have shown that the addition of TDB to DDA 
monolayers increased the collapse pressure compared to DDA alone, indicating that the 
attractive forces between the trehalose headgroup of TDB and water are greater than 
those between the quaternary ammonium head group of DDA and water. From the data in 
Figure 6.6, it would suggest that ThrCer is having a similar effect and improving the 
interaction of the monolayer mixture with water. However this did not translate into 
improved stability as seen in Figure 6.3. Whilst the addition of ThrCer to DSPC 
liposomes was seen to improve their stability, this was not the case with DDA liposomes 
(Figure 6.3) and it may be that higher concentrations of ThrCer than those employed in 
the liposomes would be required to stabilise the cationic formulations.   
 
In general, these collapse pressures at high surface pressure and small molecular area can 
be attributed to the lipids (DDA, DSPC and ThrCer) used for the study, which are 
saturated lipids. Previous studies noted that when a lipid is unsaturated with one or more 
double bonds, which in most naturally occurring lipids are in the cis configuration, this 
makes the chain bend and accordingly, the more double bonds the chain has in the cis 
configuration, the more curved the chain (Hac-Wydro & Wydro 2007). This results in a 
decreased packaging efficiency and an increased area per molecule. In contrast, saturated 
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lipids are known to form straight chains resembling rods. The saturated lipids therefore 
occupy a smaller molecular area than unsaturated lipids and their collapse pressure is 
higher (Hac-Wydro et al 2007).  
 
6.4.5 Maturation effect on DCs 
To investigate whether the adjuvant activity of liposomes with ThrCer was associated 
with the ability to induce maturation of DCs, the maturation status of DCs (Figure 6.7) in 
response to different liposomes was assessed 36 hours after addition of the liposomes. 
DCs were analysed on a FACS Calibur. The DCs had a distinct immature profile, which 
was not affected by the stimulation with the liposomes because the surface expression of 
CD80 and CD86 was unchanged. Figure 6.7 shows that none of the liposome 
formulations can maturate DC, which means that the liposomes were very pure with no 
lipopolysaccharides (LPS) contamination (Figure 6.7). Work described in here was done 
in collaboration with Prof Vincenzo Cerundolo at the Weatherall Institute of Molecular 
Medicine, University of Oxford.  
 
6.4.6 Uptake of ThrCer by DCs 
The uptake of the immunostimulatory agent, ThrCer by DCs, and presentation on CD1d 
molecules to iNKT cells were determined by measuring IFN-γ release (Figure 6.8). 
Previous studies have shown that ThrCer efficiently activates iNKT cells, resulting in DC 
maturation and activated iNKT cells rapidly produce IFN-γ (Silk et al 2008). To examine 
whether both the cationic and neutral ThrCer-containing liposomes were able to enhance 
this action, secretion of IFN-γ by iNKT cells stimulated with different concentrations 
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(100 ng ml-1 and 1 µg ml-1) and of liposomes was measured, which were loaded on to 
DCs. The results (Figure 6.8) show that both types of ThrCer-containing liposomes could 
sufficiently activate iNKT cells. When comparing concentration of ThrCer, 100 ng ml-1 
and 1 µg ml-1, a higher IFN-γ secretion was found at higher concentrations for all 
formulations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 The maturation status of APC in response to different liposomes was assessed 36 hours 
after addition of the liposomes. DCs were analysed on a FACS Calibur (Becton Dickinson). Liposomes in 
the presence and absence of ThrCer were compared as follows: Liposome 1 = DDA:ThrCer MLV with 
Liposome 5 = DDA MLV, Liposome 2 = DSPC:ThrCer MLV  with Liposome 6 = DSPC MLV, Liposome 
3 = DDA:ThrCer SUV with Liposome 7 = DDA SUV, Liposome 4 = DSPC:ThrCer SUV with Liposome 8 
= DSPC SUV. Experiment conducted at the Weatherall Institute of Molecular Medicine, University of 
Oxford.  
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In particular the DDA SUV based liposome formulation was found to produce a higher 
IFN-γ secretion at both concentrations compared to the neutral DSPC based liposomes. In 
all cases, the control liposomes (not containing ThrCer) induced minimal levels of IFN-γ 
secretion (Figure 6.8). Only a few compounds stimulate iNKT cells and the best 
characterised is the glycolipid α-GalCer, which stimulates the production of large 
quantities of IFN-γ and IL-4 by these cells. However, αGalCer leads to overstimulation of 
iNKT cells. ThrCer successfully activates iNKT cells and overcomes the problematic 
iNKT cell activation-induced anergy associated with αGalCer 1 (Garcia-Diaz et al 2009). 
From Figure 6.8, it has been demonstrated that the IFN-γ secretion was higher for the 
DDA SUV based formulation, suggesting that ThrCer encapsulation in this liposome 
formulation resulted in a higher uptake by dendritic cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 IFN-γ release from iNKT cells co-cultured with DCs pulsed with liposomes prepared as 
MLV or SUV with and without the inclusion of ThrCer. Results represent mean ± SD of triplicate 
experiments. Experiment conducted at the Weatherall Institute of Molecular Medicine, University of 
Oxford. 
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6.4.7 DC maturation in vivo 
DC maturation refers to an intricate differentiation process whereby DCs respond rapidly 
to an environmental stimulus and become capable of eliciting adaptive immunity. The 
type of stimulus determines the program of DC differentiation and the subsequent host 
immune response. DCs can directly sense pathogen components via TLRs, and respond to 
this recognition by up-regulating surface co-stimulatory molecules, secreting cytokines 
and chemokines, enhancing antigen presentation, and migrating to secondary lymphoid 
tissues (Iwasaki & Medzhitov 2004).  
 
In this study, C57BL/6 female mice and B6-NKTKO female mice were immunised with 
1µg ml-1 of one of the four liposome formulations and the levels of IFN-γ was assessed in 
the serum. LPS was used as a positive control and from Figure 6.9 the mean fluorescence 
intensity (an indicator of IFN-γ) for the control was found to be similar for both of the 
mouse strains. However, a better expression of IFN-γ was found with the B6-NKTKO 
mouse strain compared to the C57BL/6. When comparing the formulations, the mean 
fluorescence intensity, was higher for all the liposomal formulations containing ThrCer 
compared to ThrCer alone thereby showing a synergistic action/effectively delivery 
promoted by the liposomal system. The liposome formulations without ThrCer failed to 
produce any IFN-γ. Interestingly, DDA SUV gave the highest levels of IFN-γ suggesting 
a pro-inflammatory response by this formulation. The high IFN-γ levels suggest that this 
formulation was taken up by DCs and presented on CD1d molecules to NK T cells.  
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Figure 6.9 Mean fluorescence intensity. C57BL/6 female mice or B6-NKTKO female mice (n=3 per 
group) were immunised as follows with 200 µl / mouse by IV injection. Mice were immunised with either: 
1 µg ml-1 lab-grade αGalCer, 1 µg ml-1 lab grade ThrCer, 1 µg ml-1 each of the liposome formulations, 10 
µg ml-1 LPS. Spleens were removed the next day and blood taken by cardiac puncture to assess IFN-γ levels 
in the serum. Experiment conducted at the Weatherall Institute of Molecular Medicine, University of 
Oxford. 
 
The in vitro studies (Figure 6.8) showed that IFN-γ secretion was higher for the DDA 
SUV based formulation, suggesting that ThrCer encapsulation in this liposome 
formulation resulted in a higher uptake by dendritic cells. The in vivo results confirm this, 
as a higher expression of ThrCer was found with this formulation (Figure 6.9). Previous 
studies have shown that DDA is an effective type of adjuvant promoting a cell-mediated 
immune response against the intracellular pathogen M. tuberculosis (Hilgers & Snippe 
1992). A number of studies have looked at DDA and other immunomodulating agents 
(Stanfield et al 1973, Andersen 1994). Administration of Arquad 2HT, which comprises 
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DDA, in humans was promising and did not induce apparent side effects (Stanfield et al 
1973). An experimental vaccine based on culture filtrate proteins from M. tuberculosis 
and DDA generated a protective immune response against TB in mice (Andersen 1994). 
Moreover, DDA has been used as an adjuvant for a DNA vaccine against pseudorabies 
virus leading to enhanced T-cell responses and antiviral immunity (van Rooij et al 2002).  
 
 6.5 Conclusion 
Although previous studies (Sullivan & Kronenberg 2005) have demonstrated that 
αGalCer is an effective and very powerful activator of the immune system, it has also 
been found that after a single activation event with αGalCer, iNKT cells display a long 
period of anergy. During this period the iNKT cell population diminishes to nearly 
undetectable levels and are unresponsive when pulsed with further doses of αGalCer.  
 
In a study by Silk et al (2008), it was discovered that replacing the galactosyl polar-head 
group with a truncated galactose moiety addressed some of the problems associated with 
αGalCer, including the long period of anergy after a single activation and the propensity 
to induce iNKT cell-dependent lysis of DCs. One of the analogues was ThrCer. In this 
study ThrCer has been entrapped in DSPC and DDA liposomes, formulated as both MLV 
and SUV. The entrapment efficiency of ThrCer within the lipid bilayers was high for both 
zwitterionic (DSPC) and cationic (DDA) liposomes. The release of ThrCer from 
liposomes was measured in Tris and 50 % FCS (to simulate in vivo conditions) and it was 
found that both the MLV based formulations had a higher ThrCer retention compared to 
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the SUV counterparts. In terms of ThrCer packaging it was found that the addition of 
ThrCer improved the stability of the DSPC liposomes. However, this was not the case for 
the DDA-based liposomes and it may be that higher concentrations of ThrCer than those 
employed in the liposomes would be required to stabilise the cationic formulations. For 
the in vitro work, it was demonstrated that the IFN-γ secretion was higher for the DDA 
SUV liposome formulation (p<0.05), suggesting that whilst these systems had reduced 
stability compared to their DSPC counterparts, ThrCer encapsulation in this liposome 
formulation resulted in a higher uptake by dendritic cells. The in vitro data was supported 
by the in vivo results as a higher expression and up regulation of ThrCer by DCs was 
found with the DDA:ThrCer SUV formulation.  
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Chapter 7 
General discussion 
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7.1 Magnetic resonance imaging (MRI) contrast agent for imaging of fluid pressure 
MRI is a powerful technique to non-invasively produce images of objects exhibiting 
NMR signal, such as the human body, and is of particular relevance to medical imaging. 
The technique is particularly suited to imaging fluid (e.g. blood) concentration and fluid 
flow. The technique is, however, virtually insensitive to fluid pressure, although such 
measurements would be extremely relevant to medical imaging as well as for the 
investigation of fluid flow in heterogeneous porous media. Gas bubbles in liquids have 
been suggested in order to measure fluid pressure with MRI. The technique has been 
experimentally demonstrated in vitro, but theoretical calculations show that the method 
cannot be used in vivo, because it requires too high concentration of gas.  
 
In chapter 2 of the thesis, the aim was to prepare a MRI contrast agent for imaging of 
fluid pressure using liposomes that contain the gas (lipid-coated microbubbles). Gas filled 
microbubbles have seen applications predominantly as ultrasound contrast agents (for 
which they are commercially available), as they greatly enhance radiation scattering 
(Duncan & Needham 2004). They have also been demonstrated as pressure sensors for 
non-invasive manometry using magnetic resonance imaging (MRI) (Alexander et al 
1996). More recently these microbubbles have been used to spatially resolve the pressure 
of a liquid saturating a porous medium which has potential applications to improving oil 
recovery (Vangala et al 2007a). In the present work, initial studies compared four 
different methods of producing lipid-coated microbubbles in terms of stability and 
physico-chemical characteristics. The potential formulations identified from the initial 
characterisation studies were then further investigated as contrast agents for fluid 
pressure. It was found that both the formulation of the microbubble shell and the gas 
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incorporated were shown to influence stability and sensitivity: the addition of 5 % PEG 
and/or cholesterol was shown to stabilise the structures in terms of microbubble size. 
However, an overall decrease in foam volume was noted with such formulations and 
therefore microbubbles formulated from DSPC alone were adopted for further studies. In 
order to produce a liquid contrast agent exhibiting large MRI sensitivity to fluid pressure 
changes, whilst keeping micron sized gas filled bubbles homogeneously dispersed in the 
liquid, an aqueous solution of weakly concentrated polysaccharide gels as a liquid 
medium accommodating the phospholipid microbubbles was used. The inclusion of 
microbubbles into polysaccharide gel counteracted their intrinsic buoyancy without 
reducing NMR sensitivity. Furthermore, for the microbubbles formulated from DSPC, it 
was found that the sensitivity of these systems could be improved using nitrogen rather 
than air within the microbubbles. 
  
Smaller F-GPC microbubbles were also prepared which can withstand higher pressures 
than the DSPC microbubbles. Further refinement to improve the stability of F-GPC 
microbubbles will allow their biomedical application to include echocardiography and 
other diagnostic ultrasound techniques, whilst the large microbubble systems may also be 
suitable for petrochemical applications or in the imaging of various pressure regions 
within joints and chronic joint disorders. The work demonstrates an important step 
forward in the design of MRI contrast agents for human blood pressure monitoring and 
imaging, although the inclusion of paramagnetic agents in the shell of the bubbles is 
probably a necessity for such an agent to exhibit high enough sensitivity. 
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7. 2 Lipid-coated microbubbles as vaccine adjuvants 
Liposome systems are well reported for their activity as vaccine adjuvants; however novel 
lipid-based microbubbles have also been reported to enhance the targeting of antigens 
into DCs in cancer immunotherapy (Suzuki et al 2009). The aim of this chapter was to 
investigate the formulation of lipid coated microbubbles and assess their potential 
activation of macrophages using in vitro models. Cell viability and phagocytic activity 
was measured using the MTS and NAG assays, respectively. From the results, it was 
found that none of the formulations tested within the concentrations tested influenced 
either of the activities measured. In terms of the application of the lipid-coated 
microbubbles this demonstrates their further potential in diagnostic imaging given these 
lipid-coated microbubbles were demonstrated in chapter 2 to act as potential contrast 
agents that allow stable MRI measurements of fluid pressure over time. The preliminary 
studies with regard to uptake within macrophages were not encouraging to support further 
investigations into their application in this respect. Therefore, further studies into the 
development of vaccine adjuvants then focused on aqueous-filled liposome systems.    
 
7.3 Aqueous-filled liposomes as vaccine adjuvants 
The use of liposomes as vaccine adjuvants has been investigated extensively over the last 
few decades. In particular, cationic liposomal adjuvants have drawn attention, with DDA 
liposomes as a prominent candidate. However cationic liposomes are, in general, not 
sufficiently immunostimulatory, and therefore a range of immunostimulatory agents have 
been added to these formulations. One such combination consists of liposomes formed of 
DDA stabilised with the synthetic mycobacterial immunomodulator, TDB inserted into 
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the lipid bilayers at a molar ratio of 5:1. This cationic liposome system was developed to 
mediate protection against tuberculosis (TB) but, in addition, has shown promising 
protective efficacy against other infectious diseases requiring different immunological 
profiles (Christensen et al 2009). One of the proposed mechanism behind the 
immunostimulatory effect obtained with DDA:TDB is the ‘depot effect’ in which the 
liposomal carrier helps to retain the antigen at the injection site, thereby increasing the 
time of vaccine exposure to the immune cells (Henriksen-Lacey et al 2010). The depot 
effect has been suggested to be primarily due to their cationic nature. In this chapter, the 
aim of the study was to further test this hypothesis by investigating whether sterically 
stabilising the DDA:TDB system with PEG reduces aggregation, and subsequently 
influences the formation of a depot at the site of injection and the immune response.  
 
Results reported within this thesis demonstrate that higher levels of PEG i.e. 25 % was 
able to significantly inhibit the formation of a liposome depot at the injection site and also 
severely limit the retention of antigen at the site therefore resulting in a faster drainage of 
the liposomes from the site of injection. This was reflected by the immunisation study, 
where lower levels of IgG2b antibody, IFN-γ,  and IL-2 was found compared to the 
DDA:TDB formulation, and higher level of IL-5 cytokine suggesting that the pegylated 
formulations stimulate a Th2 type immune response. This study further supports the 
hypothesis that the depot formation is due to electrostatic forces between the net 
negatively charged protein and the positively charged liposomes i.e. aggregation between 
the cationic liposomes and serum proteins, thereby causing a liposomal net which retains 
the antigen.  
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7.4 Addition of immunostimulatory components CpG and poly(I:C) 
The versatility of cationic liposomes based on DDA:TDB in combination with different 
immunostimulatory ligands including, poly(I:C) a TLR 3 ligand, and CpG a TLR 9 
ligand, either entrapped within the vesicles or adsorbed onto the liposome surface was 
investigated in this chapter. Poly(I:C) (TLR 3) is a synthetic double-stranded (ds) RNA 
and CpG (TLR 9) is an immunomodulating synthetic oligonucleotide. Small unilamellar 
DDA:TDB vesicles (20 - 100 nm native size) with protein antigen adsorbed to the vesicle 
surface were the most potent in inducing both T cell (7-fold increase) and antibody (up to 
2 log increase) antigen specific responses. It was found that the addition of TLR agonists 
poly(I:C) and CpG to SUV liposomes had a small or no effect on their adjuvanticity. 
 
7.5 Incorporation of ThrCer into liposomes for presentation to iNKT cells 
DCs are able to present glycolipids to iNKT cells in vivo and very few compounds have 
been found that stimulate iNKT cells. Of these the best-characterised is the glycolipid α-
galactosylceramide (α-GalCer). It has been demonstrated that the αGalCer analogue, 
ThrCer, successfully activates iNKT cells and overcomes the problematic iNKT cell 
activation-induced anergy. ThrCer is a promising agonist for iNKT cells and may have 
therapeutic application. In this chapter, the aim of the study was to incorporate ThrCer 
into the bilayers of liposomes composed of the cationic lipid DDA or the zwitterionic 
lipid, DSPC, formulated as both MLV and SUV. For the in vitro work, the uptake of 
ThrCer by dendritic cells and presentation on CD1d molecules to iNKT cells, which 
respond by releasing IFN-γ, was also determined.  It was demonstrated that the IFN-γ 
secretion was higher for DDA SUV liposome formulation (p<0.05), suggesting that 
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whilst these systems had reduced stability compared to their DSPC counterparts, ThrCer 
encapsulation in this liposome formulation resulted in a higher uptake by dendritic cells. 
The in vitro data was supported by the in vivo results as a higher expression and up 
regulation of ThrCer by DCs was found with the DDA:ThrCer SUV formulation. 
 
7.6 Further studies  
Further studies can be conducted in continuation of this work. For the lipid-coated 
microbubbles the design of MRI contrast agents for human blood pressure monitoring and 
imaging will require the microbubbles to exhibit high enough sensitivity. The inclusion of 
paramagnetic agents in the shell of the bubbles can therefore be tested.  
 
In vitro transfection studies could be further conducted in an appropriate macrophage cell 
line or dendritic cells as a preliminary screening criteria for different vesicle pegylated 
compositions and also obtain a better correlation with immunisation experiments. 
Knowledge of physico-chemical interaction between different vesicle components and the 
subunit antigen is essential, this could be studied effectively using langmuir trough by 
monitoring surface pressure isotherms with respect to time. 
 
Finally, differential scanning calorimetry (DSC) studies can be conducted to see the 
change in phase transition temperature and the distribution of the lipids after 
incorporation of immunostimulating compounds i.e. CpG and poly(I:C) into the 
liposomes. This would also provide information on the stability of such systems.  
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